Cover
Cover | 3 Months Ended |
Mar. 31, 2022 | |
Cover [Abstract] | |
Entity Registrant Name | COSMOS HOLDINGS INC. |
Entity Central Index Key | 0001474167 |
Document Type | S-1 |
Amendment Flag | false |
Entity Small Business | true |
Entity Emerging Growth Company | false |
Entity Filer Category | Non-accelerated Filer |
Entity Incorporation State Country Code | NV |
Entity Tax Identification Number | 27-0611758 |
Entity Address Address Line 1 | 141 West Jackson Blvd, Suite 4236 |
Entity Address Address Line 2 | Suite 4236 |
Entity Address City Or Town | Chicago |
Entity Address State Or Province | IL |
Entity Address Postal Zip Code | 60604 |
City Area Code | 312 |
Local Phone Number | 536-3102 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
CONDENSED CONSOLIDATED BALANCE SHEETS | |||
Cash and cash equivalents | $ 1,010,427 | $ 286,487 | $ 628,395 |
Accounts receivable, net | 26,094,450 | 26,858,114 | 23,440,650 |
Accounts receivable - related party | 2,844,572 | 2,901,300 | 3,468,564 |
Marketable securities | 12,551 | 6,696 | 222,792 |
Inventory | 4,007,977 | 3,147,276 | 3,292,557 |
Loans receivable | 375,195 | 4,410,689 | 0 |
Prepaid expenses and other current assets | 1,944,720 | 2,987,687 | |
Prepaid expenses and other current assets - related party | 4,368,794 | 2,992,459 | 5,148,441 |
Operating lease right-of-use asset | 775,545 | 834,468 | 833,763 |
Financing lease right-of-use asset | 192,822 | 211,099 | 269,131 |
TOTAL CURRENT ASSETS | 41,627,053 | 40,878,730 | 40,772,946 |
Property and equipment, net | 1,777,889 | 1,880,659 | 1,757,213 |
Goodwill and intangible assets, net | 464,630 | 493,160 | 230,506 |
Loans receivable - long term portion | 4,227,268 | 4,410,689 | |
Other assets | 909,581 | 915,250 | 905,318 |
Deferred tax assets | 767,267 | 850,774 | 178,430 |
TOTAL ASSETS | 49,773,688 | 49,429,262 | 43,844,413 |
Accounts payable and accrued expenses | 11,781,189 | 12,126,626 | |
Accounts payable and accrued expenses - related party | 220,887 | 599,125 | 1,733 |
Accrued interest | 1,033,866 | 1,019,889 | 742,374 |
Lines of credit | 4,362,327 | 4,743,557 | |
Convertible notes payable, net of unamortized discount of $191,085 and $258,938, respectively | 448,915 | 5,462,504 | 12,042,712 |
Derivative liability - convertible note | 30,664 | 45,665 | 460,728 |
Notes payable | 6,143,075 | 5,462,504 | |
Notes payable - related party | 455,035 | 464,264 | 501,675 |
ASSETS | |||
Loans payable | 1,000,000 | 366,171 | 502,869 |
CURRENT ASSETS: | |||
Loans payable - related party | 1,703,881 | 1,293,472 | |
Taxes payable | 1,192,178 | 1,324,722 | 760,446 |
Operating lease liability, current portion | 158,359 | 138,450 | 200,204 |
Financing lease liability, current portion | 71,861 | 73,078 | 89,926 |
Other current liabilities | 1,193,683 | 1,255,824 | 361,340 |
TOTAL CURRENT LIABILITIES | 29,795,920 | 29,928,238 | 34,290,207 |
Share settled debt obligation | 1,554,590 | 1,554,590 | 1,554,590 |
Lines of credit - long-term portion | 185,872 | 366,171 | |
Notes payable - long term portion | 6,885,806 | 12,356,384 | 10,771,882 |
Loans receivable | 377,590 | 0 | |
Operating lease liability, net of current portion | 617,183 | 696,015 | 590,538 |
Financing lease liability, net of current portion | 131,016 | 148,401 | 188,172 |
Prepaid expenses and other current assets - related party | 3,263,241 | 3,468,653 | |
TOTAL LIABILITIES | 39,170,387 | 45,049,799 | 48,005,426 |
Commitments and Contingencies (see Note 14) | 0 | 0 | |
STOCKHOLDERS' EQUITY: | |||
Series A preferred stock, stated value $1,000 per share, 6,000,000 shares authorized; 6,000 and 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021; liquidation preference of $6,000,000 and $0, respectively | 5,452,300 | 0 | 0 |
Common stock, $0.001 par value; 300,000,000 shares authorized; 18,611,980 and 17,544,509 shares issued and 18,224,556 and 17,157,085 outstanding as of March 31, 2022 and December 31, 2021, respectively | 18,611 | 17,544 | 13,484 |
Additional paid-in capital | 40,648,106 | 39,675,753 | 14,333,285 |
Treasury stock, 387,424 and 387,424 shares as of March 31, 2022 and December 31, 2021 | (816,707) | (816,707) | (611,854) |
Accumulated deficit | (34,142,159) | (34,345,506) | (18,750,824) |
Accumulated other comprehensive loss | (556,850) | (151,621) | 854,896 |
TOTAL STOCKHOLDERS' EQUITY | 5,151,001 | 4,379,463 | (4,161,013) |
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY | 49,773,688 | 49,429,263 | 43,844,413 |
TOTAL CURRENT ASSETS | 41,627,053 | 40,878,730 | 40,772,946 |
TOTAL ASSETS | 49,773,688 | 49,429,262 | 43,844,413 |
CURRENT LIABILITIES: | |||
Accounts payable and accrued expenses | 12,126,626 | 11,973,981 | |
Lines of credit | 4,362,327 | 4,743,557 | 4,573,815 |
Convertible notes payable, net of unamortized discount of $191,085 and $258,938, respectively | 381,062 | 952,027 | |
Loans payable | 1,000,000 | 0 | |
Loans payable - related party | 1,293,472 | 1,629,246 | |
TOTAL CURRENT LIABILITIES | 29,795,920 | 29,928,238 | 34,290,207 |
Other liabilities | 0 | 107,168 | |
TOTAL LIABILITIES | $ 39,170,387 | $ 45,049,799 | $ 48,005,426 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Convertible notes payable, net of unamortized discount | $ 191,085 | $ 258,938 | $ 494,973 |
Common stock, shares par value | $ 0.001 | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 300,000,000 | 100,000,000 | 300,000,000 |
Common stock, shares issued | 18,611,980 | 17,544,509 | 13,485,128 |
Common stock, shares outstanding | 18,224,556 | 17,157,085 | 13,069,800 |
Preferred stock, shares par value | $ 0.001 | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 100,000,000 | 100,000,000 | 100 |
Treasury stock | 387,424 | 387,424 | 415,328 |
Preferred stock, shares issued | 0 | 0 | |
Preferred stock, shares outstanding | 0 | 0 | |
Series A Preferred Stock [Member] | |||
Preferred stock, shares par value | $ 1,000 | $ 1,000 | |
Preferred stock, shares authorized | 6,000,000 | 6,000,000 | |
Preferred stock, shares issued | 6,000 | 0 | |
Preferred stock, shares outstanding | 6,000 | 0 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) | ||||
REVENUE | $ 13,071,800 | $ 11,619,076 | $ 56,239,667 | $ 55,406,337 |
COST OF GOODS SOLD | 11,179,868 | 10,617,741 | 47,909,180 | 47,345,957 |
GROSS PROFIT | 1,891,932 | 1,001,335 | 8,330,487 | 8,060,380 |
General and administrative expenses | 868,639 | 1,688,712 | 9,208,701 | 2,102,869 |
Salaries and wages | 521,471 | 531,556 | 2,472,953 | 2,082,453 |
Sales and marketing expenses | 146,949 | 405,092 | 732,545 | 763,170 |
Depreciation and amortization expense | 112,622 | 107,073 | 449,692 | 397,595 |
TOTAL OPERATING EXPENSES | 1,649,681 | 2,732,433 | 12,863,891 | 5,346,087 |
INCOME (LOSS) FROM OPERATIONS | 242,251 | (1,731,098) | (4,533,404) | 2,714,293 |
OTHER INCOME (EXPENSE) | ||||
Other expense, net | (54,812) | (178,211) | (88,882) | 4,571 |
GROSS PROFIT | 1,891,932 | 1,001,335 | 8,330,487 | 8,060,380 |
Interest expense | (584,176) | (731,826) | (2,823,842) | (2,761,004) |
OPERATING EXPENSES | ||||
Interest income | 64,827 | 0 | ||
Non-cash interest expense | (260,527) | (50,109) | 757,021 | 34,106 |
Gain on equity investments, net | 1,678 | 440 | 2,541 | (34,443) |
Gain on extinguishment of debt | 1,004,124 | 445,636 | ||
Change in fair value of derivative liability | 15,001 | 61,373 | ||
Foreign currency transaction, net | (159,352) | (306,020) | (493,527) | 305,274 |
TOTAL OPERATING EXPENSES | 1,649,681 | 2,732,433 | 12,863,891 | 5,346,087 |
TOTAL OTHER INCOME (EXPENSE), NET | 26,763 | (758,717) | ||
INCOME (LOSS) FROM OPERATIONS | 242,251 | (1,731,098) | (4,533,404) | 2,714,293 |
INCOME (LOSS) BEFORE INCOME TAXES | 269,014 | (2,489,815) | (7,847,639) | 1,198,321 |
BENEFIT FROM (PROVISION FOR) INCOME TAXES | (65,667) | 315,912 | 114,010 | 377,535 |
NET INCOME (LOSS) | 203,347 | (2,173,903) | (7,961,649) | 820,786 |
Deemed dividend on warrants | (5,788,493) | |||
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | (5,585,146) | (2,173,903) | (15,594,682) | 820,786 |
Foreign currency translation adjustment, net | (405,229) | (473,578) | (1,006,517) | 871,235 |
TOTAL COMPREHENSIVE LOSS | $ (5,990,375) | $ (2,647,481) | $ (16,601,199) | $ 1,692,021 |
BASIC NET LOSS PER SHARE | $ (0.31) | $ (0.14) | $ (0.95) | $ 0.06 |
DILUTED NET LOSS PER SHARE | $ (0.31) | $ (0.14) | $ (0.95) | $ 0.06 |
Basic | 17,755,516 | 15,034,219 | 16,423,335 | 13,270,097 |
Diluted | 17,755,516 | 15,034,219 | 16,423,335 | 13,270,097 |
Interest income | $ 46,316 | $ 65,865 | ||
Non-cash interest expense | $ 260,527 | $ 50,109 | (757,021) | (34,106) |
Gain on extinguishment of debt | 606,667 | 942,029 | ||
Change in fair value of derivative liability | 193,513 | (4,158) | ||
TOTAL OTHER INCOME (EXPENSE), NET | (3,314,235) | (1,515,972) | ||
INCOME (LOSS) BEFORE INCOME TAXES | 269,014 | (2,489,815) | (7,847,639) | 1,198,321 |
BENEFIT FROM (PROVISION FOR) INCOME TAXES | 65,667 | (315,912) | (114,010) | (377,535) |
NET INCOME (LOSS) | $ 203,347 | $ (2,173,903) | (7,961,649) | 820,786 |
Deemed dividend on warrants | $ (7,633,033) | $ 0 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) AND MEZZANINE EQUITY - USD ($) | Total | Treasury Stock | Common Stock | Preferred Stock | Additional Paid-In Capital | Accumulated Deficit | Accumulated Other Comprehensive Income (Loss) | Common Stock | Treasury Stock |
Balance, shares at Jan. 01, 2020 | 365,328 | 13,225,387 | |||||||
Balance, amount at Jan. 01, 2020 | $ (6,460,829) | $ (411,854) | $ 13,225 | $ 13,525,749 | $ (19,571,610) | $ (16,339) | |||
Foreign currency translation adjustment, net | 871,235 | 0 | $ 0 | 0 | 0 | 871,235 | |||
Conversion of note payable into shares of common stock, shares | 259,741 | ||||||||
Conversion of note payable into shares of common stock, amount | 807,795 | $ 0 | $ 259 | 807,536 | 0 | 0 | |||
Purchase of treasury stock from third party, shares | (50,000) | ||||||||
Purchase of treasury stock from third party, amount | (200,000) | $ (200,000) | 0 | 0 | 0 | 0 | |||
Net income | 820,786 | $ 0 | $ 0 | 0 | 820,786 | 0 | |||
Balance, shares at Dec. 31, 2020 | 415,328 | 13,485,128 | |||||||
Balance, amount at Dec. 31, 2020 | (4,161,013) | $ (611,854) | $ 13,484 | 14,333,285 | (18,750,824) | 854,896 | |||
Foreign currency translation adjustment, net | (473,578) | (473,578) | |||||||
Sale of treasury stock to third party, shares | 65,000 | ||||||||
Sale of treasury stock to third party, amount | 250,000 | 249,350 | $ 650 | ||||||
Restricted stock issued to a consultant, shares | 1,800,000 | ||||||||
Restricted stock issued to a consultant, amount | 1,189,450 | 1,187,650 | $ 1,800 | ||||||
Net income | (2,173,903) | (2,173,903) | |||||||
Conversion of notes payable into shares of common stock, shares | 781,819 | ||||||||
Conversion of notes payable into shares of common stock, amount | 2,564,364 | 2,563,582 | $ 782 | ||||||
Balance, shares at Mar. 31, 2021 | 16,066,947 | 350,328 | |||||||
Balance, amount at Mar. 31, 2021 | (2,804,680) | 18,333,867 | (20,924,727) | 381,318 | $ 16,066 | $ (611,204) | |||
Balance, shares at Dec. 31, 2020 | 415,328 | 13,485,128 | |||||||
Balance, amount at Dec. 31, 2020 | (4,161,013) | $ (611,854) | $ 13,484 | 14,333,285 | (18,750,824) | 854,896 | |||
Foreign currency translation adjustment, net | (1,006,517) | $ 0 | 0 | 0 | 0 | (1,006,517) | |||
Sale of treasury stock to third party, shares | 65,000 | ||||||||
Sale of treasury stock to third party, amount | 250,000 | $ 650 | 0 | 249,350 | 0 | 0 | |||
Purchase of treasury stock from third party, shares | (94,216) | ||||||||
Purchase of treasury stock from third party, amount | (376,863) | $ (376,863) | $ 0 | 0 | |||||
Restricted stock issued to a consultant, shares | 1,800,000 | ||||||||
Restricted stock issued to a consultant, amount | 5,904,000 | 0 | $ 1,800 | 5,902,200 | 0 | 0 | |||
Net income | (7,961,649) | 0 | $ 0 | 0 | (7,961,649) | 0 | |||
Conversion of notes payable into shares of common stock, shares | 1,103,119 | ||||||||
Conversion of notes payable into shares of common stock, amount | 3,878,480 | 0 | $ 1,103 | 3,877,377 | 0 | 0 | |||
Conversions of convertible note payable, shares | 213,382 | ||||||||
Conversions of convertible note payable, amount | 959,025 | 0 | $ 214 | 958,811 | 0 | 0 | |||
Conversion of related party debt, shares | 1,000,000 | ||||||||
Conversion of related party debt, amount | 6,000,000 | 0 | $ 1,000 | 5,999,000 | 0 | 0 | |||
Beneficial conversion feature discount related to convertible notes payable | 294,000 | 0 | 0 | 294,000 | 0 | 0 | |||
Forgiveness of related party debt | 600,000 | $ 0 | $ 0 | 600,000 | 0 | 0 | |||
Cancellation of treasury shares, shares | 57,120 | (57,120) | |||||||
Cancellation of treasury shares, amount | 0 | $ 171,360 | $ (57) | (171,303) | 0 | 0 | |||
Deemed dividend on warrants | (7,633,033) | $ 0 | $ 0 | 7,633,033 | (7,633,033) | 0 | |||
Balance, shares at Dec. 31, 2021 | 387,424 | 17,544,509 | |||||||
Balance, amount at Dec. 31, 2021 | 4,379,463 | $ (816,707) | $ 17,544 | 39,675,753 | (34,345,506) | (151,621) | |||
Foreign currency translation adjustment, net | (405,229) | (405,229) | |||||||
Net income | 203,347 | 203,347 | |||||||
Conversion of notes payable into shares of common stock, shares | 238,000 | ||||||||
Conversion of notes payable into shares of common stock, amount | 973,420 | 973,182 | $ 238 | ||||||
Issuance of Series A preferred stock, net of issuance costs of $547,700, shares | 6,000 | ||||||||
Issuance of Series A preferred stock, net of issuance costs of $547,700, amount | $ 5,452,300 | ||||||||
Cashless exercise of warrants, shares | 829,471 | ||||||||
Cashless exercise of warrants, amount | (829) | $ 829 | |||||||
Balance, shares at Mar. 31, 2022 | 6,000 | 18,611,980 | 387,424 | ||||||
Balance, amount at Mar. 31, 2022 | $ 5,151,001 | $ 5,452,300 | $ 40,648,106 | $ (34,142,159) | $ (556,850) | $ 18,611 | $ (816,707) |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
Net income (loss) | $ 203,347 | $ (2,173,903) | $ (7,961,649) | $ 820,786 |
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities: | ||||
Depreciation and amortization expense | 93,042 | 80,318 | 352,422 | 274,062 |
Amortization of right-of-use assets | 19,580 | 26,755 | 97,270 | 123,533 |
Amortization of debt discounts and accretion of debt | 260,527 | 50,109 | 757,021 | 34,105 |
Bad debt expense | 1,087,339 | 96,237 | ||
Write-off of investment | 211,047 | |||
Lease expense | 54,124 | 64,543 | 260,663 | 188,400 |
Interest on finance leases | 11,576 | 13,759 | ||
Stock-based compensation | 1,189,450 | 5,904,000 | 0 | |
Deferred income taxes | 62,594 | (329,586) | (714,108) | (178,430) |
Gain on extinguishment of debt | 1,004,124 | 445,636 | (606,667) | (942,029) |
Change in fair value of the derivative liability | 15,001 | 61,373 | (193,513) | 4,158 |
(Gain) loss on change in fair value of equity investments | (2,541) | 34,443 | ||
Changes in Assets and Liabilities: | ||||
Accounts receivable | (226,934) | (729,802) | (6,256,072) | (14,514,183) |
Accounts receivable - related party | 10,967 | (197,334) | 463,504 | (1,299,818) |
Inventory | 934,400 | 246,664 | (89,582) | 393,154 |
Prepaid expenses and other current assets | (141,119) | 1,088,881 | (3,109,941) | (3,332,839) |
Prepaid expenses and other current assets - related party | (55,657) | 2,800,862 | ||
Loan receivable | (2,663,676) | 0 | ||
Other assets | (157,915) | 23,294 | (131,700) | |
Net income (loss) | 203,347 | (2,173,903) | (7,961,649) | 820,786 |
Accounts payable and accrued expenses | 300,913 | 847,525 | 3,199,770 | 3,448,613 |
Accounts payable and accrued expenses - related party | 624,349 | (240,189) | ||
Accrued interest | 20,356 | 438,149 | 292,392 | 654,297 |
Lease liabilities | (54,241) | (36,772) | (231,900) | (217,210) |
Taxes payable | (107,462) | 622,047 | 584,507 | |
Other current liabilities | (23,438) | 122,081 | 1,005,685 | (56,776) |
Other liabilities | (17,911) | (20,958) | (124,247) | (59,460) |
Interest on finance leases | 3,507 | 4,453 | 11,576 | 13,759 |
NET CASH USED IN OPERATING ACTIVITIES | (2,337,276) | (665,339) | (7,097,174) | (11,501,718) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
Proceeds from loan receivable | 91,661 | 63,699 | 0 | |
Purchase of property and equipment | (4,438) | (2,310) | (581,398) | (117,744) |
Gain on extinguishment of debt | 1,004,124 | 445,636 | (606,667) | (942,029) |
Purchase of licenses | (309,118) | 0 | ||
Change in fair value of the derivative liability | (15,001) | (61,373) | 193,513 | (4,158) |
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 87,223 | (2,310) | (826,817) | (117,744) |
(Gain) loss on change in fair value of equity investments | (1,678) | 440 | ||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
Payment of convertible note payable | (180,000) | (907,000) | (593,000) | |
Accounts receivable | 226,934 | 729,802 | 6,256,072 | 14,514,183 |
Proceeds from convertible note payable | 100,000 | 600,000 | 497,000 | |
Accounts receivable - related party | 10,967 | (197,334) | 463,504 | (1,299,818) |
Payment of related party loan | (22,432) | (65,761) | (996,136) | |
Inventory | 934,400 | 246,664 | (89,582) | 393,154 |
Payment of note payable | (2,263,471) | (512,561) | (5,230,725) | |
Prepaid expenses and other assets | (141,119) | 1,088,881 | (3,109,941) | (3,332,839) |
Prepaid expenses and other current assets - related party | (1,183,403) | (196,436) | ||
Proceeds from note payable | 591,500 | 16,556,710 | ||
Payment of related party loan | (139,594) | (149,695) | ||
Other assets | (157,915) | 23,294 | (131,700) | |
Proceeds from related party loan | 460,034 | 398,457 | 7,424,164 | 721,723 |
Payment of lines of credit | (6,244,162) | (6,219,899) | (24,006,784) | (18,428,823) |
Accounts payable and accrued expenses - related party | (370,694) | 25,996 | ||
Proceeds from lines of credit | 5,779,114 | 6,123,067 | 24,437,020 | 20,369,291 |
Payments of finance lease liability | (22,622) | (25,746) | (92,105) | (85,804) |
Purchase of treasury stock | (376,863) | (200,000) | ||
Proceeds from sale of treasury stock | 250,000 | 0 | ||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,914,441 | 380,118 | 7,267,777 | 12,460,541 |
Effect of exchange rate changes on cash | 314,306 | (251,221) | ||
NET CASH USED IN OPERATING ACTIVITIES | (2,337,276) | (665,339) | (7,097,174) | (11,501,718) |
NET CHANGE IN CASH | 723,940 | (196,588) | (341,908) | 589,858 |
CASH AT BEGINNING OF PERIOD | 286,487 | 628,395 | 628,395 | 38,537 |
CASH AT END OF PERIOD | 1,010,427 | 431,807 | 286,487 | 628,395 |
Supplemental Disclosure of Cash Flow Information | ||||
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 87,223 | (2,310) | (826,817) | (117,744) |
Cash paid during the period: | ||||
Interest | 281,889 | 208,565 | 2,059,305 | 955,376 |
Income tax | 0 | 14,127 | ||
Supplemental Disclosure of Non-Cash Investing and Financing Activities | ||||
Cancellation of treasury shares | 171,360 | 0 | ||
Discounts related to beneficial conversion features of convertible debentures | 294,000 | 0 | ||
Conversion of convertible notes payable to common stock | 649,711 | 0 | ||
Conversion of notes payable to common stock | 3,878,480 | 807,795 | ||
Conversion of loans payable related party to common stock | 6,600,000 | 0 | ||
Conversion of derivative liability to additional paid-in capital | 284,169 | 0 | ||
Deemed dividend on warrants upon conversion of convertible debt | 7,633,033 | 0 | ||
Proceeds from issuance of Series A Preferred Stock | 5,452,300 | |||
Financing fees | (224,320) | |||
Proceeds from sale of treasury stock | 250,000 | |||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 2,914,441 | 380,118 | 7,267,777 | 12,460,541 |
Effect of exchange rate changes on cash | 59,552 | 90,943 | ||
NET CHANGE IN CASH | 723,940 | (196,588) | $ (341,908) | $ 589,858 |
Conversion of notes payable to common stock | $ 973,420 | $ 2,564,364 | ||
Deemed dividend on warrants upon issuance of Series A preferred stock | 5,788,493 |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 3 Months Ended |
Mar. 31, 2022 | |
BASIS OF PRESENTATION | |
BASIS OF PRESENTATION | NOTE 1 - BASIS OF PRESENTATION The terms “COSM,” “we,” “the Company,” and “us” as used in this report refer to Cosmos Holdings, Inc. The accompanying unaudited condensed consolidated balance sheet as of March 31, 2022 and unaudited condensed consolidated statements of operations and comprehensive income for the three months ended March 31, 2022 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending December 31, 2022, or any other period. These unaudited consolidated financial statements and notes should be read in conjunction with the financial statements for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (“Form 10-K”). The accompanying condensed consolidated balance sheet as of December 31, 2021 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes in the accompanying balance sheet. |
ORGANIZATION, NATURE OF BUSINES
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN | ||
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN | NOTE 2 - ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN The Company is a publicly traded international pharmaceutical company with extensive and established distribution network across the EU through its subsidiaries, Decahedron (UK), SkyPharm (Greece) and Cosmofarm (Greece). We are a diversified and vertically integrated broad line pharmaceutical company with our own proprietary line of branded nutraceuticals. The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009, and on November 14, 2013, we changed our name to Cosmos Holdings, Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and export of nutraceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (“Decahedron”) which is a fully licensed wholesaler of pharmaceutical products, and its primary activity is the distribution, import and export of pharmaceuticals. On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. On December 19, 2018, the Company completed the purchase of all of the capital stock of Cosmofarm Ltd., a pharmaceutical wholesaler based in Athens, Greece. Going Concern The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the three months ended March 31, 2022, the Company had revenue of $13,071,800, net income of $203,347 and net cash used in operations of $2,337,276. Additionally, as of March 31, 2022, the Company had working capital of $11,831,133, an accumulated deficit of $34,142,159, and stockholders’ equity of $5,151,001. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing. The Company has undergone strategic review processes to help find a definitive solution to the Company’s accumulated deficit constraints. Options under consideration in the strategic review process include, but are not limited to, securing new debt, exchange debt to equity, restructuring current debt facilities from short term to long term and taking the proper actions for new fund raising. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund its operations. If the Company is unable to obtain adequate capital, it could be forced to curtail development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by equity and/or debt financing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations. Summary of Significant Accounting Policies Basis of Financial Statement Presentation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Principles of Consolidation Our condensed consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Effects of COVID-19 Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2022, and December 31, 2021, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in Greece and in Bulgaria all of them denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling). Reclassifications to Prior Period Financial Statements and Adjustments Certain reclassifications have been made in the Company’s financial statements of the prior period to conform to the current year presentation. As of December 31, 2021, $7,393 in accumulated depreciation has been reclassified from property and equipment to accumulated amortization of goodwill and intangible assets and $4,772 was reclassified from prepaid expenses and other current assets to marketable securities on the unaudited condensed consolidated balance sheet. For the three months ended March 31, 2021, $531,556 was reclassified from general and administrative expenses to salaries and wages on the unaudited condensed consolidated statements of operations and comprehensive income. Additionally, for the three months ended March 31, 2021, $1,333 was reclassified from customer deposits to other current liabilities on the unaudited condensed consolidated statement of cash flows. These reclassifications have no impact on previously reported net income. Account Receivable, net Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. At March 31, 2022 and December 31, 2021, the Company’s allowance for doubtful accounts was $1,668,893 and $1,702,743, respectively. Tax Receivable The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. The net VAT receivable is recorded in prepaid expense and other current assets on the condensed consolidated balance sheets. As of March 31, 2022 and December 31, 2021, the Company had a VAT net payable balance of $376,656 and $400,616 respectively, recorded in the condensed consolidated balance sheet as accounts payable and accrued expenses. Inventory Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 40 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5-10 years Computers and software 3-5 years Depreciation expense was $84,884 and $71,471 for the three months ended March 31, 2022 and 2021, respectively. Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Goodwill and Intangibles, net The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company 49,697 of goodwill. Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for its pharmaceuticals and nutraceuticals products license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2022, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $8,158 and $8,158 for the three months ended March 31, 2022 and 2021, respectively. Equity Method Investment For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company will record its share in the earnings of the investee and will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. Investments in Equity Securities Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. As of March 31, 2022, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and 16,666 shares which traded at a closing price of $0.41 per share or value of $6,822 of National Bank of Greece. Additionally, the Company has $5,729 in equity securities of Pancreta Bank, which are revalued annually. See Note 3, for additional investments in equity securities. Fair Value Measurement The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following tables presents assets that are measured and recognized at fair value as of March 31, 2022 and December 31, 2021, on a recurring basis: M arch 31, 2022 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - $ - - $ - Marketable securities - National Bank of Greece 6,822 - - 6,822 Equity securities - Pancreta Bank - 5,729 - 5,729 $ 6,822 $ 5,729 $ 12,551 December 31, 2021 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - $ - - $ - Marketable securities - National Bank of Greece 6,696 - - 6,696 Equity securities - Pancreta Bank - 4,772 - 4,772 $ 6,696 $ 4,772 $ 11,468 In addition, FASB ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Derivative Instruments Derivative financial instruments are recorded in the accompanying condensed consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s consolidated statements of operations. Customer Advances The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues. Revenue Recognition In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon transfer of the product to the customer. Stock-based Compensation The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.” Foreign Currency Translation and Transactions Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and amounts included in the accompanying condensed statements of operations and comprehensive income (loss) are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ deficit until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in comprehensive income (loss). Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the Company undergoes an annual certified audit each year in lieu of an audit by the Greek tax authorities, the Company has not taken any tax positions that warrant accrual under ASC-740-10. Retirement and Termination Benefits Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. Basic and Diluted Net Loss per Common Share Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding. Three Months Ended M arch 31, 2022 2021 Weighted average number of common shares outstanding-Basic 17,755,516 15,034,219 Potentially dilutive common stock equivalents - - Weighted average number of common and equivalent shares outstanding - Diluted 17,755,516 15,034,219 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. Recent Accounting Pronouncements On October 2021, the Financial Accounting Standards Board (“FASB”) issued accounting standards update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, Business Combinations. The new guidance should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022 and include interim periods. The guidance is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effects of the adoption of ASU No. 2021-08 on its consolidated financial statements. In May 2021, the FASB issued ASU 2021-04-Earnings Per Share (Topic 260), Debt- Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU are effective for public and nonpublic entities for fiscal years beginning after December 15, 2021, and interim periods with fiscal years beginning after December 15, 2021. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the effects of the adoption of ASU No. 2021-04 on its consolidated financial statements. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements. | NOTE 1 - ORGANIZATION AND NATURE OF BUSINESS Cosmos Holdings Inc. (“us”, “we”, or the “Company”) is an international pharmaceutical company publicly traded with extensive and established distribution network across the EU through its subsidiaries, Decahedron (UK), Skypharm (Greece) and Cosmofarm (Greece). We are a diversified and vertically integrated broad line pharmaceutical company with our own proprietary line of branded nutraceuticals. The Company was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009, and on November 14, 2013, we changed our name to Cosmos Holdings, Inc. Through its acquisition of Amplerissimo Ltd, on September 27, 2013, the Company changed its principal activities into trading of products, providing representation, and provision of consulting services to various sectors. On August 1, 2014, the Company formed SkyPharm S.A., a Greek Company (“SkyPharm”), a subsidiary that focuses on the trading, sourcing and distribution of pharmaceutical products. In February 2017, the Company acquired Decahedron Ltd., a UK Company (“Decahedron”) which is a fully licensed wholesaler of pharmaceutical products, and its primary activity is the distribution, import and export of pharmaceuticals. On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, and warrants including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. On December 19, 2018, the Company completed the purchase of all of the capital stock of Cosmofarm Ltd., a pharmaceutical wholesaler based in Athens, Greece. Going Concern The Company’s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the year ended December 31, 2021, the Company had revenue of $56,239,667, net loss of $7,961,649 and net cash used in operations of $7,097,174. Additionally, as of December 31, 2021, the Company had working capital of $10,950,492, an accumulated deficit of $34,345,506, and stockholders’ equity of $4,379,463. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing. The Company has undergone strategic review processes to help find a definitive solution to the Company’s accumulated deficit constraints. Options under consideration in the strategic review process include, but are not limited to, securing new debt, exchange debt to equity, restructuring current debt facilities from short term to long term and taking the proper actions for new fund raising. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund its operations. If the Company is unable to obtain adequate capital, it could be forced to curtail development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by equity and/or debt financing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations. Summary of Significant Accounting Policies Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated. Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The Effects of COVID-19 Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. Foreign Currency Translation and Other Comprehensive Income (Loss) The functional currency of the Company’s subsidiaries is the Euro and British Pound. For financial reporting purposes, both the Euro (“EUR”) and British Pound (“GBP”) have been translated into United States dollars ($) and/or (“USD”) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss)”. Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive loss as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of EUR or GBP to USD after the balance sheet date. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. As of December 31, 2021 and 2020, the exchange rates used to translate amounts in Euros into USD and British Pounds into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2021 December 31, 2020 Exchange rate on balance sheet dates EUR: USD exchange rate 1.1318 1.2230 GBP: USD exchange rate 1.3500 1.3662 Average exchange rate for the period EUR: USD exchange rate 1.1830 1.1410 GBP: USD exchange rate 1.3764 1.2829 Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2021 and December 31, 2020, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in Greece and in Bulgaria all of which are denominated in Euros. Additionally, the Company maintains a bank account in the United Kingdom denominated in British Pounds. As of December 31, 2021, the amounts in these accounts were $144,489, $101,589 and $4,061. As of December 31, 2020, the amounts in these accounts were $448,659, $134,935 and $1,651. Additionally, as of December 31, 2021 and 2020, the Company had cash on hand in the amount of $25,773 and $31,604, respectively. Reclassifications to Prior Period Financial Statements and Adjustments Certain reclassifications have been made in the Company’s financial statements of the prior period to conform to the current year presentation. $22,340 in customer deposits as of December 31, 2020, has been reclassified to other current liabilities and $502,869 was reclassified from lines of credit to lines of credit - long-term portion on the consolidated balance sheet. For the year ending December 31, 2020, $2,082,453 was reclassified from general and administrative expenses to salaries and wages on the consolidated statements of operations and comprehensive income. For the year ended December 31, 2020, 230,505 was reclassified from customer deposits to other current liabilities and $96,237 in bad debt expenses was reclassified from accounts receivable on the consolidated statement of cash flows. These reclassifications have no impact on previously reported net income. Accounts Receivable, net Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. At December 31, 2021 and 2020, the Company’s allowance for doubtful accounts was $1,702,743 and $715,845, respectively. Tax Receivables The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. The net VAT receivable is recorded in prepaid expense and other current assets on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company had a VAT net payable balance of $400,616 and $159,198 respectively, recorded in the consolidated balance sheet as accounts payable and accrued expenses. Inventory Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. Property and Equipment, net Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 40 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5-10 years Computers and software 3-5 years Depreciation expense was $319,337 and 240,886 for the years ended December 31, 2021 and 2020, respectively. Impairment of Long-Lived Assets In accordance with ASC 360-10, long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. For the years ended December 31, 2021 and 2020, the Company had no impairment of long-lived assets. Goodwill and Intangibles, net The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill. Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of December 31, 2021, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $33,085 and $33,176 for the years ended December 31, 2021 and 2020, respectively. Equity Method Investment For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in “Equity earnings of affiliate” in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. Investments in Equity Securities Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. As of December 31, 2021, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp., 16,666 shares which traded at a closing price of 0.40 per share or value of 6,696 of National Bank of Greece. Additionally, the Company has $4,416 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. As of December 31, 2020, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp., 40,000 shares which traded at a closing price of $5.45 per share, or value of $218,183 of Diversa S.A. and 16,666 shares which traded at a closing price of $0.28 per share or value of $4,609 of National Bank of Greece. Additionally, the Company had $4,772 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. See Note 2, for additional investments in equity securities. Fair Value Measurement The Company applies FASB ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following table presents assets that are measured and recognized at fair value as of December 31, 2021 and 2020, on a recurring basis: December 31, 2021 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - - - $ - Marketable securities - Diversa S.A. - - - - Marketable securities - National Bank of Greece 6,696 - - 6,696 $ 6,696 $ 6,696 December 31, 2020 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - - - $ - Marketable securities - Diversa S.A. 218,183 - - 218,183 Marketable securities - National Bank of Greece 4,609 - - 4,609 $ 222,792 $ 222,792 In addition, FASB ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Derivative Instruments Derivative financial instruments are recorded in the accompanying consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s consolidated statements of operations. Customer Advances The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues. Revenue Recognition In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon delivery of the product. Stock-based Compensation The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.” Foreign Currency Translations and Transactions Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net earnings. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company’s clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2021 2020 Number of 10% clients 1 1 Percentage of total revenue 15.33 % 14.82 % Percentage of total AR 35.08 % 14.65 % Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the Company undergoes an annual certified audit each year in lieu of an audit by the Greek tax authorities, the Company has not taken any tax positions that warrant accrual under ASC-740-10. Retirement and Termination Benefits Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgements related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of December 31, 2021 and December 31, 2020, was $0 and $107,167, respectively, and has been recorded as a long-term liability within the consolidated balance sheets. Basic and Diluted Net Income (Loss) per Common Share Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding. Years Ended December 31, 2021 2020 Weighted average number of common shares outstanding Basic 16,423,335 13,270,097 Potentially dilutive common stock equivalents - 37,698 Weighted average number of common and equivalent shares outstanding - Diluted 16,423,335 13,307,795 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. Recent Accounting Pronouncements October 2021, the Financial Accounting Standards Board (“FASB”) issued accounting standards update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, Business Combinations. The new guidance should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022 and include interim periods. The guidance is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effects of the adoption of ASU No. 2021-08 on its consolidated financial statements. In May 2021, the FASB issued ASU 2021-04-Earnings Per Share (Topic 260), Debt- Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU are effective for public and nonpu |
MARKETABLE SECURITIES
MARKETABLE SECURITIES | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
MARKETABLE SECURITIES | ||
MARKETABLE SECURITIES | NOTE 3 - MARKETABLE SECURITIES Distribution and Equity Agreement On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement (the “Distribution and Equity Acquisition Agreement”) with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intends to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market. The Distribution and Equity Acquisition Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. The transaction closed on May 22, 2018 after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD 13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors. Since Marathon was a newly formed entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described below, the Company exchanged the Marathon shares in May and July 2018. Share Exchange Agreements On May 17, 2018, the Company entered into a Share Exchange Agreement (the “SEA”) with Marathon, ICC International Cannabis Corp (“ICC”) formerly known as Kaneh Bosm Biotechnology Inc. (“KBB”) and certain other sellers of Marathon capital stock. Under the SEA, the Company transferred 2.5 million shares in Marathon to ICC, a corporation incorporated under the laws of the Province of British Columbia and a public reporting issuer on the Canadian Securities Exchange, in exchange for 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $1,953,000 in the year ended December 31, 2018. On July 16, 2018, the Company completed a Share Exchange Agreement (the “New SEA”) with Marathon, ICC, and certain other sellers of Marathon capital stock whereby the Company transferred its remaining one-half interest (2.5 million shares) in Marathon to KBB for an additional 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of 2,092,200 in the year ended December 31, 2018. The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC. The Company determined the fair value of both exchanges based on an actively quoted stock price of ICC received in exchange for the Marathon shares. The Company continues to fair value its investment in ICC with changes recognized in earnings each period and was recorded as an unrealized gain on exchange of investment during the six months ended March 31, 2022 of $0. The value of the investments as of March 31, 2022 and December 31, 2021, was $0 and $0, respectively. Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement, if certain milestones are achieved. Refer to Note 12 for the accounting associated with the cash of CAD $2 million received upfront. Variable consideration to be received in the future upon achieving the gross sales milestones described above, is constrained as the Company estimates that it is probable that a significant reversal of revenue could occur. In assessing the constraint, the Company considered its limited experience with the Products, new geographic markets and similar transactions, which affect the Company’s ability to estimate the likelihood of a probable revenue reversal. Therefore, no revenue has been recognized for the period ended March 31, 2022. The Company will continue to reassess variable consideration at each reporting period and update the transaction price when it becomes probable that a significant revenue reversal would not occur. As of March 31, 2022, in addition to the 3,000,000 ICC shares valued at $0, as noted above, marketable securities also consisted of the following: 16,666 shares which traded at a closing price of 0.41 per share or value of $6,822 of National Bank of Greece. Additionally, the Company has $5,729 in equity securities of Pancreta Bank, which are revalued annually. The Company recorded a net unrealized gain on the fair value of these investments of $1,678 during the three months ended March 31, 2022. CosmoFarmacy LP In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 which was later increased to EUR 500,000. The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of March 31, 2022 and December 31, 2021 was $166,395 and $169,770, respectively, and is included in “Other assets” in the accompanying condensed consolidated balance sheet. | NOTE 2 -MARKETABLE SECURITIES Distribution and Equity Agreement On March 19, 2018, the Company entered into a Distribution and Equity Acquisition Agreement (the “Distribution and Equity Acquisition Agreement”) with Marathon Global Inc. (“Marathon”), a company incorporated in the Province of Ontario, Canada. Marathon was formed to be a global supplier of cannabis, cannabidiol (CBD) and/or any cannabis extract products, extracts, ancillaries and derivatives (collectively, the “Products”). The Company was appointed the exclusive distributor of the Products initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. The Company has no present intention to distribute any Products under this Agreement in the United States or otherwise participate in cannabis operations in the United States. The Company intends to await further clarification from the U.S. Government on cannabis regulation prior to determining whether to enter the domestic market. The Distribution and Equity Acquisition Agreement is to remain in effect indefinitely unless Marathon fails to provide Market Competitive (as defined) product pricing and Marathon has not become profitable within five (5) years of the agreement. The transaction closed on May 22, 2018, after the due diligence period, following which the Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. The Company was also given the right to nominate one director to the Marathon board of directors. Marathon is an entity with no assets and no activity, the Company attributed no value to the 5 million shares in Marathon which was received as consideration for the distribution services. As described below, the Company exchanged the Marathon shares in May and July 2018. Share Exchange Agreements On May 17, 2018, the Company entered into a Share Exchange Agreement (the “SEA”) with Marathon, ICC International Cannabis Corp (“ICC”) formerly known as Kaneh Bosm Biotechnology Inc. (“KBB”) and certain other sellers of Marathon capital stock. Under the SEA, the Company transferred 2.5 million shares in Marathon to ICC, a Company incorporated under the laws of the Province of British Columbia and a public reporting issuer on the Canadian Securities Exchange, in exchange for 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $1,953,000 included in “Gains on exchange of equity investments” in the consolidated statements of operations. On July 16, 2018, the Company completed a Share Exchange Agreement (the “New SEA”) with Marathon, ICC, and certain other sellers of Marathon capital stock whereby the Company transferred its remaining one-half interest (2.5 million shares) in Marathon to KBB for an additional 5 million shares of ICC. The Company accounted for the exchange at fair value and recognized a gain on exchange of its investment in Marathon of $2,092,200 in the year ended December 31, 2018. The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC. The Company determined the fair value of both exchanges based on an actively quoted stock price of ICC received in exchange for the Marathon shares. The Company continues to fair value its investment in ICC with changes recognized in earnings each period and was recorded as an unrealized gain on exchange of investment during the year ended December 31, 2021 of $0. The value of the investments as of December 31, 2021 and December 31, 2020, was $0 and $0, respectively. Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement, if certain milestones are achieved. Refer to Note 11 for the accounting associated with the cash of CAD $2 million received upfront. Variable consideration to be received in the future upon achieving the gross sales milestones described above, is constrained as the Company estimates that it is probable that a significant reversal of revenue could occur. In assessing the constraint, the Company considered its limited experience with the Products, new geographic markets and similar transactions, which affect the Company’s ability to estimate the likelihood of a probable revenue reversal. Therefore, no revenue has been recognized for the years ended December 31, 2021 and 2020. The Company will continue to reassess variable consideration at each reporting period and update the transaction price when it becomes probable that a significant revenue reversal would not occur. As of December 31, 2020, in addition to the 3,000,000 ICC shares valued at $0, as noted above, marketable securities also consisted of the following: 40,000 shares which traded at a closing price of $5.45 per share, or value of 218,183 of Diversa S.A. and 16,666 shares which traded at a closing price of $0.28 per share or value of $4,609 of National Bank of Greece. The Company recorded a net unrealized loss on the fair value of these investments of 2,246 during the year ended December 31, 2020. As of December 31, 2021, in addition to the 3,000,000 ICC shares valued at $0, as noted above, marketable securities also consisted of the following: 16,666 shares, which traded at a closing price of $0.40 per share or value of $6,696, of National Bank of Greece. The Company recorded a net unrealized gain on the fair value of these investments of $2,541 during the year ended December 31, 2021 and a realized loss of $211,047 related to the write off of the Diversa S.A. shares that were delisted. CosmoFarmacy LP In September 2019, the Company entered into an agreement with an unaffiliated third party to incorporate CosmoFarmacy L.P. for the purpose of providing strategic management consulting services and the retail trade of pharmaceutical products, and OTC to pharmacies. CosmoFarmacy was incorporated with a 30-year term through May 31, 2049. The unaffiliated third party is the general partner (the “GP”) of the limited partnership and is responsible for management and decision-making associated with CosmoFarmacy. The initial share capital was set to EUR 150,000 which was later increased to EUR 500,000. The GP contributed the pharmacy license (the “License”) valued at EUR 350,000 (30-year term) to operate the business of CosmoFarmacy in exchange for a 70% equity ownership. The Company is a limited partner and contributed cash of EUR 150,000 for the remaining 30% equity ownership. CosmoFarmacy is not publicly traded, and the Company’s investment has been recorded using the equity method of accounting. The value of the investment as of December 31, 2021 and 2020, was $169,770 and 183,450, respectively, and is included in “Other assets” on the Company’s consolidated balance sheet. |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
PROPERTY AND EQUIPMENT | ||
PROPERTY AND EQUIPMENT | NOTE 4 - PROPERTY AND EQUIPMENT Property and equipment consists of the following: M arch 31, 2022 December 31, 2021 Leasehold improvements $ 508,920 $ 519,278 Vehicles 94,735 96,657 Furniture, fixtures and equipment 2,027,470 2,065,100 Computers and software 140,452 141,490 2,771,577 2,822,525 Less: Accumulated depreciation and amortization (993,688 ) (934,473 ) Total $ 1,777,889 $ 1,888,052 | NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment, net consists of the following at December 31,: 2021 2020 Leasehold improvements $ 519,278 $ 560,711 Vehicles 96,657 105,057 Furniture, fixtures and equipment 2,065,100 1,632,654 Computers and software 141,490 149,005 2,822,525 2,447,427 Less: Accumulated depreciation and amortization (941,866 ) (690,214 ) Total $ 1,880,659 $ 1,757,213 |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
GOODWILL AND INTANGIBLE ASSETS | ||
GOODWILL AND INTANGIBLE ASSETS | NOTE 5 - GOODWILL AND INTANGIBLE ASSETS Intangible assets consist of the following at: M arch 31, 2022 December 31, 2021 License $ 339,860 $ 345,739 Trade name / mark 36,997 36,997 Customer base 176,793 176,793 553,650 559,529 Less: Accumulated amortization (138,717 ) (123,459 ) Subtotal 414,933 436,070 Goodwill 49,697 49,697 Total $ 464,630 $ 485,767 | NOTE 4 - GOODWILL AND INTANGIBLE ASSETS Goodwill and intangible, net assets consist of the following at December 31,: 2021 2020 License $ 345,739 $ 50,000 Trade name /mark 36,997 36,997 Customer base 176,793 176,793 559,529 263,790 Less: Accumulated amortization (116,066 ) (82,981 ) Subtotal 443,463 180,809 Goodwill 49,697 49,697 Total $ 493,160 $ 230,506 |
LOAN RECEIVABLE
LOAN RECEIVABLE | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
LOAN RECEIVABLE | ||
LOAN RECEIVABLE | NOTE 6 - LOAN RECEIVABLE On October 30, 2021, the Company entered into an agreement for a ten-year loan with a third-party to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. As of December 31, 2021, the Company had a short-term receivable balance of 377,590 and a long-term receivable balance of $4,410,689 under this loan. During the three months ended March 31, 2022, the Company received €81,696 ($90,626) in principal payments such that as of March 31, 2022, the Company had a short-term receivable balance of $375,195 and a long-term receivable balance of $4,227,268 under this loan. | NOTE 5 - LOAN RECEIVABLE On October 30, 2021, the Company entered into an agreement for a ten-year loan with a third-party to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made. Interest is calculated at a rate of 5.5% per annum on a 360-day basis. Under the terms of the agreement, the Company is to receive 120 equal payments over the term of the loan. During the year ended December 31, 2021, the Company received €53,845 ($60,942) in principal payments. As of December 31, 2021, the Company has a short-term receivable balance of $377,590 and a long-term receivable balance of $4,410,689 under this loan. |
CAPITAL STRUCTURE
CAPITAL STRUCTURE | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
CAPITAL STRUCTURE | ||
CAPITAL STRUCTURE | NOTE 8 - CAPITAL STRUCTURE Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, of which 6,000,000 are designated as Series A convertible preferred stock. The preferred stock has liquidation preference over the common stock and are non-voting. As of March 31, 2022 and December 31, 2021, 6,000 and 0, respectively, preferred shares have been issued. On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada. The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series by resolution. The Series A Preferred Stock is convertible into the Company’s Common Stock as determined by dividing the number of shares of Series A Preferred Stock to be converted by the lower of (i) $4.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five (5) days prior to the date of Uplisting, subject to a floor of $3.00 (the “Conversion Price”). The holders of the Series A Preferred Stock are not entitled to receive distributions in the event of liquidation, dissolution or winding up of the Company, either voluntary or involuntary. On February 28, 2022, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain investors and an insider for a private placement of the Company’s securities (the “Private Placement”). The Private Placement consisted of the sale of 6,000 shares of the Company’s Series A Convertible Preferred Stock, or the Series A Shares, at a price of $1.000 per share, and 2,000,000 warrants to purchase shares of common stock, or the Warrants, for aggregate gross proceeds of approximately $6 million. The Warrants are exercisable to purchase shares of common stock at $3.30 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants. The Company determined that the 2,000,000 warrants are additional value being distributed to the preferred stockholders and presented the warrants’ fair value of $5,788,493 as a deemed dividend in the unaudited condensed consolidated statements of operations and comprehensive income (loss). The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $3.30, b) common stock fair value of $3.42, c) volatility of 118%, d) discount rate of $1.71%, and e) dividend rate of 0%. The closing of the Private Placement occurred on February 28, 2022. As a condition to the closing of the sale, the Company’s common stock received conditional approval for listing and trading on the Nasdaq Capital Market and commenced trading on February 28, 2022, under the trading symbol, COSM. Concurrent with the issuance of the Series A Shares, the Company executed a registration rights agreement (the “Registration Rights Agreement”) to register the resale of the shares of common stock issuable upon conversion of the Series A Shares and the shares of common stock issuable upon exercise of the warrants issued in connection with the Series A Shares. The Company is required to file its initial registration statement within 45 days following February 28, 2022. The Effectiveness Date is required to be 60 days after February 28, 2022, or 75 days following the SEC’s full review, and any additional registration statements that may be required are to be filed within 20 days following the date required by the SEC. If the Company fails to timely file its initial registration statement, or any additional registration statement, or otherwise comply with the requirements of the Registration Rights Agreement, the Company shall pay each holder 2% of the subscription amount in cash until cured, with an additional penalty of 18% if the cash payment is not made within seven days of the cash payable date. The Series A Shares rank senior to all of the Company’s Common Stock and any other equity securities that the Company may issue in the future with respect to payment of dividends and distribution of assets upon liquidation, dissolution or winding up. While the Series A Shares are outstanding, the Company may not amend, alter or change adversely the powers, preferences or rights given to the Series A Shares, create, or authorize the creation of, any additional class or series of capital stock of the Company (or any security convertible into or exercisable for any class or series of capital stock of the Company), including any class or series of capital stock of the Company that ranks superior to or in parity with the Series A Shares, alter, amend, modify, or repeal its Articles of Incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series A Shares, increase or decrease the number of authorized shares of Series A Shares, any agreement, commitment or transaction that would result in a Change of Control, any sale or disposition of any material assets outside of the ordinary course of business of the Company, any material change in the principal business of the Company, including the entry into any new line of business or exit of any current line of business, and circumvent a right or preference of the Series A Shares. Any holder of the Series A Shares shall have the right by written election to the Company to convert all or any portion of the outstanding Series A Preferred Shares. Immediately upon effectiveness of a registration statement registering for resale all of the Registrable Securities (as defined in the Registration Rights Agreement), all outstanding Series A Preferred Shares shall automatically convert into Common Stock, subject to certain beneficial ownership limitations. Mezzanine Equity The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 at its initial net carrying value in the amount of $5,452,300. The Series A Shares are recorded as mezzanine equity in accordance with ASC 480 because the Company may be obligated to issue a variable number of shares at a fixed price known at inception and there is no maximum number of shares that could potentially be issued upon conversion. In this instance, cash settlement would be presumed and the Series A Shares are classified as mezzanine equity in accordance with ASC 480-10-S99. Immediately upon effectiveness of the registration statement registering for resale of all the common stock issuable under the Series A Shares, all outstanding Series A Shares shall automatically convert into common stock. Common Stock The Company is authorized to issue 300 million shares of common stock. As of March 31, 2022 and December 31, 2021, the Company had 18,611,980 and 17,544,509 shares of our common stock issued, respectively, and 18,224,556 and 17,157,085 shares outstanding, respectively. Consulting Agreement The Company entered into a Consulting Agreement (the “Agreement”) effective as of February 5, 2021, with a non-affiliated consultant (the “Consultant”). The Company engaged the Consultant to perform consulting services relating to Company management, debt structure, business plans and business development in connection with any capitalization transactions involving the Company and any newly created or existing entities. The Agreement is for a term of nine (9) months with an initial term of ninety (90) days (the “Initial Term”). The Agreement is terminable by the Company for any reason upon written notice at any time after the Initial Term. The Company agreed to pay Consultant and its assignees an aggregate of 1,800,000 restricted shares of Common Stock, earned at the rate of 200,000 shares per month, which shall be issued and fully paid for in consideration of the Consultant’s considerable expertise and experience and its commitment to work for the Company. However, in the event the Agreement is terminated for any reason after the Initial Term, the shares are subject to a claw back for any months remaining after the Termination Date. The shares were valued on the date of the agreement at $3.28 per share or $5,904,000, which was be amortized over the term of the agreement. As of March 31, 2022 and 2021, the Company has expensed $0 and $1,189,451 under the agreement. Debt Exchange Agreements As of February 5, 2021, The Company entered into an Amended and Restated Debt Exchange Agreement (the “Agreement”) with the “Lender that provided for the issuance by the Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company (See Note 11). The market price at the time this Agreement was negotiated was $3.28 per share and the Company recorded a gain on debt extinguishment of $445,636 during the three months ended March 31, 2021. As of March 31, 2021, the Company recorded $2,564,363 as an equity increase related to the extinguishment of debt. Debt Conversions During the three months ended March 31, 2022, the Company issued 238,000 shares of common stock upon the conversion of $1,190,000 of notes payable. The Company recorded $973,420 as a capital contribution and an increase in equity related to the conversion of the $1,190,000 reduced by $216,580 recorded as a gain upon extinguishment of debt upon modification. The $216,580 gain upon extinguishment was determined using the fair value of the Company of $4.09 per share at the extinguishment commitment date. Exercise of Warrants During the three months ended March 31, 2022, the Company issued 829,471 shares of common stock upon the cashless exercise of 2,748,797 warrant shares. Potentially Dilutive Securities No options warrants or other potentially dilutive securities other than those disclosed above have been issued as of March 31, 2022. | NOTE 6 - CAPITAL STRUCTURE Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, which have liquidation preference over the common stock and are non-voting. As of December 31, 2021, and 2020, no preferred shares have been issued. On and effective October 4, 2021, the Company amended and restated its articles of incorporation (the Amended and Restated Articles”) and filed a certificate of designation (the “COD”) for its Series A Preferred Stock (the “Series A Preferred Stock”) with the State of Nevada. The Amended and Restated Articles allow the Company’s Board of Directors the authority to authorize the issuance of preferred stock from time to time in one or more classes or series by resolution. The Series A Preferred Stock is convertible into the Company’s Common Stock as determined by multiplying the number of shares of Series A Preferred Stock to be converted by the lower of (i) $4.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five (5) days prior to the date of Uplisting, subject to a floor of $3.00 (the “Conversion Price”). The holders of the Series A Preferred Stock are not entitled to receive distributions in the event of liquidation, dissolution or winding up of the Company, either voluntary or involuntary. Common Stock The Company is authorized to issue 300 million shares of common stock. As of December 31, 2021 and 2020, the Company had 17,544,509 and 13,485,128 shares of our common stock issued, respectively, and 17,157,085 and 13,069,800 shares outstanding, respectively. Sale of Treasury Shares On February 5, 2021, the Company entered into a Stock Purchase Agreement (the “February SPA”) with an unaffiliated third-party. The February SPA provides for the Company’s to sell 65,000 shares of the Company’s common stock held in treasury at $3.85 per share or a total of $250,000. Cancellation of Treasury Shares On September 15, 2021, the Company cancelled 57,120 shares of common stock valued at $171,360 that were held in Treasury. Purchase of Treasury Shares On July 31, 2020, the Company entered into a Stock Purchase Agreement (the “July SPA”) with a shareholder. The July SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. During the year ended December 31, 2020, the Company made $40,000 in payments. On August 31, 2020, the Company entered into two Stock Purchase Agreements (the “August SPAs”) with a shareholder. The August SPAs provide for the Company’s purchase of an aggregate total of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. During the year ended December 31, 2020, the Company made $40,000 in payments. On September 30, 2020, the Company entered into a Stock Purchase Agreement (the “September SPA”) with a shareholder. The September SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. During the year ended December 31, 2020, the Company made $40,000 in payments. On October 31, 2020, the Company entered into a Stock Purchase Agreement (the “October SPA”) with a shareholder. The October SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. During the year ended December 31, 2020, the Company made $40,000 in payments. On November 30, 2020, the Company entered into a Stock Purchase Agreement (the “November SPA”) with a shareholder. The November SPA provides for the Company’s purchase of 10,000 shares of the Company’s common stock at $4.00 per share or an aggregate of $40,000. During the year ended December 31, 2020, the Company made $40,000 in payments. On December 29, 2021, the Company entered into a Stock Purchase Agreement (the “December SPA”) with a shareholder. The December SPA provides for the Company’s purchase of 94,216 shares of the Company’s common stock at $4.00 per share or an aggregate of $376,863. Consulting Agreement The Company entered into a Consulting Agreement (the “Agreement”) effective as of February 5, 2021, with a non-affiliated consultant (the “Consultant”). The Company engaged the Consultant to perform consulting services relating to Company management, debt structure, business plans and business development in connection with any capitalization transactions involving the Company and any newly created or existing entities. The Agreement is for a term of nine (9) months with an initial term of ninety (90) days (the “Initial Term”). The Agreement is terminable by the Company for any reason upon written notice at any time after the Initial Term. The Company agreed to pay Consultant and its assignees an aggregate of 1,800,000 restricted shares of Common Stock, earned at the rate of 200,000 shares per month, which shall be issued and fully paid for in consideration of the Consultant’s considerable expertise and experience and its commitment to work for the Company. However, in the event the Agreement is terminated for any reason after the Initial Term, the shares are subject to a claw back for any months remaining after the Termination Date. The shares were valued on the date of the agreement at $3.28 per share or $5,904,000, which was be amortized over the term of the agreement. As of December 31, 2021, the Company has recorded $5,904,000 in stock-based compensation for the 1,800,000 shares earned. Debt Exchange Agreements As of February 5, 2021, The Company entered into an Amended and Restated Debt Exchange Agreement (the “Agreement”) with the “Lender that provided for the issuance by the Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company (See Note 11). The market price at the time this Agreement was negotiated was $3.28 per share and the Company recorded a gain on debt extinguishment of $445,636 during the year ended December 31, 2021. As of December 31, 2021, the Company recorded $2,564,363 as an equity increase related to the extinguishment of debt. On June 23, 2021, the Company entered into a Debt Exchange Agreement (the “June Debt Exchange Agreement”) to exchange various loans with Greg Siokas (See Note 8), in the aggregate principal amount of $3,000,000 (the “Debt”). The Company agreed to issue the Lender shares of common stock of the Company at an exchange rate of $6.00 per share (the “Exchange Shares”) in exchange for the principal amount of Debt of $3,000,000 or 500,000 shares of common stock. On June 23, 2021, the fair value of the Company’s shares of common stock was $5.00 per share. For the year ended December 31, 2021, the Company recorded $3,000,000 as an increase in equity in accordance with ASC 850-10-20 due to the related party relationship and ASC 470-50-40-2, which provides guidance on extinguishments of related party debt. Accordingly, extinguishment transactions between related entities are in essence capital transaction, and no gain is recorded in the consolidated statements of operations for the difference between the fair value of $5.00 per share and the exchange rate of $6.00 per share. On July 13, 2021, the Company entered into a Debt Exchange Agreement (the “July 13 Agreement”) with Grigorios Siokas, the Company’s Chief Executive Officer (See Note 8). The July 13 Agreement provided for the issuance by the Company of 166,667 shares of common stock, at the rate of $6.00 per share, or an aggregate of $1,000,000, in exchange for $1,000,000 of existing loans by Mr. Siokas to the Company. On July 13, 2021, the fair value of the Company’s shares of common stock was $4.03 per share. For the year ended December 31, 2021, the Company recorded $1,000,000 as an increase in equity in accordance with ASC 850-10-20 due to the related party relationship and ASC 470-50-40-2, which provides guidance on extinguishments of related party debt. Accordingly, extinguishment transactions between related entities are in essence capital transaction, and no gain is recorded in the consolidated statements of operations for the difference between the fair value of $4.03 per share and the exchange rate of $6.00 per share. On July 19, 2021, the Company entered into a Debt Exchange Agreement (the “July 19 Agreement”) with Grigorios Siokas, the Company’s Chief Executive Officer (See Note 8). The July 19 Agreement provided for the issuance by the Company of 208,333 shares of common stock, at the rate of $6.00 per share, or an aggregate of $1,250,000, in exchange for $1,250,000 of existing loans by Mr. Siokas to the Company. On July 19, 2021, the fair value of the Company’s shares of common stock was $4.30 per share. For the year ended December 31, 2021, the Company recorded $1,250,000 as an increase in equity in accordance with ASC 850-10-20 due to the related party relationship and ASC 470-50-40-2 which provides guidance on extinguishments of related party debt. Accordingly, extinguishment transactions between related entities are in essence capital transaction, and no gain is recorded in the consolidated statements of operations for the difference between the fair value of $4.30 per share and the exchange rate of $6.00 per share. On August 4, 2021, the Company entered into a Debt Exchange Agreement (the “August 4 Agreement”) with a senior institutional lender (the “Lender”), SkyPharm S.A., a wholly-owned Greek subsidiary of the Company, and Grigorios Siokas, the Company’s Chief Executive Officer, as Guarantor. The parties to the Agreement had entered into a senior loan, as amended, as of June 30, 2020 (the “Loan”) pursuant to which the Loan had been reduced to EUR 2,700,000 ($3,302,100) (the “Debt”). The August 4 Agreement provides for the issuance by the Company of 321,300 shares of common stock (the “Exchange Shares”), at the rate of $5.00 per share, in exchange for the repayment of $1,606,500 (€1,350,000) principal amount effective upon the closing of the Agreement and 238,000 shares at an exchange rate of $5.00 per share, or at market value if the price is above $5.00 per share, upon listing of the Company’s common stock on Nasdaq in exchange for €1,000,000 of the Debt. On August 4, 2021, the fair value of the Company’s shares of common stock was $4.09 per share. For the year ending December 31, 2021, the Company recorded a gain on the settlement of debt in the amount of $292,383 in the consolidated statements of operations for the difference between the fair value of $4.09 per share and the exchange rate of $5.00 per share. As of December 31, 2021, the Company recorded $1,314,117 as an increase in equity related to the extinguishment of debt. On December 8, 2021, the Company entered into a Debt Exchange Agreement (the “December 8 Agreement”) with the Company’s Chief Executive Officer (See Note 8). The December 8 Agreement provided for the issuance by the Company of 125,000 shares of common stock, at the rate of $6.00 per share, or an aggregate of $750,000, in exchange for $750,000 of existing loans by Mr. Siokas to the Company. On December 8, 2021, the fair value of the Company’s shares of common stock was $3.44 per share. For the year ended December 31, 2021, the Company recorded $750,000 as a capital contribution and an increase in equity in accordance with ASC 850-10-20 due to the related party relationship and ASC 470-50-40-2 which provides guidance on extinguishments of related party debt. Accordingly, extinguishment transactions between related entities are in essence capital transaction, and no gain is recorded in the consolidated statements of operations for the difference between the fair value of $3.44 per share and the exchange rate of $6.00 per share. Debt Conversions During the year ended December 31, 2021, the Company issued 213,382 shares of common stock to convert $550,144 of principal and accrued interest in accordance with a convertible promissory note issued to Platinum (as defined in Note 10). The Company recorded $959,025 as a capital contribution and an increase in equity related to the conversion of $550,144 of debt, $284,169 for the reduction of the derivative liability recorded as additional paid-in capital, and $124,711 recorded as a loss on debt extinguishment. Potentially Dilutive Securities No options warrants or other potentially dilutive securities other than those disclosed above have been issued as of December 31, 2021. |
INCOME TAXES
INCOME TAXES | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
INCOME TAXES | ||
INCOME TAXES | NOTE 7 - INCOME TAXES The Company is incorporated in the United States of America and is subject to United States federal taxation. No provisions for income taxes have been made as the Company had no U.S. taxable income for the three months ended March 31, 2022 and 2021. The Company’s Greece subsidiaries are governed by the income tax laws of Greece. The corporate tax rate in Greece is 22% on income reported in the statutory financial statements after appropriate tax adjustments. The Company’s United Kingdom subsidiaries are governed by the income tax laws of the United Kingdom. The corporate tax rate in the United Kingdom is 19% on income reported in the statutory financial statements after appropriate tax adjustments. As of March, 31 2022 and 2021, the Company’s effective tax rate differs from the U.S. federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in in the United States. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. As of March 31, 2022 and December 31, 2021, the Company has maintained a valuation allowance against all net deferred tax assets in the United States only. Foreign valuation allowances were reversed on December 31, 2020. For the three months ended March 31, 2022 and 2021, the Company has recorded a tax benefit (expense) in any jurisdiction where it is subject to income tax, in the amount of ($65,667) and $315,912, respectively, on the condensed consolidated statement of operations and comprehensive income (loss). | NOTE 7 - INCOME TAXES The Company provides for income taxes using an asset and liability approach under which deferred income taxes are provided for based upon enacted tax laws and rates applicable to periods in which the taxes become payable. The domestic and foreign components of income (loss) before (benefit) provision for income taxes were as follows: 12/31/2021 12/31/2020 Domestic $ (8,365,297 ) $ (2,901,276 ) Foreign 517,659 4,099,597 $ (7,847,638 ) $ 1,198,321 The components of the (benefit) provision for income taxes are as follows: 12/31/2021 12/31/2020 Current tax provision Federal $ - $ - State - - Foreign 802,364 555,965 Total current tax provision $ 802,364 $ 555,965 Deferred tax provision Domestic $ - $ - State - - Foreign (688,354 ) (178,430 ) Total deferred tax provision $ (688,354 ) $ (178,430 ) Total current provision $ 114,010 $ 377,535 The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2021 and 2020 is as follows: 12/31/2021 12/31/2020 US Income (loss) before income taxes $ (7,847,639 ) $ 1,198,321 Taxes under statutory US tax rates $ (1,648,004 ) $ 251,647 Increase (decrease) in taxes resulting from: Increase in valuation allowance $ 3,001,899 $ 216,518 Foreign tax rate differential $ (24,977 ) $ (55,540 ) Permanent differences $ (734,428 ) $ (218,216 ) US tax on foreign income $ 493,028 $ 604,419 163(j) catch up (76,888 ) - Prior period adjustments $ 52,034 $ (97,829 ) State taxes $ (948,654 ) $ (323,464 ) Income tax expense $ 114,010 $ 377,535 Companies subject to the Global Intangible Low-Taxed Income provision (GILTI) have the option to account for the GILTI tax as a period cost if and when incurred, or to recognize deferred taxes for outside basis temporary differences expected to reverse as GILTI. We have elected to account for GILTI as a period cost. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities consist of the following: 12/31/2021 12/31/2020 Net operating loss carryforward $ 4,515,900 $ 1,494,424 Capital loss carryforward 801,744 801,744 Section 163(j) carryforward - - Nonqualified stock options 96,104 170,297 Foreign exchange 13,438 - Allowance for doubtful accounts 374,604 - Accrued expenses 528,895 7,389 Mark to market adjustment in securities 358,761 357,829 Lease liability 253,620 247,797 Gain on extinguishment of debt - 179,958 Depreciation (6,765 ) 4,226 Total deferred tax assets 6,936,211 3,263,664 Intangibles (8,139 ) (10,729 ) Inventory (14,728 ) - Right of use asset (243,207 ) (253,818 ) Goodwill (10,979 ) (14,473 ) Total deferred tax liabilities (277,053 ) (279,020 ) Valuation allowance (5,808,384 ) (2,806,214 ) Net deferred tax assets (liabilities) $ 850,774 $ 178,430 At December 31, 2021, the Company had U.S. net operating loss ("NOL") carryforwards of approximately $12,513,177 that may be offset against future taxable income, subject to limitation under IRC Section 382. Of the $12.5 million Federal NOL carryforwards, $2.5 million are pre-2018 and begin to expire in 2031. The remaining balance of $10 million, are limited to utilization of 80% of taxable income but do not have an expiration. At December 31, 2021, the Company had fully utilized all the Greek NOL carryforwards and has an NOL of $546,683 in the UK. A valuation allowance exists for the U.S. operations, but not for the non-U.S. operations, based on a more likely than not criterion and in consideration of all available positive and negative evidence. ASC 740 requires that the tax benefit of net operating losses ("NOLs"), temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is "more likely than not." Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's history of domestic operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance, on our U.S. net domestic deferred tax assets. In 2020, foreign (Greece and United Kingdom) valuation allowances were released, aggregating $200,000. Management considered all available evidence to when evaluating the realizability of foreign deferred tax assets by jurisdiction and concluded primarily based upon a strong earnings history that these deferred tax assets were more-likely-than-not realizable. The Company applied the "more-likely-than-not" recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of December 31, 2021 and December 31, 2020, respectively. We recognize interest accrued related to unrecognized tax benefits and penalties as income tax expense. The Company files income tax returns in Illinois, United States, and in foreign jurisdictions including Greece, and United Kingdom. As of December 31, 2021, all domestic tax years are open to tax authority examination due the availability of net operating loss deductions, 2010 through 2021. In Greece, the statute of limitations is open for five years, 2016 through 2021. In United Kingdom, the statute of limitations is open for four years, 2017 through 2021. Currently, there are no ongoing tax authority income tax examinations. As of December 31, 2021, the Company had $1.7 million of undistributed earnings and profits for which no deferred tax liabilities have been recorded, since the Company intends to indefinitely reinvest such earnings to fund the international operations and certain obligations of the subsidiary. Should the above undistributed earnings be distributed in the form of dividends or otherwise, the distributions would result in $350.3 thousand of tax expense. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
RELATED PARTY TRANSACTIONS | ||
RELATED PARTY TRANSACTIONS | NOTE 9 - RELATED PARTY TRANSACTIONS Doc Pharma S.A. As of March 31, 2022, the Company has a prepaid balance of $4,368,794 and an accounts payable balance of $220,518, resulting in a net prepaid balance of $4,148,276 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of $2,844,572. As of December 31, 2021, the Company has a prepaid balance of $3,263,241 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company had a receivable balance of $2,901,300 and an accounts payable balance of $565,756 During the three months ended March 31, 2022 and 2021, the Company purchased a total of $687,382 and $589,261 of products from Doc Pharma S.A., respectively. During the three months ended March 31, 2022 and 2021 the Company had $383,688 and $290,598, in revenue from Doc Pharma S.A., respectively. On October 10, 2020, the Company entered into a contract manufacturer outsourcing “CMO” agreement with DocPharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and good manufacturing practice (“GMP”) protocols as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium Life ® On May 17, 2021, Doc Pharma and the Company entered into a Research and Development “R&D” agreement whereby Doc Pharma will be responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life ® Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past. Notes Payable - Related Party A summary of the Company’s related party notes payable as of March 31, 2022 and December 31, 2021 is presented below: March 31, 2022 December 31, 2021 Beginning balance $ 464,264 $ 501,675 Foreign currency translation (9,229 ) (37,411 ) Ending balance $ 455,035 $ 464,264 Grigorios Siokas On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum, matured on March 18, 2019 pursuant to the original agreement and was extended until December 31, 2021. The note is not in default and the maturity date has been extended again until December 31, 2023. As of December 31, 2021 the Company had an outstanding balance of €400,000 ($452,720) and accrued interest of €177,313 ($200,683). As of March 31, 2022, the Company has an outstanding balance of €400,000 ($443,720) and accrued interest of €181,948 ($201,835). Grigorios Siokas is the Company’s CEO and principal shareholder. Dimitrios Goulielmos On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of December 31, 2021, the Company had a principal balance of €10,200 ($11,544). A principal balance of €10,200 ($11,315) remained as of March 31, 2022. Dimitrios Goulielmos is a current director and former CEO of the Company. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2022, the Company recorded a gain of $9,229. Loans Payable - Related Party A summary of the Company’s related party loans payable during the three months ended March 31, 2022, and the year ended December 31, 2021 is presented below: March 31, 2022 December 31, 2021 Beginning balance $ 1,293,472 $ 1,629,246 Proceeds 456,085 6,377,156 Payments (22,186 ) (133,552 ) Conversion of debt - (6,000,000 ) Settlement of lawsuit - (600,000 ) Foreign currency translation (23,490 ) 20,623 Ending balance $ 1,703,881 $ 1,293,472 Grigorios Siokas From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2021, the Company had an outstanding principal balance under these loans of $1,293,472 in loans payable to Grigorios Siokas. During the three months ended March 31, 2022, the Company borrowed additional proceeds of €321,000 ($356,085), and $100,000 and repaid €20,000 ($22,186) of these loans. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the three months ended March 31, 2022 the Company recorded a gain of $23,490. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons. | NOTE 8 - RELATED PARTY TRANSACTIONS On the date of our inception, we issued 2 million shares of our common stock to our then three officers and directors which were recorded at no value (offsetting increases and decreases in common stock and additional paid-in capital). Doc Pharma S.A. As of December 31, 2021, the Company has a prepaid balance of $3,263,241 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company has a receivable balance of $2,901,300 and an accounts payable balance of $565,756. As of December 31, 2020, the Company has a prepaid balance of $3,468,653 to Doc Pharma S.A. related to purchases of inventory. Additionally, the Company had a receivable balance of $3,468,564. During the years ended December 31, 2021 and 2020, the Company purchased a total of $3,084,805 and $5,983,809 of products from Doc Pharma S.A., respectively. During the years ended December 31, 2021 and 2020 the Company had $978,321 and $2,843,260 revenue from Doc Pharma S.A., respectively. On October 10, 2020, the Company entered into a contract manufacturer outsourcing (“CMO”) agreement with Doc Pharma whereby Doc Pharma is responsible for the development and manufacturing of pharmaceutical products and nutritional supplements according to the Company’s specifications based on strict pharmaceutical standards and Good Manufacturing Practice (“GMP”) protocols, as the National Organization for Medicines requires. The Company has the exclusive ownership rights for trading and distribution of its own branded nutritional supplements named “Sky Premium Life ® On May 17, 2021, Doc Pharma and the Company entered into a Research and Development (“R&D”) agreement whereby Doc Pharma is responsible for the research, development, design, registration, copy rights and licenses of 250 nutritional supplements for the final products called Sky Premium Life ® Doc Pharma S.A is considered a related party to the Company due to the fact that the CEO of Doc Pharma is the wife of Grigorios Siokas, the Company’s CEO and principal shareholder, who also served as a principal of Doc Pharma S.A. in the past. Notes Payable - Related Party A summary of the Company’s related party notes payable during the years ended December 31, 2021 and 2020 is presented below: 2021 2020 Beginning Balance $ 501,675 $ 1,375,532 Payments - (996,136 ) Foreign currency translation (37,411 ) 122,279 Ending Balance $ 464,264 $ 501,675 Grigorios Siokas On December 20, 2018, the €1,500,000 ($1,718,400) note payable, originally borrowed pursuant to a Loan Agreement with a third-party lender, dated March 16, 2018, was transferred to Grigorios Siokas. The note bears an interest rate of 4.7% per annum and matured on March 18, 2019, pursuant to the original agreement. The note is not in default and the maturity date has been extended until December 31, 2021. As of December 31, 2020, the note had an outstanding principal balance of €400,000 ($489,200) and accrued interest of €158,287 ($193,585). As of December 31, 2021, the Company has an outstanding balance of €400,000 ($452,720) and accrued interest of €177,313 ($200,683). Grigorios Siokas is the Company’s CEO and principal shareholder. Dimitrios Goulielmos On November 21, 2014, the Company entered into an agreement with Dimitrios Goulielmos, as amended on November 4, 2016. Pursuant to the amendment, this loan has no maturity date and is non-interest bearing. As of December 31, 2020, the Company had a principal balance of €10,200 ($12,475). A principal balance of €10,200 ($11,544) remained as of December 31, 2021. Dimitrios Goulielmos is a current director and former CEO of the Company. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the years ended December 31, 2021, and 2020, the Company recorded a foreign currency translation gain of $37,411 and a loss of $122,279, respectively. Loans Payable - Related Party A summary of the Company’s related party loans payable during the years ended December 31, 2021 and 2020 is presented below: 2021 2020 Beginning balance $ 1,629,246 $ 1,026,264 Proceeds 6,377,156 725,563 Payments (133,552 ) (149,695 ) Conversion of debt (6,000,000 ) - Settlement of lawsuit (600,000 ) - Foreign currency translation 20,623 27,114 Ending balance $ 1,293,472 $ 1,629,246 Grigorios Siokas From time to time, Grigorios Siokas loans the Company funds in the form of non-interest bearing, no-term loans. As of December 31, 2020, the Company had an outstanding principal balance under these loans of $1,629,246 in loans payable to Grigorios Siokas. On May 10, 2021, the Company entered into a Debt Exchange agreement (“May Debt Exchange”) related to a lawsuit from on or about July 25, 2019, whereby Mark Rubenstein, individually and as a shareholder of the Company, brought the action styled Rubenstein v. Siokas, et al. During the year ended December 31, 2021, the Company entered into various agreements (as defined in Note 6) with Mr. Siokas whereby the Company exchanged an aggregate total of $6,000,000 of debt into 1,000,000 shares of Common Stock at above market prices. During the year ended December 31, 2021, the Company borrowed additional proceeds of €1,803,000 ($2,040,635), €230,000 ($275,306) and $4,061,215 and repaid €118,000 ($133,552) of these loans. During the year ending December 31, 2021, the Company converted $2,250,000 of the July 20 Note at a conversion price of $6.00 and issued 375,000 shares of common stock. As of December 31, 2021, the Company had an outstanding balance under these notes and loans of $1,293,472. The above balances are adjusted for the foreign currency rate as of the balance sheet date. For the years ended December 31, 2021 and 2020, the Company recorded a loss of $20,623 and $27,114, respectively. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons. |
LINES OF CREDIT
LINES OF CREDIT | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
LINES OF CREDIT | ||
LINES OF CREDIT | NOTE 10 - LINES OF CREDIT A summary of the Company’s lines of credit as of March 31, 2022 and December 31, 2021 is presented below: March 31, 2022 December 31, 2021 National $ 2,887,143 $ 3,265,236 Alpha 927,008 947,333 Pancreta 417,671 489,985 National - COVID 316,377 407,174 Subtotal 4,548,199 5,109,728 Reclassification of National-COVID - Long-term (185,872 ) (366,171 ) Ending balance $ 4,362,327 $ 4,743,557 The line of credit with National Bank of Greece is renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2” facility) and 4.35% (plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit), (“COSME 1” facility). The maximum borrowing allowed for the 6% line of credit was $3,300,168 and $2,489,960 as of March 31, 2022 and December 31, 2021, respectively. The outstanding balance of the facility was $1,833,394 and $2,185,413, as of March 31, 2022 and December 31, 2021, respectively. The maximum borrowing allowed for the 4.35% lines of credit, was $1,109,300 and $1,131,800 as of March 31, 2022 and December 31, 2021, respectively. The outstanding balance of the facilities was $1,053,749 and $1,079,823 as of March 31, 2022 and December 31, 2021, respectively. The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $1,109,300 and $1,131,800 as of March 31, 2022 and December 31, 2021, respectively. The outstanding balance of the facility was $927,008 and $947,333, as of March 31, 2022 and December 31, 2021, respectively. The Company entered into a line of credit with Pancreta Bank on February 23, 2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed as of March 31, 2022 and December 31, 2021 was $554,650 and $565,900, respectively. The outstanding balance of the facility as of March 31, 2022 and December 31, 2021, was $417,671 and $489,985, respectively. Interest expense for the three months ended March 31, 2022 and 2021, was $17,175 and $16,501, respectively. Under the agreements, the Company is required to maintain certain financial ratios and covenants. These lines of credit were assumed in the Company’s acquisition of Cosmofarm. As of March 31, 2022 and December 31, 2021, the Company was in compliance with these ratios and covenants. The above lines of credit are guaranteed and backed by customer receivable checks and they are not considered to be a direct debt obligation for the Company. They are a type of factoring, where the postponed customer checks are assigned by the Company to the bank, in order to be financed at a pre-agreed rate. COVID-19 Government Funding Interest expense for three months ended March 31, 2022 and 2021 was $413 and $0, respectively. | NOTE 9 - LINES OF CREDIT A summary of the Company’s lines of credit as of December 31, 2021, and 2020 is presented below: December 31, 2021 December 31, 2020 National $ 3,265,236 $ 3,540,550 Alpha 947,333 1,106,894 Pancreta 489,985 - National - COVID 407,174 429,240 Subtotal 5,109,728 5,076,684 Reclassification of National-COVID - Long-term (366,171 ) (502,869 ) Ending balance $ 4,743,557 $ 4,573,815 The line of credit with National Bank of Greece is renewed annually with current interest rates of 6.00%, 4.35% (“COSME 2” facility) and 4.35% (plus the 6-month Euribor plus any contributions currently in force by law on certain lines of credit), (“COSME 1” facility). The maximum borrowing allowed for the 6% line of credit was $2,489,960 and $2,690,600 as of December 31, 2021 and 2020, respectively. The outstanding balance of the facility was $2,185,413 and $2,411,182, as of December 31, 2021 and 2020, respectively. The maximum borrowing allowed for the 4.35% lines of credit, was $1,131,800 and $1,223,000 as of December 31, 2021 and 2020, respectively. The outstanding balance of the facilities was $1,079,823 and $1,129,368 as of December 31, 2021 and 2020, respectively. The line of credit with Alpha Bank of Greece is renewed annually with a current interest rate of 6.00%. The maximum borrowing allowed was $1,131,800 and $1,123,000 as of December 31, 2021 and 2020, respectively. The outstanding balance of the facility was $947,333 and $1,106,894, as of December 31, 2021 and 2020, respectively. The Company entered into a line of credit with Pancreta Bank on February 23, 2021. The line of credit is renewed annually with a current interest rate of 6.10%. The maximum borrowing allowed as of December 31, 2021 was $565,900. The outstanding balance of the facility as of December 31, 2021, was $489,985. Interest expense for the year ended December 31, 2021 and 2020, was $283,415 and $270,655, respectively. Under the agreements, the Company is required to maintain certain financial ratios and covenants. These lines of credit were assumed in the Company’s acquisition of Cosmofarm. As of the years ended December 31, 2021 and 2020, the Company was in compliance with these ratios and covenants. The above lines of credit are guaranteed and backed by customer receivable checks and they are not considered to be a direct debt obligation for the Company. They are a type of factoring, where the postponed customer checks are assigned by the Company to the bank, in order to be financed at a pre-agreed rate. COVID-19 Government Funding On June 23, 2020, the Company’s subsidiary, Cosmofarm, entered into an agreement with the “National Bank of Greece SA” (the “Bank”) to borrow a maximum of €500,000 ($611,500) under a proposed plan which will operate the same as the line of credit above. The proposed plan has a maturity date of sixty (60) months from the date of the first disbursement, which includes a grace period of nine months. The total amount of the initial proceeds was paid in 3 equal monthly installments. The line of credit is interest bearing from the date of receipt and is payable every three (3) months at an interest rate of 2.7%. The outstanding balance was €359,758 ($407,174) and €350,973 ($429,240) at December 31, 2021 and 2020, respectively of which $366,171 is classified as Lines of credit - long-term portion on the consolidated balance sheet. Interest expense for the years ended December 31, 2021 and 2020 was $1,753 and $3,910, respectively. |
CONVERTIBLE DEBT
CONVERTIBLE DEBT | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
CONVERTIBLE DEBT | ||
CONVERTIBLE DEBT | NOTE 11 - CONVERTIBLE DEBT A summary of the Company’s convertible debt at March 31, 2022 and December 31, 2021 is presented below: March 31, 2022 December 31, 2021 Beginning balance convertible notes $ 640,000 $ 1,447,000 New notes - 625,000 Payments - (907,000 ) Conversion to common stock - (525,000 ) Subtotal notes 640,000 640,000 Debt discount at year end (191,085 ) (258,938 ) Convertible note payable, net of discount $ 448,915 $ 381,062 All of the convertible debt is classified as short-term within the consolidated balance sheet as it all matures and will be paid back within fiscal year 2022. December 21, 2020 Securities Purchase Agreement On December 21, 2020 (the “Issue Date”), Cosmos Holdings, Inc. (“Cosmos”, the “Borrower” or the “Company”) entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”) pursuant to a Securities Purchase Agreement (the “SPA”). The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) had not been converted or have not been otherwise satisfied in full or (ii) an Event of Default (as defined in the SPA) occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined in the SPA) or (iii), an Event of Default (collectively, the “Maturity Date”). During the year ended December 31, 2021, the Company converted an aggregate total of $525,000 in principal and $25,144 in accrued interest and fees into 213,382 shares of the Company’s common stock at an average price per share of $2.58. Upon conversion, the 213,382 shares were issued at a fair value of $959,024 which was recorded as equity. Accordingly, upon conversion, the Company reduced its outstanding debt by $550,144, reduced its derivative liability by $284,169, and recorded a loss on extinguishment of $124,711. As of March 31, 2022 and December 31, 2021, the Company had a principal balance of $15,000 each period and had accrued approximately $7,000 in interest expense each period. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company determined a beneficial conversion feature and derivative liability exists because The Company measured the beneficial conversion feature’s intrinsic value on December 16, 2020, and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. As of March 31, 2022 and December 31, 2021 and $568,826 and $494,973, respectively, of the debt discount has been amortized. As of March 31, 2022 and December 31, 2021, the fair value of the derivative liability was $3,949 and $5,822, respectively. For the three months ended March 31, 2022 and 2021, the Company record a gain on the change in fair value of the derivative of $1,873 and $44,215, respectively. January 7, 2021 Subscription Agreement On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bears an interest rate of 8% per annum and matures on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or (ii) October 31, 2021. Upon the consummation of a NEO listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 25% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the NEO listing. In the event that a NEO listing is not consummated on or before October 31, 2021, the note holder will have the option, in part or in full, to have the note repaid with interest, or convert the note into Company common stock at a 25% discount to the 30-day volume-weighted average price of the Common Shares on the most senior stock exchange in North American on which the common shares are trading prior to conversion. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on January 7, 2021, and determined that the embedded derivative was valued at $62,619 which was recorded as a debt discount and additional paid-in capital, and is being amortized over the life of the loan. As of March 31, 2022 and December 31, 2021, $62,619 of the debt discount has been amortized. As of March 31, 2022 and December 31, 2021, the fair value of the derivative liability was $26,716 and $39,843, respectively. For the three months ended March 31, 2022, the Company recorded a gain of $13,127 from the change in fair value of derivative liability as other income in the consolidated statements of operations and comprehensive income (loss). Convertible Promissory Note and Securities Purchase Agreement On September 17, 2021 (the “Issue Date”), the Company entered into a convertible promissory note and securities purchase agreement with an unaffiliated third party. Convertible Promissory Note The Company issued the convertible promissory note for a purchase price of $525,000 in principal amount for cash proceeds of $500,000. The note was issued with an original issue discount (“OID”) of $25,000, bears an interest rate of 10% per annum and matures on the earlier of (i) the consummation of the Company listing its common shares on the Nasdaq Stock Market or (ii) September 17, 2022. Upon the consummation of a Nasdaq listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 30% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the Nasdaq listing, subject to a conversion floor of $3.00. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on September 17, 2021, at $294,000 which, together with the OID of $25,000 was recorded as a debt discount and is being amortized over the life of the loan. For the year ended December 31, 2021, $60,063 of the debt discount has been amortized. As of December 31, 2021, the Company had accrued a principal balance of $525,000, had accrued $15,166 in interest expense, and had remaining debt discount of $258,937 which resulted in a net convertible note payable of $266,063. For the three months ended March 31, 2022, $127,916 of the debt discount has been amortized. As of March 31, 2022, the Company had accrued a principal balance of $525,000, had accrued $28,291 in interest expense, and had remaining debt discount of $191,084 which resulted in a net convertible note payable of $333,916. Derivative Liabilities The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the three months ended March 31, 2022: Amount Balance on January 1, 2022 $ 45,665 Issuances to debt discount - Reduction of derivative related to conversions - Change in fair value of derivative liabilities (15,001 ) Balance on March 31, 2022 $ 30,664 The fair value of the derivative conversion features and warrant liabilities as of March 31, 2022 and December 31, 2021 were calculated using a Monte-Carlo option model valued with the following assumptions: March 31, December 31, 2022 2021 Dividend yield 0 % 0 % Expected volatility 87.9 % 106.8%-107.3 % Risk free interest rate 1.40 % 0.41%-0.44 % Contractual terms (in years) 0.50 0.50 - 0.52 | NOTE 10 - CONVERTIBLE DEBT A summary of the Company’s convertible debt during the years ended December 31, 2021 and 2020 is presented below: 2021 2020 Beginning balance convertible notes $ 1,447,000 $ 1,500,000 New notes 625,000 540,000 Payments (907,000 ) (593,000 ) Conversion to common stock (525,000 ) - Subtotal notes 640,000 1,447,000 Debt discount at year end (258,938 ) (494,973 ) Convertible note payable, net of discount $ 381,062 $ 952,027 All of the convertible debt is classified as short-term within the consolidated balance sheet as it all matures and will be paid back within fiscal year 2022. Securities Purchase Agreement executed on May 15, 2019 On May 15, 2019, the Company entered into a Securities Purchase Agreement with an institutional investor (the “Buyer”). Upon the closing of this financing, on May 17, 2019, the Company issued a Senior Convertible Note (the “May 2019 Note”) to the Buyer in the principal amount of $1,500,000. The May 2019 Note provided that the Company will repay the principal amount of the May 2019 Note on or before March 15, 2020. On March 23, 2020, the Company entered into a Forbearance and Amendment Agreement (the “Agreement”) with an institutional investor (the “Buyer”). The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): (September 16, 2020 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date”), (b) during the Forbearance Period waive the prepayment premium to any Company Optional Redemption, and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to September 16, 2020. The Scheduled Required Prepayments are $100,000 upon signing the Agreement and five (5) monthly payments thereafter aggregating $200,000 with all amounts outstanding under the Note due on September 16, 2020. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers and directors and advisors of the Company) or factoring and purchase order indebtedness, the Company shall affect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments. On September 23, 2020, the Company entered into a Second Forbearance and Amendment Agreement (the “Agreement”) with an institutional investor (the “Buyer”). The Note was due to be paid in full on or before September 16, 2020 and was not paid (the “Existing Default”). The Note provides that upon an Event of Default, the Buyer may, among other things, require the Company to redeem all or a portion of the Note at a redemption premium of 120%, multiplied by the product of the conversion rate ($6.00 per share) and the then current market price. The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): June 16, 2021 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date), (b) during the Forbearance Period (as defined) waive the prepayment premium to any Company Optional Redemption (which will result in the 120% redemption premium effectively replaced with 100%), and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to June 16, 2021. The Scheduled Required Prepayments are $63,000 upon signing the Agreement and eight (8) monthly payments thereafter aggregating $480,000 with the remaining $607,000 outstanding under the Note due on June 16, 2021. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers, directors and 10% or greater shareholders of the Company) or factoring and purchase order indebtedness, the Company shall affect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments. On June 18, 2021, the Company modified the terms of its outstanding debt by entering into a Third Forbearance Agreement (the “Third Agreement”) whereby the Company agreed to make certain payments to the creditor and the creditor will accept such payments as full discharge of the outstanding debt. The Agreement provides that the Buyer will (a) forbear (i) from taking any action with respect to the Existing Default and (ii) from issuing any demand for redemption of the Note on the basis of the Existing Default until the earlier of: (1): November 16, 2021 (or, if earlier, such date when all amounts outstanding under the Note shall be paid in full or converted into shares of Common Stock in accordance therewith) and (2) the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date), (b) during the Forbearance Period (as defined) waive the prepayment premium to any Company Optional Redemption (which will result in the 120% redemption premium effectively replaced with 100%), and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to November 16, 2021. The Scheduled Required Prepayments are $62,000 upon the first scheduled required prepayment and five (5) payments thereafter aggregating $287,000 with the remainder outstanding under the Note due on November 16, 2021. In addition, there are mandatory prepayments in the event the Company completes a Subsequent Placement (as defined) or long-term debt (other than from the Buyer or from officers, directors and 10% or greater shareholders of the Company) or factoring and purchase order indebtedness, the Company shall effect a Company Optional Redemption amount equal to 50% of the gross proceeds (less reasonable expenses of counsel and any investment bank) together with all Scheduled Required Payments. The Company performed an analysis to determine if at least a 10% difference between the present value of the new loan’s cash flows and the present value of the old loan’s remaining cash flows and determined that yes there is more than a 10% difference. The Company will experience a cash flow increase of approximately 15% due to the modification; therefore, the cash flow is considered substantially different, and the Company has applied extinguishment accounting. The May 2019 Note is convertible at any time by the Holder into 250,000 shares of common stock, par value $0.001 per share at the rate of $6.00 per share, subject to adjustment (the “Conversion Price”). Upon an Event of Default (regardless of whether such event has been cured), the Buyer may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the then Volume-Weighted Average Price (as defined, the “VWAP”). The Company considered the need for the conversion feature to be bifurcated under ASC 815 and determined that it does not meet the requirements. Additionally, the Company determined the effective conversion rate under ASC 470-20 and determined that the instrument is out of the money and no beneficial conversion feature was recorded. The May 2019 Note is senior in right of payment to all other existing and future indebtedness of the Company except Permitted Senior Indebtedness (as defined in the May 2019 Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions. The May 2019 Note includes customary Events of Default and provides that the Buyer may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Note at a redemption premium equal to the greater of: (i) the product of the redemption premium of one hundred twenty-five (125%) percent, multiplied by the conversion amount, and (ii) the product of the conversion rate ($6.00 per share) multiplied by the product of 125% multiplied by the then current market price. The Buyer may also require redemption of the May 2019 Note upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Company has the right to redeem the May 2019 Note at any time, in whole or in part, in cash at a price equal to 120% of the then outstanding conversion amount. Conversion of the May 2019 Note is subject to a blocker provision which prevents any holder from converting the May 2019 Note into shares of common stock if its beneficial ownership of the common stock would exceed 9.99% of the Company’s issued and outstanding common stock. During the year ended December 31, 2020, the Company repaid $593,000 such that as of December 31, 2020, the Company had a principal balance $907,000 on the May 2019 Note and the Company had accrued $15,420 in interest expense. During the year ended December 31, 2021, the Company repaid all outstanding principal and accrued interest on the May 2019 Note. Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for this transaction equal to six (6%) percent of the total gross proceeds of the offering. This 6% fee or $90,000 was recorded as debt discount along with the $30,000 in legal fees associated with the May 2019 Note. These fees will be amortized over the term of the note. $29,509 was amortized during the year ended December 31, 2020 resulting in the full amortization of the fees. December 21, 2020 Securities Purchase Agreement On December 21, 2020 (the “Issue Date”), Cosmos Holdings, Inc. (“Cosmos”, the “Borrower” or the “Company”) entered into a convertible promissory note with Platinum Point Capital, LLC (the “Holder”, “Lender” or “Platinum”) pursuant to a Securities Purchase Agreement (the “SPA”). The Company issued the $540,000 Note in exchange for $500,000 in cash and included a $40,000 Original Issue Discount (“OID”) and paid $3,000 in financing costs. The principal amount together with interest at the rate of eight percent (8.0%) per annum, compounded annually (the “Interest Rate”), will be paid to the Lenders on or before the Maturity Date (December 31, 2021 or as defined below). Accrued interest shall be calculated on the basis of a 360-day year for the actual number of days elapsed. In the event that on or before the Maturity Date, the Note either (i) had not been converted or have not been otherwise satisfied in full or (ii) an Event of Default (as defined in the SPA) occurs, then the applicable rate of interest on the outstanding amount of the Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined in the SPA) or (iii), an Event of Default (collectively, the “Maturity Date”). On July 14, 2021, August 16, 2021 and December 21, 2021 the Company converted an aggregate total of $525,000 in principal and $25,144 in accrued interest and fees into 213,382 shares of the Company’s common stock at an average price per share of $2.58. As of December 31, 2021, the Company had a principal balance of $15,000 and had accrued $6,568 in interest expense. Upon conversion, the 213,382 shares were issued at a fair value of $959,024 which was recorded as equity. Accordingly, upon conversion, the Company reduced its outstanding debt by $550,144, reduced its derivative liability by $284,169, and recorded a loss on extinguishment of $124,711. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company determined a beneficial conversion feature and derivative liability exists because The Company measured the beneficial conversion feature’s intrinsic value on December 16, 2020, and determined that the embedded derivative was valued at $456,570 which was recorded as a debt discount, and together with the original issue discount and transaction expenses of $43,000, in the aggregate of $499,570, is being amortized over the life of the loan. For the years ended December 31, 2021 and 2020, $494,973 and $4,597, respectively, of the debt discount has been amortized. As of December 31, 2021 and 2020, the fair value of the derivative liability was $5,822 and $460,728, respectively. The Company recorded a decrease in the derivative of $284,169 related to the conversions, which was recorded to additional paid-in capital. For the year ended December 31, 2021, the Company recorded a gain of $170,737 and for the year ended December 31, 2020 the Company recorded a loss of $4,158 from the change in fair value of derivative liability as other income in the consolidated statements of operations and comprehensive income (loss). January 7, 2021 Subscription Agreement On January 7, 2021 (the “Issue Date”), the Company entered into a subscription agreement with an unaffiliated third party, whereby the Company issued for a purchase price of $100,000 in principal amount, a convertible promissory note. The note bears an interest rate of 8% per annum and matures on the earlier of (i) consummation of the Company listing its common shares on the NEO Stock Exchange or (ii) October 31, 2021. Upon the consummation of a NEO listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 25% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the NEO listing. In the event that a NEO listing is not consummated on or before October 31, 2021, the note holder will have the option, in part or in full, to have the note repaid with interest, or convert the note into Company common stock at a 25% discount to the 30-day volume-weighted average price of the Common Shares on the most senior stock exchange in North American on which the common shares are trading prior to conversion. As of September 30, 2021, the Company had a principal balance of $100,000 and had accrued $5,736 in interest expense. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature and a derivative liability which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on January 7, 2021, and determined that the embedded derivative was valued at $62,619 which was recorded as a debt discount and additional paid-in capital, and is being amortized over the life of the loan. For the year ended December 31, 2021, $62,619 of the debt discount has been amortized. As of December 31, 2021, the fair value of the derivative liability was $39,843 and for the year ended December 31, 2021, the Company recorded a gain of $22,776 from the change in fair value of derivative liability as other income in the consolidated statements of operations and comprehensive income (loss). Convertible Promissory Note and Securities Purchase Agreement On September 17, 2021 (the “Issue Date”), the Company entered into a convertible promissory note and securities purchase agreement with an unaffiliated third party. Convertible Promissory Note The Company issued the convertible promissory note for a purchase price of $525,000 in principal amount for cash proceeds of $500,000. The note was issued with an original issue discount (“OID”) of $25,000, bears an interest rate of 10% per annum and matures on the earlier of (i) the consummation of the Company listing its common shares on the Nasdaq Stock Exchange or (ii) September 17, 2022. Upon the consummation of a Nasdaq listing, the total principal and accrued interest outstanding on the note will convert into shares of the Company’s common stock at a 30% discount to the prices of the common shares sold in the financing to be conducted in conjunction with the Nasdaq listing, subject to a conversion floor of $3.00. The Company determined that the embedded conversion feature of the convertible promissory note meets the definition of a beneficial conversion feature which is accounted for separately. The Company measured the beneficial conversion feature’s intrinsic value on September 17, 2021, at $294,000 which, together with the OID of $25,000 was recorded as a debt discount and is being amortized over the life of the loan. For year ended December 31, 2021, $60,063 of the debt discount has been amortized. As of December 31, 2021, the Company had accrued a principal balance of $525,000, had accrued $15,166 in interest expense, and had remaining debt discount of $258,937 which resulted in a net convertible note payable of $266,063. Securities Purchase Agreement On September 17, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with the third party whereby the Company agree to issue 5,000,000 shares of Series A Preferred Stock at a purchase price of $1.00 per share or $5,000,000 in the aggregate, and a Warrant (the “Warrant”) to purchase 100% of the number of shares of the Company’s Common Stock issuable upon conversion of the Series A Preferred Stock. The Series A Preferred Stock will be convertible into the Company’s Common Stock as determined by multiplying the number of shares of Series A Preferred Stock to be converted by the lower of (i) $4.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five (5) days prior to the date of Uplisting, subject to a floor of $3.00 per share. The shares of common stock issuable upon conversion of Series A Preferred Stock and exercise of the Warrants are subject to a Registration Right Agreement. The Warrant has an exercise price equal to 110% of the Conversion Price of the Series A Preferred Stock and expires five (5) years from the date of issuance. The SPA is subject to certain conditions to close. As of December 31, 2021 and the date of this filing, the conditions to close had not been met, the funds have not been transferred, the preferred shares and the warrant was not issued. The SPA automatically terminated on March 31, 2022. Derivative Liabilities The table below provides a summary of the changes in fair value, including net transfers in and/or out of all financial liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the years ended December 31, 2021 and 2020: Amount Balance on January 1, 2020 $ - Issuances to debt discount 456,570 Change in fair value of derivative liabilities 4,158 Balance on December 31, 2020 460,728 Issuances to debt discount 62,619 Reduction of derivative related to conversions (284,169 ) Change in fair value of derivative liabilities (193,513 ) Balance on December 31, 2021 $ 45,665 The fair value of the derivative conversion features and warrant liabilities as of December 31, 2021 and 2020 were calculated using a Monte-Carlo option model valued with the following assumptions: December 31, December 31, 2021 2020 Dividend yield 0 % 0 % Expected volatility 106.8%-107.3 % 140.4%-142.5 % Risk free interest rate 0.41%-0.44 % 0.11%-0.12 % Contractual terms (in years) 0.50 - 0.52 1.00 - 1.04 |
DEBT
DEBT | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
DEBT | ||
DEBT | NOTE 12 - DEBT A summary of the Company’s third-party debt as of March 31, 2022 and December 31, 2021 presented below: March 31, 2022 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 1,299,784 $ 6,207,010 $ 10,077,977 $ 234,117 $ 17,818,888 Proceeds - - - - - Payments (124,242 ) (107,894 ) (2,030,814 ) (2,262,950 ) Conversion of debt (1,190,000 ) - - (1,190,000 ) Recapitalized upon debt modification - (198,040 ) (1,204,356 ) - (1,402,396 ) Accretion of debt 78,445 - - 78,445 Foreign currency translation 54,861 (41,505 ) (21,433 ) (5,029 ) (13,106 ) Subtotal 118,848 5,859,571 6,821,374 229,088 13,028,881 Notes payable - long-term - - (6,664,025 ) (221,781 ) (6,885,806 ) Notes payable - short-term $ 118,848 $ 5,859,571 $ 157,349 $ 7,307 $ 6,143,075 December 31, 2021 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 3,302,100 $ 6,446,000 $ 12,631,284 $ 435,210 $ 22,814,594 Proceeds - - 565,900 - 565,900 Payments (141,475 ) (57,835 ) (62,878 ) (3,233 ) (265,421 ) Conversion of debt (1,606,500 ) - (3,010,000 ) - (4,616,500 ) Recapitalized upon debt modification (86,670 ) - - - (86,670 ) Debt forgiveness - - - (169,770 ) (169,770 ) Foreign currency translation (167,671 ) (181,155 ) (46,329 ) (28,090 ) (423,245 ) Subtotal 1,299,784 6,207,010 10,077,977 234,117 17,818,888 Notes payable - long-term - (2,450,000 ) (9,854,906 ) (51,478 ) (12,356,384 ) Notes payable - short-term $ 1,299,784 $ 3,757,010 $ 223,071 $ 182,639 $ 5,462,504 Our outstanding debt as of March 31, 2022 is repayable as follows: March 31, 2022 2022 $ 4,116,483 2023 9,699,419 2024 253,694 2025 227,261 2026 and thereafter 140,923 Total debt 14,437,780 Less: fair value adjustments to assumed debt obligations (1,408,899 ) Less: notes payable - current portion (6,143,075 ) Notes payable - long term portion $ 6,885,806 Loan Facility Agreement On August 4, 2021, the Company entered into an exchange agreement for the existing loan facility agreement with Synthesis Peer-to-Peer Income Fund, whereby the Company agreed to the following: · Issue on August 4, 2021, 321,300 shares of common stock to settle $1,606,500 (€1,350,000) of debt. The Company recorded a gain on settlement of $292,383 upon the issuance of the 321,300 shares · Agreed to issue no more than 238,000 shares of common stock upon approval of the listing of the Company’s common stock to the Nasdaq to settle $1,190,000 (€1,000,000) of debt. The Company issued these shares on February 28, 2022. Upon issuance of the 238,000 shares of common stock, the Company recorded a gain on extinguishment of debt in the amount of $216,580 determined using the fair value of the Company’s common stock at the commitment date of $4.09 per share. The Company evaluated the August 4, 2021, exchange agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. Upon extinguishment, the Company recorded a loss upon extinguishment in the amount of $6,642 and recorded the new debt at fair value based on the present value of future cash flows using a discount rate of 11.66%. As of March 31, 2022 and December 31, 2021, the Company has accrued interest expense of $16,849 and $4,414, respectively, and the principal balance of the debt is $118,848 and $1,299,784, respectively, which is classified as Notes payable on the unaudited condensed consolidated balance sheet. The debt is subject to acceleration in an Event of Default (as defined in the Notes). This agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. Trade Facility Agreements On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”) as amended on November 16, 2017, and May 16, 2018. On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 and USD $4,000,000. Interest on the new balances commenced on October 1, 2018, at 6% per annum plus one-month Euribor, when it is positive, on the Euro balance and 6% per annum plus one-month Libor on the USD balance. The USD $4,000,000 loan matured on August 31, 2021. On March 3 rd On December 30, 2020, the Company transferred the Euro €2,000,000 loan to a new third-party lender. The terms remained the same except interest will now accrue at 5.5% per annum plus Euribor. The principal is to be repaid in a total of five quarterly installments beginning October 31, 2021 of 50,000 Euro each with a final repayment of 1,800,000 Euro payable on the earlier of 24 months after December 30, 2020 or October 31, 2022. During the year ended December 31, 2021, the Company repaid $56,508 of the €2,000,000 balance such that as of December 31, 2021, the Company had principal balances of €1,950,000 ($2,207,010) and $4,000,000 under the agreements, of which $2,450,000 is classified as notes payable-long term on the consolidated balance sheet and the Company had accrued $10,466 in interest expense related to these agreements. On March 3, 2022, the Company entered into a modification agreement to extend the maturity date to January 10, 2023 and payments under the $4,000,000 loan. The loan was considered a modification under ASC 470-50 because the change in the present value of cash flows is less than 10%. The Company capitalized fees paid upon modification of $200,000 that are being amortized over the life of the loan. During the three months ended March 31, 2022, the Company repaid $55,465 of the €1,950,000 balance and $50,059 of the $4,000,000 balance such that as of March 31, 2022, the Company had principal balances of €1,900,000 ($2,107,670) and $3,751,901 under the agreements which are recorded as short term. As of March 31, 2022, the Company had accrued $81,813 in interest expense related to these agreements. Third Party Debt On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. As of December 31, 2021, the Company had an outstanding principal balance of €8,000 ($9,054) and accrued interest of €6,318 ($7,151). As of March 31,2022, the Company had an outstanding principal balance of €8,000 ($8,874) and accrued interest of €6,439 ($7,143). May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes May 18, 2020 Senior Promissory Note On May 18, 2020, the Company executed a Senior Promissory Note (the “May 18 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender. The May 18 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 18 Note matured on December 31, 2020. The May 18 Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 18 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2021 the Company had a principal balance of $2,000,000 on this note, which is classified as Notes payable - long term portion on the consolidated balance sheet. July 3, 2020 Senior Promissory Note On July 3, 2020, the Company executed a Senior Promissory Note (the “July 3 Note”) in the principal amount of $5,000,000 payable to an unaffiliated third-party lender. The July 3 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The July 3 Note matures on June 30, 2022 unless in default. The July 3 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the July 3 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. The Company used the proceeds from the July 3 Note to repay the principal outstanding on the May 5 Note ($2,000,000), the May 8 Note ($2,000,000), and the February Note ($1,000,000). As of December 31, 2021, the Company had a principal balance of $5,000,000 on this note, which is classified as Notes payable - long term portion on the consolidated balance sheet. As of December 31, 2021, the Company had accrued an aggregate total of $210,574 in interest expense related to these loans. August 4, 2020 Senior Promissory Note On August 4, 2020, the Company executed a Senior Promissory Note (the “August 4 Note”) in the principal amount of $3,000,000 payable to an unaffiliated third-party lender. The August 4 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The August 4 Note matured on December 31, 2020. The August 4 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the August 4 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. On October 29, 2020, the Company entered into a debt exchange agreement with the lender whereby the Company issued 259,741 shares of common stock at the rate of $3.85 per share in exchange for an aggregate of $1,000,000 principal amount of the existing loan. The fair market value of the Company’s common stock on the date of exchange was $3.11 per share and as such, the Company recorded a gain of $192,205. Interest continued to accrue on the remaining debt and the converted amount until December 31, 2020. As of December 31, 2020, the Company had a principal balance of $2,000,000 on this note and prepaid interest of $8,514. As of December 31, 2021, the Company had a principal balance of $2,000,000 on this note, which is classified as Notes payable - long term portion on the consolidated balance sheet, and $60,166 in accrued interest expense. Modification of May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes On February 23, 2022, the Company entered into modification agreements to extend the due dates of the May 18 Note, July 3 Note, and August 4 Note to June 30, 2023 of $9,000,000, in the aggregate. The Company paid restructuring fees totaling $506,087 upon modification. The Company determined the modification should be recorded as debt extinguishment in accordance with ASC 470 because the present value of the remaining cash flows under the terms of the new debt instrument is at least 10% different from the present value of the remaining cash flows under the terms of the original instrument. The Company recorded the new debt at fair value in the amount of $7,706,369 and a gain upon extinguishment in the amount of $787,544. During the three months ended March 31, 2022, the Company made principal payments in the amount of $2,000,000 and recorded non-cash interest expense in the amount of $89,275 for the accretion of debt. As of March 31, 2022, the Company had a principal balance of $5,795,644 in relation to the May 18 Note, July 3 Note, and August 4 Note, in the aggregate. As of March 31, 2022, the Company has accrued an aggregate total of $443,341 of accrued interest on these notes, in the aggregate. November 19, 2020 Debt Agreement On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grievance from the first deposit date, which was November 19, 2020, for principal repayment. The principal is to be repaid in 18 quarterly installments of €27,000 with the first payment due 9 months from the first deposit. During the year ended December 31, 2021, the Company repaid €55,556 ($62,878) of the principal and as of December 31, 2021, the Company has accrued interest of $5,642 related to this note and a principal balance of €444,444 ($503,022), of which $377,270 is classified as Notes payable - long term portion on the consolidated balance sheet. During the three months ended March 31, 2022, the Company repaid €27,778 ($30,814) of the principal and as of March 31, 2022, the Company has accrued interest of $4,815 related to this note and a principal balance of €416,667 ($462,208), of which $429,582 is classified as Notes payable - long term portion on the consolidated balance sheet July 30, 2021 Debt Agreement On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,000 commencing three months from the end of the grace period. As of December 31, 2021, the Company has accrued interest of $3,100 and a principal balance of €500,000 ($565,900), of which $477,637 is classified as Notes payable - long term portion on the consolidated balance sheet. As of March 31, 2022, the Company has accrued interest of $3,042 and a principal balance of €500,000 ($554,650), of which $438,799 is classified as Notes payable - long term portion on the accompanying condensed consolidated balance sheet. COVID-19 Government Loans On May 12, 2020, the Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 the Company received a €300,000 ($366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly installments beginning on January 1, 2022 and bears an interest rate of 0.94% per annum. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. During the year ended December 31, 2021, the Company received a waiver of 50% forgiveness of the loan and recorded $177,450 as other income. As of December 31, 2021 the principal balance was $169,770. As of March 31, 2022, the principal balance was $166,395. On June 24, 2020, the Company received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a six-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement. The Company may prepay this loan without penalty at any time. The Company repaid £2,335 ($3,233) of principal during the year ended December 31, 2021, and the balance as of December 31, 2021 was £47,665 ($64,347). As of March 31, 2022, the principal balance was £47,665 ($62,693). Distribution and Equity Agreement As discussed in Note 3 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products (as defined) initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. As discussed in Note 3, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2019, the Company would be required to issue 635,829 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial None of the above loans were made by any related parties. | NOTE 11 - DEBT A summary of the Company’s third-party debt during the years ended December 31, 2021 and 2020 is presented below: December 31, 2021 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 3,302,100 $ 6,446,000 $ 12,631,284 $ 435,210 $ 22,814,594 Proceeds - - 565,900 - 565,900 Payments (141,475 ) (57,835 ) (62,878 ) (3,233 ) (265,421 ) Conversion of debt (1,606,500 ) - (3,010,000 ) - (4,616,500 ) Recapitalized upon debt modification (86,670 ) - - - (86,670 ) Debt forgiveness - - - (169,770 ) (169,770 ) Foreign currency translation (167,671 ) (181,155 ) (46,329 ) (28,090 ) (423,245 ) Subtotal 1,299,784 6,207,010 10,077,977 234,117 17,818,888 Notes payable - long-term - (2,450,000 ) (9,854,906 ) (51,478 ) (12,356,384 ) Notes payable - short-term $ 1,299,784 $ 3,757,010 $ 223,071 $ 182,639 $ 5,462,504 December 31, 2020 Loan Facility Bridge Loans Trade Facility Third Party COVID Loans Total Beginning balance $ 3,078,442 $ 191,287 $ 6,245,400 $ 2,514,595 $ - $ 12,029,724 Proceeds - - - 16,121,500 435,210 16,556,710 Payments - (191,287 ) - (5,006,115 ) - (5,230,725 ) Conversion of debt (807,795 ) (807,795 ) Debt extinguishment (12,066 ) - - (192,205 ) - (204,271 ) Foreign currency translation 269,047 - 200,600 1,304 - 470,951 Subtotal 3,302,100 - 6,446,000 12,631,284 435,210 22,814,594 Notes payable - long-term (2,843,475 ) - (2,384,850 ) (5,543,557 ) - (10,771,882 ) Notes payable - short-term $ 458,625 $ - $ 4,061,150 $ 7,087,727 $ 435,210 $ 12,042,712 Our outstanding debt as of December 31, 2021 is repayable as follows: December 31, 2021 2022 $ 5,549,174 2023 11,709,951 2024 264,255 2025 268,724 2026 and thereafter 113,454 Total debt 17,905,558 Less: fair value adjustments to assumed debt obligations (86,670 ) Less: notes payable - current portion (5,462,504 ) Notes payable - long term portion $ 12,356,384 Loan Facility Agreement On June 30, 2020, SkyPharm entered into a settlement agreement on an existing loan facility agreement with Synthesis Peer-to-Peer Income Fund, whereby SkyPharm agreed to make certain payments to the creditor and the creditor will accept such payments as full discharge of outstanding debt. In accordance with the settlement agreement, interest will accrue from June 30, 2020, until repayment in full at a rate of 6% per annum for the first year and 5.25% per annum for the second year calculated on the balance outstanding from day to day during such period. Interest is due on the 10 th On August 4, 2021, the Company entered into an exchange agreement whereby the Company agreed to the following: · Issue on August 4, 2021, 321,300 shares of common stock to settle $1,606,500 (€1,350,000) of debt. The Company recorded a gain on settlement of $292,383 upon the issuance of the 321,300 shares · Agreed to issue no more than 238,000 shares of common stock upon approval of the listing of the Company’s common stock to the Nasdaq to settle $1,190,000 (€1,000,000) of debt. The Company issued these shares subsequent to December 31, 2021 (see Note 17) The Company evaluated the August 4, 2021, exchange agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment because a substantial conversion feature was added to the debt terms. Upon extinguishment, the Company recorded a loss upon extinguishment in the amount of $6,642 and recorded the new debt at fair value based on the present value of future cash flows using a discount rate of 11.66%. As of December 31, 2021, the Company has accrued interest expense of $4,414 and the principal balance of the debt is $1,299,784, which is classified as Notes payable on the consolidated balance sheet. The debt is subject to acceleration in an Event of Default (as defined in the Notes). This agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. Trade Facility Agreements On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”) as amended on November 16, 2017, and May 16, 2018. On October 17, 2018, the Company entered into a further amended agreement with Synthesis whereby the current balance on the TFF as of October 1, 2018, which was €4,866,910 ($5,629,555) and related accrued interest of €453,094 ($524,094) would be split into two principal balances of Euro €2,000,000 and USD $4,000,000. Interest on the new balances commenced on October 1, 2018, at 6% per annum plus one-month Euribor, when it is positive, on the Euro balance and 6% per annum plus one-month Libor on the USD balance. The USD $4,000,000 loan matured on August 31, 2021. On March 3 rd On December 30, 2020, the Company transferred the Euro €2,000,000 loan to a new third-party lender. The terms remained the same except interest will now accrue at 5.5% per annum plus Euribor. The principal is to be repaid in a total of five quarterly installments beginning October 31, 2021 of 50,000 Euro each with a final repayment of 1,800,000 Euro payable on the earlier of 24 months after December 30, 2020 or October 31, 2022. As of December 31, 2020, the Company had principal balances of €2,000,000 ($2,446,000), of which $2,384,850 is classified as Notes payable - long term portion on the consolidated balance sheet, and $4,000,000 under the agreements and the Company had accrued $402 and $16,185 respectively, in interest expense related to these agreements. During the year ended December 31, 2021, the Company repaid $56,508 of the €2,000,000 balance such that as of December 31, 2021, the Company had principal balances of €1,950,000 ($2,207,010) and $4,000,000 under the agreements, of which $2,450,000 is classified as notes payable-long term on the consolidated balance sheet and the Company had accrued $10,466 and $104,220 respectively, in interest expense related to these agreements. Third Party Debt On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($42,832) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. During the year ended December 31, 2020, the Company repaid €5,000 ($5,862) of this loan. As of December 31, 2020, the Company had an outstanding principal balance of €8,000 ($9,784) and accrued interest of €4,785 ($5,852). As of December 31, 2021, the Company had an outstanding principal balance of €8,000 ($9,054) and accrued interest of €6,318 ($7,151). Conversion of Senior Promissory Notes In the year ending December 31, 2019, the Company executed Senior Promissory Notes (the “Debt”) in an aggregate total of $2,500,000 to an unaffiliated third-party lender (the “Lender”). In the year ended December 31, 2020, the Company executed additional Senior Promissory Notes to an unaffiliated third-party lender in an aggregate principal total of $510,000. As of December 31, 2020, the Company had an aggregate principal balance of $3,010,000 on this Debt and the Company had accrued $527,604 in interest expense. On February 5, 2021, The Company entered into an Amended and Restated Debt Exchange Agreement (the “Agreement”) with the “Lender that provided for the issuance by the Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company. The market price at the time this Agreement was negotiated was $3.28 per share and the Company recorded a gain on debt extinguishment of $445,636. All accrued and unpaid interest, $563,613 as of December 31, 2021, as well as any unpaid fees, shall be paid in three (3) equal monthly installments following the closing of a planned Canadian public offering. Pursuant to this Agreement, Grigorios Siokas, the Company’s Chief Executive Officer and principal shareholder, will be released from all personal guarantees on the Debt. February 25, 2020 Senior Promissory Note On February 25, 2020, the Company executed a Senior Promissory Note (the “February Note”) in the principal amount of $1,000,000 payable to an unaffiliated third-party lender. The February Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The February Note matured on April 30, 2020. The February Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the February Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. In July 2020, the Company used a portion of the proceeds from the July 3, 2020 senior promissory note to repay the principal of the February Note. The Company was not in default at that time. The Company also repaid all accrued interest related to the February Note. May 5, 2020 Senior Promissory Note On May 5, 2020, the Company executed a Senior Promissory Note (the “May 5 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender who had previously loaned the Company $1,000,000. The May 5 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 5 Note matured on December 31, 2020. The May 5 Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 5 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. In July 2020, the Company used a portion of the proceeds from the July 3, 2020 senior promissory note to repay the principal of the May 5 Note. The Company also repaid the accrued interest related to this note. May 8, 2020 Senior Promissory Note On May 8, 2020, the Company executed a Senior Promissory Note (the “May 8 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender who had previously loaned the Company $3,000,000. The May 8 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 8 Note matured on June 8, 2020. The May 8 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 8 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. In July 2020, the Company used a portion of the proceeds from the July 3, 2020 senior promissory note to repay the principal of the May 8 Note. The Company also repaid the accrued interest related to this note. May 18, 2020 and July 3, 2020 Senior Promissory Notes May 18, 2020 Senior Promissory Note On May 18, 2020, the Company executed a Senior Promissory Note (the “May 18 Note”) in the principal amount of $2,000,000 payable to an unaffiliated third-party lender. The May 18 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 18 Note matured on December 31, 2020. On February 23, 2022, the Company entered into an allonge with the lender extending the maturity date to June 30, 2023 (See Note 17). The May 18 Note is subject to acceleration in an Event of Default. Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the May 18 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. As of December 31, 2021 and 2020, the Company had a principal balance of $2,000,000 on this note, which is classified as Notes payable - long term portion on the consolidated balance sheet. July 3, 2020 Senior Promissory Note On July 3, 2020, the Company executed a Senior Promissory Note (the “July 3 Note”) in the principal amount of $5,000,000 payable to an unaffiliated third-party lender. The July 3 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The July 3 Note matures on June 30, 2022 unless in default. On February 23, 2022, the Company entered into an allonge with the lender extending the maturity date to June 30, 2023 (See Note 17). The July 3 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the July 3 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. The Company used the proceeds from the July 3 Note to repay the principal outstanding on the May 5 Note ($2,000,000), the May 8 Note ($2,000,000), and the February Note ($1,000,000). As of December 31, 2021 and 2020, the Company had a principal balance of $5,000,000 on this note, which is classified as Notes payable - long term portion on the consolidated balance sheet. As of December 31, 2021 and 2020, the Company had accrued an aggregate total of $210,574 and $148,685, respectively, in interest expense related to these loans. August 4, 2020 Senior Promissory Note On August 4, 2020, the Company executed a Senior Promissory Note (the “August 4 Note”) in the principal amount of $3,000,000 payable to an unaffiliated third-party lender. The August 4 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The August 4 Note matured on December 31, 2020. On February 23, 2022, the Company entered into an allonge with the lender extending the maturity date to June 30, 2023 (See Note 17). The August 4 Note is subject to acceleration in an Event of Default (as defined). Grigorios Siokas, the Company’s CEO, personally guaranteed repayment of the August 4 Note. The guaranty is unconditional and irrevocable and constitutes a guaranty of performance and of payment when due, and not just of collection. On October 29, 2020, the Company entered into a debt exchange agreement with the lender whereby the Company issued 259,741 shares of common stock at the rate of $3.85 per share in exchange for an aggregate of $1,000,000 principal amount of the existing loan. The fair market value of the Company’s common stock on the date of exchange was $3.11 per share and as such, the Company recorded a gain of $192,205. Interest will continue to accrue on the remaining debt and the converted amount until December 31, 2020. As of December 31, 2020, the Company had a principal balance of $2,000,000 on this note and prepaid interest of $8,514. As of December 31, 2021, the Company had a principal balance of $2,000,000 on this note, which is classified as Notes payable - long term portion on the consolidated balance sheet, and $60,166 in accrued interest expense. November 19, 2020 Debt Agreement On November 19, 2020, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($611,500). The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grievance from the first deposit date, which was November 19, 2020, for principal repayment. The principal is to be repaid in 18 quarterly installments of €27,000 with the first payment due 9 months from the first deposit. As of December 31, 2020, the Company had no accrued interest and a principal balance of €500,000 ($611,500), of which $543,557 is classified as Notes payable - long term portion on the consolidated balance sheet. During the year ended December 31, 2021, the Company repaid €55,556 ($62,878) of the principal and as of December 31, 2021, the Company has accrued interest of $5,642 related to this note and a principal balance of €444,444 ($503,022), of which $377,270 is classified as Notes payable - long term portion on the consolidated balance sheet. July 30, 2021 Debt Agreement On July 30, 2021, the Company entered into an agreement with a third-party lender in the principal amount of €500,000 ($578,850). The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,000 commencing three months from the end of the grace period. As of December 31, 2021, the Company has accrued interest of $3,100 and a principal balance of €500,000 ($565,900), of which $477,637 is classified as Notes payable - long term portion on the consolidated balance sheet. COVID-19 Government Loans On May 12, 2020, the Company’s subsidiary, SkyPharm, was granted and on May 22, 2020 the Company received a €300,000 ($366,900) loan from the Greek government. The loan will be repaid in 40 equal monthly installments beginning on January 1, 2022 and bears an interest rate of 0.94% per annum. As a condition to the loan, the Company was required to retain the same number of employees until October 31, 2020. During the year ended December 31, 2021, the Company received a waiver of 50% forgiveness of the loan and recorded $177,450 as other income. As of December 31, 2021 the principal balance was $169,770. On June 24, 2020, the Company received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a six-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement. The Company may prepay this loan without penalty at any time. The Company repaid £2,335 ($3,233) of principal during the year ended December 31, 2021, and the balance as of December 31, 2021 was £47,665 ($64,347). Distribution and Equity Agreement As discussed in Note 2 above, the Company entered into a Distribution and Equity Acquisition Agreement with Marathon. The Company was appointed the exclusive distributor of the Products (as defined) initially throughout Europe and on a non-exclusive basis wherever else lawfully permitted. As consideration for its services, Company received: (a) a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in Common Shares of the Company if it fails to meet certain performance milestones. The Company is entitled to receive an additional CAD $2,750,000 upon the Company’s receipt of gross sales of CAD $6,500,000 and an additional CAD $2,750,000 upon receipt of gross sales of CAD $13,000,000. As discussed in Note 2, the Company attributed no value to the shares received in Marathon pursuant to (a) above. In relation to the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2021, the Company would be required to issue 431,270 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial instruments issued by the Company were not affected. None of the above loans were made by any related parties. |
LEASES
LEASES | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
LEASES | ||
LEASES | NOTE 13 - LEASES The Company has various lease agreements with terms up to 10 years, comprising leases of office space, cars leases for the distribution of pharmaceutical products, equipment hires, etc. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the interest rate of our long-term debt on the date of inception. Operating Leases The Company’s weighted-average remaining lease term relating to its operating leases is 6.47 years, with a weighted-average discount rate of 6.74%. The Company incurred lease expense for its operating leases of $54,124 and $65,577 which was included in “General and administrative expenses,” for the three months ended March 31, 2022 and 2021, respectively. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of March 31, 2022. Maturity of Lease Liability Remainder of 2022 $ 154,095 2023 177,914 2024 108,485 2025 108,485 Thereafter 408,810 Total undiscounted operating lease payments $ 957,789 Less: Imputed interest (182,247 ) Present value of operating lease liabilities 775,542 Finance leases The Company’s weighted-average remaining lease term relating to its finance leases is 2.93 years, with a weighted-average discount rate of 6.74%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance leases as of March 31, 2022. Maturity of Lease Liability Remainder of 2022 $ 62,941 2023 73,387 2024 56,654 2025 26,870 Thereafter 3,694 Total undiscounted finance lease payments $ 223,546 Less: Imputed interest (20,669 ) Present value of finance lease liabilities $ 202,877 The Company incurred interest expense on its finance leases of $3,507 which was included in “Interest expense,” for the three months ended March 31, 2022. The Company incurred amortization expense on its finance leases of $19,580 which was included in “Depreciation and amortization expense,” for the three months ended March 31, 2022. The total cash used for the Company’s finance leases for the three months ended March 31, 2022 amounted to $22,358. | NOTE 12 - LEASES The Company has various lease agreements with terms up to 10 years, comprising leases of office space. Some leases include options to purchase, terminate or extend for one or more years. These options are included in the lease term when it is reasonably certain that the option will be exercised. The assets and liabilities from operating and finance leases are recognized at the commencement date based on the present value of remaining lease payments over the lease term using the Company’s secured incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 months or less, are not recorded on the balance sheet. The Company’s operating leases do not provide an implicit rate that can readily be determined. Therefore, we use a discount rate based on our incremental borrowing rate, which is determined using the interest rate of our long-term debt on the date of inception. The Company’s weighted-average remaining lease term relating to its operating leases is 6.6 years, with a weighted-average discount rate of 6.74%. The Company incurred lease expense for its operating leases of $260,664 and $188,400 which was included in “General and administrative expenses,” for the years ended December 31, 2021 and 2020, respectively. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of December 31, 2021. Maturity of Lease Liability 2022 $ 211,538 2023 182,316 2024 111,026 2025 111,026 2026 and thereafter 418,723 Total undiscounted operating lease payments $ 1,034,629 Less: Imputed interest (200,164 ) Present value of operating lease liabilities $ 834,465 The Company’s weighted-average remaining lease term relating to its finance leases is 3.2 years, with a weighted-average discount rate of 6.74%. The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s finance leases as of December 31, 2021: Maturity of Lease Liability 2022 $ 85,231 2023 72,849 2024 55,765 2025 27,744 2026 and thereafter 4,211 Total undiscounted finance lease payments $ 245,800 Less: Imputed interest (24,321 ) Present value of finance lease liabilities $ 221,479 The Company had financing cash flows used in finances leases of $92,105 and $85,804 for the years ended December 31, 2021 and 2020, respectively. The Company incurred interest expense on its finance leases of $11,576 and $13,759 which was included in “Interest expense,” for the years ended December 31, 2021 and 2020, respectively. The Company incurred amortization expense on its finance leases of $97,270 and $123,533 which was included in “Depreciation and amortization expense,” for the years ended December 31, 2021 and 2020, respectively. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
COMMITMENTS AND CONTINGENCIES | ||
COMMITMENTS AND CONTINGENCIES | NOTE 14 - COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of March 31, 2022, the following litigations were pending. None of the below is expected to have a material financial or operational impact. Solgar Inc. is suing SkyPharm SA for product homogeneity regarding the nutraceutical line "Sky Premium Life". As a result, Solgar requested the prohibition for SkyPharm to manufacture, import and sell, market or in any way possess and distribute, including Internet sales and advertise in any way in the Greek market of "Sky Premium Life" due to homogeneity with Solgar's products. Lawsuit with data no 4545/2021 of the company "Solgar Inc." against SkyPharm before the Court of First Instance of Thessaloniki, according to which Solgar Inc. requests to prohibit SkyPharm SA's use of the nutraceutical line "Sky Premium Life" packages as its characteristics are similar to Solgar Inc.’s and is also seeking the withdrawal of existing ones from the market. Solgar Inc. has further requested to be awarded compensation for non-pecuniary damage amounting to 20,000€ (financial obligation). The case was heard on January 28, 2022 and the Company is awaiting a decision. The lawyer assesses that the outcome of the trial's decision will be positive for SkyPharm SA. Compilation and submission of a memorandum against the National Medicines Agency with no. 127351/16.12.2021 document. On July 22, 2015, the National Medicines Agency approved the license of wholesale sale of pharmaceutical products of the pharmaceutical company under the name SkyPharm SA with set validity at five years and an expiration date of July 22, 2022. Subsequently, SkyPharm SA on June 15, 2020, legally and timely submitted the application for renewal of the wholesale license of pharmaceutical products to the National Medicines Agency even though the period under review is characterized by the Covid - 19 pandemic The National Medicines Agency did not respond, therefore the Company asked from the lawyer to immediately ask for the decision of the renewal. Two months after the filing of no. 3459 / 15.01.2021 letter of the attorney and almost nine months after the no. 627615.06.2020 company application for the renewal and the National Medicines Agency replied by rejecting the renewal request on March 9, 2021 (ref. 62769 / 20-25.02.2021). In addition, document No. 127351-16.12.2021 of EOF to SkyPharm states that after an inspection of EOF at the premises of the company "Doc Pharma", SkyPharm did not have a wholesale license in force in violation of article 106 par. 1b and par. 1c of the ministerial decision D.YG3a / GP.32221 / 29-4-2019 and issued invoices dated February 26, 2021 and March 8, 2021). The National Medicines Agency has not yet replied to the renewal request. Order for payment by the court which derived from a fine related to tax audit that concerns financial year 2014. The ruling with no. 483/16.12.2020 was against Cosmofarm SA. The defendant appealed against the decision by the ruling with no.11541/09.03.2021.This appeal was dismissed due to inactive passage of 120 days. Because of this inactive passage, Cosmofarm appealed against Greek tax authorities, no.6704/29.11.2021. There was an obligation of additional tax and fines imposition of 91,652.27€ that Cosmfarm has already paid and claim back through the appeal (financial claim). The trial is pending. The lawyer assesses that they cannot assume the final outcome of this case. Advisory Agreements On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on NASDAQ. Peter Goldstein, a then director of the Company is a principal of the Consultant. As consideration for services rendered, the Company will pay the consultant $4,000 a month until the Company commences trading on NASDAQ. Upon NASDAQ listing, the Company shall pay $10,000 per month, with $4,000 per month paid on a monthly basis and $6,000 per month accrued until such time as the Company raises an aggregate of $10,000,000. In addition, the consultant will receive a $100,000 bonus upon NASDAQ listing and when the Company has raised an aggregate of $10,000,000. Finally, the Company has agreed that the Consultant shall receive a total of 250,000 shares of the Company’s common stock, 50,000 of such shares that have been previously issued pursuant to previous agreements and 200,000 shares to be issued when the Company commences trading on NASDAQ. On July 7, 2021, the Company entered into an agreement with a non-exclusive financial advisor and placement agent. The term of the agreement is a minimum of 45 days and will continue until 5 business days following the date in which a party receives written notice from the other party of termination. As consideration for services rendered, the Company shall pay: a) a cash fee equal to 10% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering; b) 1% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering for unaccountable expenses; c) warrants to purchase shares of the Company’s common stock equal to 10% of the number of shares issued in the offering or to be issued thereafter upon conversion of any convertible securities issued in the offering. These warrants will have a 5-year term and an exercise price equal to the price per share of common stock sold in the offering or conversion or exercise price into common stock of any convertible security sold and will have the same provisions, terms, conditions, rights and preferences as the securities sold in the offering; d) a cash fee equal to 10% of the exercise price of all securities constituting warrants, options or other rights to purchase securities sold in the offering payable only upon exercise. On July 7, 2021, the Company entered into a 6-month agreement with a non-exclusive agent, advisor or underwriter in any offering of securities of the Company. At the closing of any offering the Company will compensate the agent: a) a cash fee or as an underwritten offering an underwriter discount equal to 7% of the aggregate gross proceeds raised in each offering. For all investors referred directly to the Company by the agent, a cash fee or as an underwritten offering an underwriter discount equal to 5% of the aggregate gross proceeds invested by such investors. b) the Company shall issue to the agent or its designees at each closing, warrants to purchase shares of the Company’s common stock equal to 5% of the aggregate number of shares of common stock placed in each offering. c) out of the proceeds of each closing, the Company also agreed to pay the agent up to $35,000 for non-accountable expenses (up to $50,000 for a public offering) along with up to $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses (increase to up to $100,000 for public offerings) plus additional miscellaneous costs. The agent would also have the right of first refusal from the date of the agreement until the 12-month anniversary following consummation of any offerings for total proceeds of at least $3 million raised by investors introduced by the agent. | NOTE 13 - COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of December 31, 2021 and 2020, there were no pending or threatened lawsuits, other than the May Debt Exchange transaction disclosed in Note 8, that could reasonably be expected to have a material effect on the results of the Company’s operations. Advisory Agreements On April 18, 2018, SkyPharm S.A. entered into a ten-year Advisory Agreement with Synthesis Management Limited (the “Advisor”). The Advisor was retained to assist SkyPharm to secure corporate finance capital. The Advisor shall be paid €104,000 per year during the ten-year term. On July 1, 2021, the Company entered into a two-year advisory agreement with a third party (the “Consultant”) for advisory and consulting services related to the Company’s intention to become listed on NASDAQ. Peter Goldstein, a director of the Company is a principal of the Consultant. As consideration for services rendered, the Company will pay the consultant $4,000 a month until the Company commences trading on NASDAQ. Upon NASDAQ listing, the Company shall pay $10,000 per month, with $4,000 per month paid on a monthly basis and $6,000 per month accrued until such time as the Company raises an aggregate of $10,000,000. In addition, the consultant will receive a $100,000 bonus upon NASDAQ listing and when the Company has raised an aggregate of $10,000,000. Finally, the Company has agreed that the Consultant shall receive a total of 250,000 shares of the Company’s common stock, 50,000 of such shares that have been previously issued pursuant to previous agreements and 200,000 shares to be issued when the Company commences trading on NASDAQ. On July 7, 2021, the Company entered into an agreement with a non-exclusive financial advisor and placement agent. The term of the agreement is a minimum of 45 days and will continue until 5 business days following the date in which a party receives written notice from the other party of termination. As consideration for services rendered, the Company shall pay: a) a cash fee equal to 10% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering; b) 1% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering for unaccountable expenses; c) warrants to purchase shares of the Company’s common stock equal to 10% of the number of shares issued in the offering or to be issued thereafter upon conversion of any convertible securities issued in the offering. These warrants will have a 5-year term and an exercise price equal to the price per share of common stock sold in the offering or conversion or exercise price into common stock of any convertible security sold and will have the same provisions, terms, conditions, rights and preferences as the securities sold in the offering; d) a cash fee equal to 10% of the exercise price of all securities constituting warrants, options or other rights to purchase securities sold in the offering payable only upon exercise. On July 7, 2021, the Company entered into a 6-month agreement with a non-exclusive agent, advisor or underwriter in any offering of securities of the Company. At the closing of any offering the Company will compensate the agent: a) a cash fee or as an underwritten offering an underwriter discount equal to 7% of the aggregate gross proceeds raised in each offering. For all investors referred directly to the Company by the agent, a cash fee or as an underwritten offering an underwriter discount equal to 5% of the aggregate gross proceeds invested by such investors. b) The Company shall issue to the agent or its designees at each closing, warrants to purchase shares of the Company’s common stock equal to 5% of the aggregate number of shares of common stock placed in each offering. c) Out of the proceeds of each closing, the Company also agreed to pay the agent up to $35,000 for non-accountable expenses (up to $50,000 for a public offering) along with up to $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses (increase to up to $100,000 for public offerings) plus additional miscellaneous costs. The agent would also have the right of first refusal from the date of the agreement until the 12-month anniversary following consummation of any offerings for total proceeds of at least $3 million raised by investors introduced by the agent. |
EARNINGS PER SHARE
EARNINGS PER SHARE | 12 Months Ended |
Dec. 31, 2021 | |
EARNINGS PER SHARE | |
EARNINGS PER SHARE | NOTE 14 - EARNINGS PER SHARE Basic net income (loss) per share is computed by dividing net income (loss) attributable to the Company, decreased with respect to net income or increased with respect to net loss by dividends declared on preferred stock by using the weighted-average number of common shares outstanding. The dilutive effect of incremental common shares potentially issuable under outstanding options, warrants and restricted shares is included in diluted earnings per share in 2021 and 2020 utilizing the treasury stock method. The computations of basic and diluted per share data were as follows: 2021 2020 Numerator for Basic and Diluted Earnings Per Share: Net income (loss) $ (15,594,682 ) $ 820,786 Denominator for Basic Earnings Per Share: Weighted Average Shares 16,423,335 13,270,097 Potentially Dilutive Common Shares - 37,698 Adjusted Weighted Average Shares 16,423,335 13,307,795 Basic and Diluted Net Income (Loss) per Share (0.95 ) 0.06 The following table summarized the potential shares of common stock that were excluded from the computation of diluted net loss per share for the years ended December 31, 2021 and 2020 as such shares would have had an anti-dilutive effect: 2021 2020 Common Stock Warrants 3,567,827 - Common Stock Options 37,000 - Convertible Debt 218,977 - Total 3,823,804 - |
STOCK OPTIONS AND WARRANTS
STOCK OPTIONS AND WARRANTS | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
STOCK OPTIONS AND WARRANTS | ||
STOCK OPTIONS AND WARRANTS | NOTE 15 - STOCK OPTIONS AND WARRANTS As of March 31, 2022, there were 0 options outstanding and exercisable. A summary of the Company’s option activity during the three months ended March 31, 2022 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance outstanding, January 1, 2022 37,000 $ 1.32 0.01 $ 75,850 Granted - - - - Forfeited - - - - Exercised - - - - Expired (37,000 ) - - - Balance outstanding, March 31, 2022 - $ - - $ - Exercisable, March 31, 2022 - $ - - $ - As of March 31, 2022, there were 2,949,411 warrants outstanding and 2,949,411 warrants exercisable with expiration dates from May 2023 through August 2027. A summary of the Company’s warrant activity during the three months ended March 31, 2022 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance outstanding, January 1, 2022 3,698,238 $ 2.02 2.03 $ 4,992,621 Granted 2,000,000 - - - Forfeited - - - - Exercised (2,748,797 ) - - - Expired - - - - Balance outstanding, March 31, 2022 2,949,441 $ 2.89 4.24 $ 113,933 Exercisable, March 31, 2022 2,949,411 $ 2.89 4.24 $ 113,933 | NOTE 15 - STOCK OPTIONS AND WARRANTS As of December 31, 2021, there were 37,000 options outstanding and 37,000 options exercisable with expiration dates of January 2022. A summary of the Company’s option activity during the years ended December 31, 2021 and 2020 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, January 1, 2020 74,000 $ 1.32 1.47 $ 64,800 Granted - - - - Forfeited (12,000 ) - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 62,000 $ 1.19 0.60 $ 242,200 Granted - - - - Forfeited - - - - Exercised - - - - Expired (25,000 ) - - - Balance Outstanding, December 31, 2021 37,000 $ 1.32 0.01 $ 75,850 Exercisable, December 31, 2021 37,000 $ 1.32 0.01 $ 75,850 As of December 31, 2021, there were 3,698,238 warrants outstanding and 3,698,238 warrants exercisable with expiration dates from May 2023 through March 2024. Warrant Anti-Dilution Adjustment and Deemed Dividend The Company’s warrants outstanding contain certain anti-dilution adjustments if the Company issues shares of its common stock at a lower price per share than the applicable exercise price of the underlying warrant. If any such dilutive issuance occurs prior to the exercise of such warrant, the exercise price will be adjusted downward to a price equal to the common stock issuance, and the number of warrants that may be purchase upon exercise is increased proportionately so that the aggregate exercise price payable under the warrant shares shall be the same as the aggregate exercise price in effect immediately prior to such adjustment. On December 21, 2021, the Company issued its common stock upon conversion of its convertible debt at an issuance price of $2.02 per share. As a result, the Company issued additional warrants to the Company’s existing warrant holders to purchase 2,533,565 shares of common stock with an exercise price of $2.02 per share. The new warrants were issued with a weighted average contractual term of 2.04 years. The deemed dividend was recorded as an increase to accumulated deficit and additional paid-in capital and reduced net income available to common shareholders by the same amount. The Company valued (a) the fair value of the warrants immediately before the re-pricing in the amount of $1,915,077, (b) the fair value of the warrants immediately after the re-pricing in the amount of $9,548,110, and (c) recorded the difference as deemed dividend in the amount of $7,633,033. The warrants were valued using the Black-Scholes option pricing model using the following terms: a) fair value of common stock of $3.75, b) exercise prices of $5.00, $6.00 and $7.50 before re-pricing, c) exercise price of $2.02 after re-pricing, d) terms of 1.40 years, 1.97 years, 2.20 years and 2.26 years, e) dividend rate of 0%, and f) risk free interest rate of 0.41%. A summary of the Company’s warrant activity for the years ending December 31, 2021 and 2020 is as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, January 1, 2020 1,164,673 $ 6.41 4.01 $ - Granted - - - - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 1,164,673 $ 6.41 3.01 $ 5,360 Granted 2,533,565 2.02 2.04 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2021 3,698,238 $ 2.02 2.03 $ 4,992,621 Exercisable, December 31, 2021 3,698,238 $ 2.02 2.03 $ 4,992,621 |
DISAGGREGATION OF REVENUE
DISAGGREGATION OF REVENUE | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
DISAGGREGATION OF REVENUE | ||
DISAGGREGATION OF REVENUE | NOTE 16 - DISAGGREGATION OF REVENUE ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue. The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. The following table presents our revenue disaggregated by country for the three months ended: March 31, March 31, Country 2022 2021 Germany - 13,613 Greece 13,009,038 11,453,496 Italy - 15,727 Denmark - 54,686 Cyprus - 14,723 UK 51,426 66,831 Croatia 11,336 - Total $ 13,071,800 $ 11,619,076 | NOTE 16 - DISAGGREGATION OF REVENUE ASC 606-10-50-5 requires that entities disclose disaggregated revenue information in categories (such as type of good or service, geography, market, type of contract, etc.). ASC 606-10-55-89 explains that the extent to which an entity’s revenue is disaggregated depends on the facts and circumstances that pertain to the entity’s contracts with customers and that some entities may need to use more than one type of category to meet the objective for disaggregating revenue. The Company disaggregates revenue by country to depict the nature and economic characteristics affecting revenue. The following table presents our revenue disaggregated by country for the years ended: Country 2021 2020 Croatia $ 18,441 $ 24,840 Cyprus 112,640 36,987 Denmark 53,710 537,098 France - 18,988 Germany 13,370 1,314,381 Greece 55,564,240 51,259,784 Ireland - 36,349 Italy 15,446 75,183 Jordan - 29,635 Libya - 1,028 Netherlands - 188,890 Poland - 29,358 UK 461,820 1,853,816 Total $ 56,239,667 $ 55,406,337 |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
SUBSEQUENT EVENTS | ||
SUBSEQUENT EVENTS | NOTE 17 - SUBSEQUENT EVENTS Conversion of Principal and Accrued Interest On May 1, 2022 the Company issued 39,339 shares of common stock to convert $26,515 principal and accrued interest in accordance with a convertible promissory note issued to Platinum Point Capital LLC. Following the conversion, the outstanding balance of the above Note is $0. Departure and Appointment of Board Members Effective April 28, 2022, Peter Goldstein resigned from the Board of Directors (the “Board”) the Company and from the Board’s audit committee. Mr. Goldstein’s resignation did not result from any disagreement concerning any matter relating to the Company’s operations, policies or practices. On April 28, 2022, the Board appointed Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board’s audit committee. Exercise of Warrants On April 27, 2022, the Company issued 455,316 shares of common stock upon the cashless exercise of 739,374 warrant shares. | NOTE 17 - SUBSEQUENT EVENTS Extension of Maturity Dates on Existing Promissory Notes On February 23, 2022, the Company entered into allonges to extend the maturity dates of existing Senior Promissory Notes to June 30, 2023 (See Note 11). Security Purchase Agreement - Preferred Stock On February 28, 2022, the Company entered into a securities purchase agreement, or the Purchase Agreement, with certain investors and an insider for a private placement of the Company’s securities (the “Private Placement”). The Private Placement consisted of the sale of 6,000 shares of the Company’s Series A Convertible Preferred Stock, or the Series A Shares, at a price of $1,000.00 per share, and 2,000,000 warrants to purchase shares of common stock, or the Warrants, for aggregate gross proceeds of approximately $6 million. The closing of the Private Placement occurred on February 28, 2022. As a condition to the closing of the sale, the Company’s common stock received conditional approval for listing and trading on the Nasdaq Capital Market and commenced trading on February 28, 2022, under the trading symbol COSM. Settlement of Debt On February 28, 2022, the Company issued 238,000 shares of common stock upon the triggering event which was approval of the listing of the Company’s common stock to the Nasdaq to settle $1,190,000 (€1,000,000) of debt. Extension to Debt Agreement On March 3 rd th |
ORGANIZATION, NATURE OF BUSIN_2
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Policies) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN | ||
Going Concern | The Company’s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the three months ended March 31, 2022, the Company had revenue of $13,071,800, net income of $203,347 and net cash used in operations of $2,337,276. Additionally, as of March 31, 2022, the Company had working capital of $11,831,133, an accumulated deficit of $34,142,159, and stockholders’ equity of $5,151,001. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing. The Company has undergone strategic review processes to help find a definitive solution to the Company’s accumulated deficit constraints. Options under consideration in the strategic review process include, but are not limited to, securing new debt, exchange debt to equity, restructuring current debt facilities from short term to long term and taking the proper actions for new fund raising. The condensed consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund its operations. If the Company is unable to obtain adequate capital, it could be forced to curtail development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by equity and/or debt financing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations. | The Company’s consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplates the continuation of the Company as a going concern. For the year ended December 31, 2021, the Company had revenue of $56,239,667, net loss of $7,961,649 and net cash used in operations of $7,097,174. Additionally, as of December 31, 2021, the Company had working capital of $10,950,492, an accumulated deficit of $34,345,506, and stockholders’ equity of $4,379,463. It is management’s opinion that these conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the date of this filing. The Company has undergone strategic review processes to help find a definitive solution to the Company’s accumulated deficit constraints. Options under consideration in the strategic review process include, but are not limited to, securing new debt, exchange debt to equity, restructuring current debt facilities from short term to long term and taking the proper actions for new fund raising. The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund its operations. If the Company is unable to obtain adequate capital, it could be forced to curtail development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations, the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by equity and/or debt financing. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described herein and eventually secure other sources of financing and attain profitable operations. |
Concentrations of Credit Risk | Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company’s clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2021 2020 Number of 10% clients 1 1 Percentage of total revenue 15.33 % 14.82 % Percentage of total AR 35.08 % 14.65 % | |
Basis of Financial Statement Presentation | The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. | The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America. |
Principles of Consolidation | Our condensed consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated. | Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, SkyPharm S.A., Decahedron Ltd. and Cosmofarm Ltd. All significant intercompany balances and transactions have been eliminated. |
Use of Estimates | The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
The Effects of COVID-19 | Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. | Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Annual Report on Form 10-K. These estimates may change, as new events occur, and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions. |
Foreign Currency Translations and Transactions | Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and amounts included in the accompanying condensed statements of operations and comprehensive income (loss) are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ deficit until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in comprehensive income (loss). | The functional currency of the Company’s subsidiaries is the Euro and British Pound. For financial reporting purposes, both the Euro (“EUR”) and British Pound (“GBP”) have been translated into United States dollars ($) and/or (“USD”) as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss)”. Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive loss as other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of EUR or GBP to USD after the balance sheet date. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. As of December 31, 2021 and 2020, the exchange rates used to translate amounts in Euros into USD and British Pounds into USD for the purposes of preparing the consolidated financial statements were as follows: December 31, 2021 December 31, 2020 Exchange rate on balance sheet dates EUR: USD exchange rate 1.1318 1.2230 GBP: USD exchange rate 1.3500 1.3662 Average exchange rate for the period EUR: USD exchange rate 1.1830 1.1410 GBP: USD exchange rate 1.3764 1.2829 Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net earnings. |
Cash and Cash Equivalents | For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of March 31, 2022, and December 31, 2021, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in Greece and in Bulgaria all of them denominated in Euros. The Company also maintains bank accounts in the United Kingdom, denominated in Euros and Great Britain Pounds (British Pounds Sterling). | For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2021 and December 31, 2020, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in Greece and in Bulgaria all of which are denominated in Euros. Additionally, the Company maintains a bank account in the United Kingdom denominated in British Pounds. As of December 31, 2021, the amounts in these accounts were $144,489, $101,589 and $4,061. As of December 31, 2020, the amounts in these accounts were $448,659, $134,935 and $1,651. Additionally, as of December 31, 2021 and 2020, the Company had cash on hand in the amount of $25,773 and $31,604, respectively. |
Reclassifications to Prior Period Financial Statements and Adjustments | Certain reclassifications have been made in the Company’s financial statements of the prior period to conform to the current year presentation. As of December 31, 2021, $7,393 in accumulated depreciation has been reclassified from property and equipment to accumulated amortization of goodwill and intangible assets and $4,772 was reclassified from prepaid expenses and other current assets to marketable securities on the unaudited condensed consolidated balance sheet. For the three months ended March 31, 2021, $531,556 was reclassified from general and administrative expenses to salaries and wages on the unaudited condensed consolidated statements of operations and comprehensive income. Additionally, for the three months ended March 31, 2021, $1,333 was reclassified from customer deposits to other current liabilities on the unaudited condensed consolidated statement of cash flows. These reclassifications have no impact on previously reported net income. | Certain reclassifications have been made in the Company’s financial statements of the prior period to conform to the current year presentation. $22,340 in customer deposits as of December 31, 2020, has been reclassified to other current liabilities and $502,869 was reclassified from lines of credit to lines of credit - long-term portion on the consolidated balance sheet. For the year ending December 31, 2020, $2,082,453 was reclassified from general and administrative expenses to salaries and wages on the consolidated statements of operations and comprehensive income. For the year ended December 31, 2020, 230,505 was reclassified from customer deposits to other current liabilities and $96,237 in bad debt expenses was reclassified from accounts receivable on the consolidated statement of cash flows. These reclassifications have no impact on previously reported net income. |
Account receivable, net | Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. At March 31, 2022 and December 31, 2021, the Company’s allowance for doubtful accounts was $1,668,893 and $1,702,743, respectively. | Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables’ portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. At December 31, 2021 and 2020, the Company’s allowance for doubtful accounts was $1,702,743 and $715,845, respectively. |
Tax Receivables | The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. The net VAT receivable is recorded in prepaid expense and other current assets on the condensed consolidated balance sheets. As of March 31, 2022 and December 31, 2021, the Company had a VAT net payable balance of $376,656 and $400,616 respectively, recorded in the condensed consolidated balance sheet as accounts payable and accrued expenses. | The Company pays Value Added Tax (“VAT”) or similar taxes (“input VAT”), income taxes, and other taxes within the normal course of its business in most of the countries in which it operates related to the procurement of merchandise and/or services it acquires and/or on sales and taxable income. The Company also collects VAT or similar taxes on behalf of the government (“output VAT”) for merchandise and/or services it sells. If the output VAT exceeds the input VAT, this creates a VAT payable to the government. If the input VAT exceeds the output VAT, this creates a VAT receivable from the government. The VAT tax return is filed on a monthly basis offsetting the payables against the receivables. In observance of EU regulations for intra-EU cross-border sales, our subsidiaries in Greece, SkyPharm and Cosmofarm, do not charge VAT for sales to wholesale drug distributors registered in other European Union member states. The net VAT receivable is recorded in prepaid expense and other current assets on the consolidated balance sheets. As of December 31, 2021 and 2020, the Company had a VAT net payable balance of $400,616 and $159,198 respectively, recorded in the consolidated balance sheet as accounts payable and accrued expenses. |
Inventory | Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. | Inventory is stated at the lower-of-cost or net realizable value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e., packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. The Company writes down inventories to net realizable value based on physical condition, expiration date, current market conditions, as well as forecasted demand. The Company’s inventories are not highly susceptible to obsolescence. Many of the Company’s inventory items are eligible for return to our suppliers when pre-agreed product requirements, including, but not limited to, physical condition and expiration date, are not met. |
Property and Equipment, net | Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 40 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5-10 years Computers and software 3-5 years Depreciation expense was $84,884 and $71,471 for the three months ended March 31, 2022 and 2021, respectively. | Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 40 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5-10 years Computers and software 3-5 years Depreciation expense was $319,337 and 240,886 for the years ended December 31, 2021 and 2020, respectively. |
Impairment of Long-Lived Assets | In accordance with ASC 360-10, Long-lived Assets, property and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. | In accordance with ASC 360-10, long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. For the years ended December 31, 2021 and 2020, the Company had no impairment of long-lived assets. |
Goodwill and Intangibles, net | The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company 49,697 of goodwill. Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for its pharmaceuticals and nutraceuticals products license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of March 31, 2022, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $8,158 and $8,158 for the three months ended March 31, 2022 and 2021, respectively. | The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. On December 19, 2018, as a result of the acquisition of Cosmofarm, the Company recorded $49,697 of goodwill. Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. As of December 31, 2021, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $33,085 and $33,176 for the years ended December 31, 2021 and 2020, respectively. |
Equity Method Investment | For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company will record its share in the earnings of the investee and will include it within the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. | For those investments in common stock or in-substance common stock in which the Company has the ability to exercise significant influence over the operating and financial policies of the investee, the investment is accounted for under the equity method. The Company records its share in the earnings of the investee and is included in “Equity earnings of affiliate” in the consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognizes an impairment loss to adjust the investment to its then current fair value. |
Investments in Equity Securities | Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. As of March 31, 2022, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp and 16,666 shares which traded at a closing price of $0.41 per share or value of $6,822 of National Bank of Greece. Additionally, the Company has $5,729 in equity securities of Pancreta Bank, which are revalued annually. See Note 3, for additional investments in equity securities. | Investments in equity securities are accounted for at fair value with changes in fair value recognized in net income (loss). Equity securities are classified as short-term or long-term based on the nature of the securities and their availability to meet current operating requirements. Equity securities that are readily available for use in current operations are reported as a component of current assets in the accompanying consolidated balance sheets. Equity securities that are not considered available for use in current operations would be reported as a component of long-term assets in the accompanying consolidated balance sheets. For equity securities with no readily determinable fair value, the Company elects a measurement alternative to fair value. Under this alternative, the Company measures the investments at cost, less any impairment, and adjusted for changes resulting from observable price changes in transactions for identical or similar investments of the investee. The election to use the measurement alternative is made for each eligible investment. As of December 31, 2021, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp., 16,666 shares which traded at a closing price of 0.40 per share or value of 6,696 of National Bank of Greece. Additionally, the Company has $4,416 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. As of December 31, 2020, investments consisted of 3,000,000 shares, which traded at a closing price of $0 per share or a value of $0 of ICC International Cannabis Corp., 40,000 shares which traded at a closing price of $5.45 per share, or value of $218,183 of Diversa S.A. and 16,666 shares which traded at a closing price of $0.28 per share or value of $4,609 of National Bank of Greece. Additionally, the Company had $4,772 in equity securities of Pancreta bank, which are not publicly traded and recorded at cost. See Note 2, for additional investments in equity securities. |
Fair Value Measurement | The Company applies ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following tables presents assets that are measured and recognized at fair value as of March 31, 2022 and December 31, 2021, on a recurring basis: M arch 31, 2022 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - $ - - $ - Marketable securities - National Bank of Greece 6,822 - - 6,822 Equity securities - Pancreta Bank - 5,729 - 5,729 $ 6,822 $ 5,729 $ 12,551 December 31, 2021 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - $ - - $ - Marketable securities - National Bank of Greece 6,696 - - 6,696 Equity securities - Pancreta Bank - 4,772 - 4,772 $ 6,696 $ 4,772 $ 11,468 In addition, FASB ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. | The Company applies FASB ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”), for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The following table presents assets that are measured and recognized at fair value as of December 31, 2021 and 2020, on a recurring basis: December 31, 2021 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - - - $ - Marketable securities - Diversa S.A. - - - - Marketable securities - National Bank of Greece 6,696 - - 6,696 $ 6,696 $ 6,696 December 31, 2020 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - - - $ - Marketable securities - Diversa S.A. 218,183 - - 218,183 Marketable securities - National Bank of Greece 4,609 - - 4,609 $ 222,792 $ 222,792 In addition, FASB ASC 825-10-25, Fair Value Option, (“ASC 825-10-25”), expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. |
Customer Advances | The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues. | The Company receives prepayments from certain customers for pharmaceutical products prior to those customers taking possession of the Company’s products. The Company records these receipts as customer advances until it has met all the criteria for recognition of revenue including passing control of the products to its customer, at such point, the Company will reduce the customer advances balance and credit the Company’s revenues. |
Derivatives Instruments | Derivative financial instruments are recorded in the accompanying condensed consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s consolidated statements of operations. | Derivative financial instruments are recorded in the accompanying consolidated balance sheets at fair value in accordance with ASC 815. When the Company enters into a financial instrument such as a debt or equity agreement (the “host contract”), the Company assesses whether the economic characteristics of any embedded features are clearly and closely related to the primary economic characteristics of the remainder of the host contract. When it is determined that (i) an embedded feature possesses economic characteristics that are not clearly and closely related to the primary economic characteristics of the host contract, and (ii) a separate, stand-alone instrument with the same terms would meet the definition of a financial derivative instrument, then the embedded feature is bifurcated from the host contract and accounted for as a derivative instrument. The estimated fair value of the derivative feature is recorded in the accompanying consolidated balance sheets separately from the carrying value of the host contract. Subsequent changes in the estimated fair value of derivatives are recorded as a gain or loss in the Company’s consolidated statements of operations. |
Revenue Recognition | In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon transfer of the product to the customer. | In accordance with ASC 606, Revenue from Contracts with Customers, the Company uses a five-step model for recognizing revenue by applying the following steps: (1) identify the contract with the customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when (or as) the performance obligations are satisfied by transferring the promised goods to the customer. Once these steps are met, revenue is recognized upon delivery of the product. |
Stock-based Compensation | The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.” | The Company records stock-based compensation in accordance with ASC 718, Stock Compensation (“ASC 718”) and Staff Accounting Bulletin No. 107 (“SAB 107”) regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock-based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASU 2018-07, “Compensation-Stock Compensation-Improvements to Nonemployee Share-Based Payment Accounting.” |
Income Taxes | The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At March The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the Company undergoes an annual certified audit each year in lieu of an audit by the Greek tax authorities, the Company has not taken any tax positions that warrant accrual under ASC-740-10. | The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in Greece and the United Kingdom The corporate income tax rate is 22% in Greece and 19% in United Kingdom. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December The Company uses a “more likely than not” criterion for recognizing the income tax benefit of uncertain tax positions and establishing measurement criteria for income tax benefits. The Company has evaluated the impact of these positions and due to the fact that the Company undergoes an annual certified audit each year in lieu of an audit by the Greek tax authorities, the Company has not taken any tax positions that warrant accrual under ASC-740-10. |
Retirement and Termination Benefits | Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgments related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. | Under Greek labor law, employees are entitled to lump-sum compensation in the event of termination or retirement. The amount depends on the employee’s work experience and renumeration as of the day of termination or retirement. If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. The Company periodically reviews the uncertainties and judgements related to the application of the relevant labor law regulations to determine retirement and termination benefits obligations of its Greek subsidiaries. The Company has evaluated the impact of these regulations and has identified a potential retirement and termination benefits liability. The amount of the liability as of December 31, 2021 and December 31, 2020, was $0 and $107,167, respectively, and has been recorded as a long-term liability within the consolidated balance sheets. |
Basic and Diluted Net Loss per Common Share | Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding. Three Months Ended M arch 31, 2022 2021 Weighted average number of common shares outstanding-Basic 17,755,516 15,034,219 Potentially dilutive common stock equivalents - - Weighted average number of common and equivalent shares outstanding - Diluted 17,755,516 15,034,219 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. | Basic income per share is calculated by dividing income available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted income per share is calculated by dividing income available to common stockholders by the weighted average number of common shares outstanding for the period and, when dilutive, potential shares from stock options and warrants to purchase common stock, using the treasury stock method. In accordance with ASC 260, Earnings Per Share, the following table reconciles basic shares outstanding to fully diluted shares outstanding. Years Ended December 31, 2021 2020 Weighted average number of common shares outstanding Basic 16,423,335 13,270,097 Potentially dilutive common stock equivalents - 37,698 Weighted average number of common and equivalent shares outstanding - Diluted 16,423,335 13,307,795 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. |
Recent Accounting Pronouncements | On October 2021, the Financial Accounting Standards Board (“FASB”) issued accounting standards update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, Business Combinations. The new guidance should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022 and include interim periods. The guidance is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effects of the adoption of ASU No. 2021-08 on its consolidated financial statements. In May 2021, the FASB issued ASU 2021-04-Earnings Per Share (Topic 260), Debt- Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU are effective for public and nonpublic entities for fiscal years beginning after December 15, 2021, and interim periods with fiscal years beginning after December 15, 2021. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the effects of the adoption of ASU No. 2021-04 on its consolidated financial statements. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements. | October 2021, the Financial Accounting Standards Board (“FASB”) issued accounting standards update (“ASU”) 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires contract assets and contract liabilities (i.e., deferred revenue) acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The new guidance creates an exception to the general recognition and measurement principles of ASC 805, Business Combinations. The new guidance should be applied prospectively and is effective for all public business entities for fiscal years beginning after December 15, 2022 and include interim periods. The guidance is effective for all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the effects of the adoption of ASU No. 2021-08 on its consolidated financial statements. In May 2021, the FASB issued ASU 2021-04-Earnings Per Share (Topic 260), Debt- Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options, to clarify and reduce diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU are effective for public and nonpublic entities for fiscal years beginning after December 15, 2021, and interim periods with fiscal years beginning after December 15, 2021. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the effects of the adoption of ASU No. 2021-04 on its consolidated financial statements. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial statements. |
ORGANIZATION, NATURE OF BUSIN_3
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN | ||
Schedule of Property and Equipment | Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 40 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5-10 years Computers and software 3-5 years | Estimated Useful Life Leasehold improvements and technical works Lesser of lease term or 40 years Vehicles 6 years Machinery 20 years Furniture, fixtures and equipment 5-10 years Computers and software 3-5 years |
Schedule of Assets Measured and Recognized at Fair Value on a Recurring Basis | M arch 31, 2022 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - $ - - $ - Marketable securities - National Bank of Greece 6,822 - - 6,822 Equity securities - Pancreta Bank - 5,729 - 5,729 $ 6,822 $ 5,729 $ 12,551 December 31, 2021 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - $ - - $ - Marketable securities - National Bank of Greece 6,696 - - 6,696 Equity securities - Pancreta Bank - 4,772 - 4,772 $ 6,696 $ 4,772 $ 11,468 | December 31, 2021 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - - - $ - Marketable securities - Diversa S.A. - - - - Marketable securities - National Bank of Greece 6,696 - - 6,696 $ 6,696 $ 6,696 December 31, 2020 Total Carrying Level 1 Level 2 Level 3 Value Marketable securities - ICC International Cannabis Corp. $ - - - $ - Marketable securities - Diversa S.A. 218,183 - - 218,183 Marketable securities - National Bank of Greece 4,609 - - 4,609 $ 222,792 $ 222,792 |
Schedule of Reconciliation of Basic Shares Outstanding to Fully Diluted Shares Outstanding | Three Months Ended M arch 31, 2022 2021 Weighted average number of common shares outstanding-Basic 17,755,516 15,034,219 Potentially dilutive common stock equivalents - - Weighted average number of common and equivalent shares outstanding - Diluted 17,755,516 15,034,219 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
PROPERTY AND EQUIPMENT | ||
Schedule of Property and Equipment | M arch 31, 2022 December 31, 2021 Leasehold improvements $ 508,920 $ 519,278 Vehicles 94,735 96,657 Furniture, fixtures and equipment 2,027,470 2,065,100 Computers and software 140,452 141,490 2,771,577 2,822,525 Less: Accumulated depreciation and amortization (993,688 ) (934,473 ) Total $ 1,777,889 $ 1,888,052 | 2021 2020 Leasehold improvements $ 519,278 $ 560,711 Vehicles 96,657 105,057 Furniture, fixtures and equipment 2,065,100 1,632,654 Computers and software 141,490 149,005 2,822,525 2,447,427 Less: Accumulated depreciation and amortization (941,866 ) (690,214 ) Total $ 1,880,659 $ 1,757,213 |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
GOODWILL AND INTANGIBLE ASSETS | ||
Schedule of Goodwill and Intangible Assets | M arch 31, 2022 December 31, 2021 License $ 339,860 $ 345,739 Trade name / mark 36,997 36,997 Customer base 176,793 176,793 553,650 559,529 Less: Accumulated amortization (138,717 ) (123,459 ) Subtotal 414,933 436,070 Goodwill 49,697 49,697 Total $ 464,630 $ 485,767 | 2021 2020 License $ 345,739 $ 50,000 Trade name /mark 36,997 36,997 Customer base 176,793 176,793 559,529 263,790 Less: Accumulated amortization (116,066 ) (82,981 ) Subtotal 443,463 180,809 Goodwill 49,697 49,697 Total $ 493,160 $ 230,506 |
INCOME TAXES (Tables)
INCOME TAXES (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
INCOME TAXES | |
Schedule of income before income tax domestic and foreign | 12/31/2021 12/31/2020 Domestic $ (8,365,297 ) $ (2,901,276 ) Foreign 517,659 4,099,597 $ (7,847,638 ) $ 1,198,321 12/31/2021 12/31/2020 Current tax provision Federal $ - $ - State - - Foreign 802,364 555,965 Total current tax provision $ 802,364 $ 555,965 Deferred tax provision Domestic $ - $ - State - - Foreign (688,354 ) (178,430 ) Total deferred tax provision $ (688,354 ) $ (178,430 ) Total current provision $ 114,010 $ 377,535 |
Schedule of provision for income taxes | 12/31/2021 12/31/2020 US Income (loss) before income taxes $ (7,847,639 ) $ 1,198,321 Taxes under statutory US tax rates $ (1,648,004 ) $ 251,647 Increase (decrease) in taxes resulting from: Increase in valuation allowance $ 3,001,899 $ 216,518 Foreign tax rate differential $ (24,977 ) $ (55,540 ) Permanent differences $ (734,428 ) $ (218,216 ) US tax on foreign income $ 493,028 $ 604,419 163(j) catch up (76,888 ) - Prior period adjustments $ 52,034 $ (97,829 ) State taxes $ (948,654 ) $ (323,464 ) Income tax expense $ 114,010 $ 377,535 |
Significant components of deferred tax assets and liabilities | 12/31/2021 12/31/2020 Net operating loss carryforward $ 4,515,900 $ 1,494,424 Capital loss carryforward 801,744 801,744 Section 163(j) carryforward - - Nonqualified stock options 96,104 170,297 Foreign exchange 13,438 - Allowance for doubtful accounts 374,604 - Accrued expenses 528,895 7,389 Mark to market adjustment in securities 358,761 357,829 Lease liability 253,620 247,797 Gain on extinguishment of debt - 179,958 Depreciation (6,765 ) 4,226 Total deferred tax assets 6,936,211 3,263,664 Intangibles (8,139 ) (10,729 ) Inventory (14,728 ) - Right of use asset (243,207 ) (253,818 ) Goodwill (10,979 ) (14,473 ) Total deferred tax liabilities (277,053 ) (279,020 ) Valuation allowance (5,808,384 ) (2,806,214 ) Net deferred tax assets (liabilities) $ 850,774 $ 178,430 |
RELATED PARTY TRANSACTIONS (Tab
RELATED PARTY TRANSACTIONS (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
RELATED PARTY TRANSACTIONS | ||
Schedule of Related Party Notes Payable | March 31, 2022 December 31, 2021 Beginning balance $ 464,264 $ 501,675 Foreign currency translation (9,229 ) (37,411 ) Ending balance $ 455,035 $ 464,264 | 2021 2020 Beginning Balance $ 501,675 $ 1,375,532 Payments - (996,136 ) Foreign currency translation (37,411 ) 122,279 Ending Balance $ 464,264 $ 501,675 |
Schedule of Related Party Loans Payable | March 31, 2022 December 31, 2021 Beginning balance $ 1,293,472 $ 1,629,246 Proceeds 456,085 6,377,156 Payments (22,186 ) (133,552 ) Conversion of debt - (6,000,000 ) Settlement of lawsuit - (600,000 ) Foreign currency translation (23,490 ) 20,623 Ending balance $ 1,703,881 $ 1,293,472 | |
Summary of Related Party Loans Payable | 2021 2020 Beginning balance $ 1,629,246 $ 1,026,264 Proceeds 6,377,156 725,563 Payments (133,552 ) (149,695 ) Conversion of debt (6,000,000 ) - Settlement of lawsuit (600,000 ) - Foreign currency translation 20,623 27,114 Ending balance $ 1,293,472 $ 1,629,246 |
LINES OF CREDIT (Tables)
LINES OF CREDIT (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
LINES OF CREDIT | ||
Schedule of Lines of Credit | March 31, 2022 December 31, 2021 National $ 2,887,143 $ 3,265,236 Alpha 927,008 947,333 Pancreta 417,671 489,985 National - COVID 316,377 407,174 Subtotal 4,548,199 5,109,728 Reclassification of National-COVID - Long-term (185,872 ) (366,171 ) Ending balance $ 4,362,327 $ 4,743,557 | |
Summary of Lines of Credit | December 31, 2021 December 31, 2020 National $ 3,265,236 $ 3,540,550 Alpha 947,333 1,106,894 Pancreta 489,985 - National - COVID 407,174 429,240 Subtotal 5,109,728 5,076,684 Reclassification of National-COVID - Long-term (366,171 ) (502,869 ) Ending balance $ 4,743,557 $ 4,573,815 |
CONVERTIBLE DEBT (Tables)
CONVERTIBLE DEBT (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
CONVERTIBLE DEBT | ||
Derivative Liabilities | Amount Balance on January 1, 2022 $ 45,665 Issuances to debt discount - Reduction of derivative related to conversions - Change in fair value of derivative liabilities (15,001 ) Balance on March 31, 2022 $ 30,664 March 31, December 31, 2022 2021 Dividend yield 0 % 0 % Expected volatility 87.9 % 106.8%-107.3 % Risk free interest rate 1.40 % 0.41%-0.44 % Contractual terms (in years) 0.50 0.50 - 0.52 | Amount Balance on January 1, 2020 $ - Issuances to debt discount 456,570 Change in fair value of derivative liabilities 4,158 Balance on December 31, 2020 460,728 Issuances to debt discount 62,619 Reduction of derivative related to conversions (284,169 ) Change in fair value of derivative liabilities (193,513 ) Balance on December 31, 2021 $ 45,665 December 31, December 31, 2021 2020 Dividend yield 0 % 0 % Expected volatility 106.8%-107.3 % 140.4%-142.5 % Risk free interest rate 0.41%-0.44 % 0.11%-0.12 % Contractual terms (in years) 0.50 - 0.52 1.00 - 1.04 |
Schedule of Convertible Debt | March 31, 2022 December 31, 2021 Beginning balance convertible notes $ 640,000 $ 1,447,000 New notes - 625,000 Payments - (907,000 ) Conversion to common stock - (525,000 ) Subtotal notes 640,000 640,000 Debt discount at year end (191,085 ) (258,938 ) Convertible note payable, net of discount $ 448,915 $ 381,062 | 2021 2020 Beginning balance convertible notes $ 1,447,000 $ 1,500,000 New notes 625,000 540,000 Payments (907,000 ) (593,000 ) Conversion to common stock (525,000 ) - Subtotal notes 640,000 1,447,000 Debt discount at year end (258,938 ) (494,973 ) Convertible note payable, net of discount $ 381,062 $ 952,027 |
DEBT (Tables)
DEBT (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
DEBT | ||
Summary of Outstanding Debt | March 31, 2022 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 1,299,784 $ 6,207,010 $ 10,077,977 $ 234,117 $ 17,818,888 Proceeds - - - - - Payments (124,242 ) (107,894 ) (2,030,814 ) (2,262,950 ) Conversion of debt (1,190,000 ) - - (1,190,000 ) Recapitalized upon debt modification - (198,040 ) (1,204,356 ) - (1,402,396 ) Accretion of debt 78,445 - - 78,445 Foreign currency translation 54,861 (41,505 ) (21,433 ) (5,029 ) (13,106 ) Subtotal 118,848 5,859,571 6,821,374 229,088 13,028,881 Notes payable - long-term - - (6,664,025 ) (221,781 ) (6,885,806 ) Notes payable - short-term $ 118,848 $ 5,859,571 $ 157,349 $ 7,307 $ 6,143,075 December 31, 2021 Loan Facility Trade Facility Third Party COVID Loans Total Beginning balance $ 3,302,100 $ 6,446,000 $ 12,631,284 $ 435,210 $ 22,814,594 Proceeds - - 565,900 - 565,900 Payments (141,475 ) (57,835 ) (62,878 ) (3,233 ) (265,421 ) Conversion of debt (1,606,500 ) - (3,010,000 ) - (4,616,500 ) Recapitalized upon debt modification (86,670 ) - - - (86,670 ) Debt forgiveness - - - (169,770 ) (169,770 ) Foreign currency translation (167,671 ) (181,155 ) (46,329 ) (28,090 ) (423,245 ) Subtotal 1,299,784 6,207,010 10,077,977 234,117 17,818,888 Notes payable - long-term - (2,450,000 ) (9,854,906 ) (51,478 ) (12,356,384 ) Notes payable - short-term $ 1,299,784 $ 3,757,010 $ 223,071 $ 182,639 $ 5,462,504 | December 31, 2020 Loan Facility Bridge Loans Trade Facility Third Party COVID Loans Total Beginning balance $ 3,078,442 $ 191,287 $ 6,245,400 $ 2,514,595 $ - $ 12,029,724 Proceeds - - - 16,121,500 435,210 16,556,710 Payments - (191,287 ) - (5,006,115 ) - (5,230,725 ) Conversion of debt (807,795 ) (807,795 ) Debt extinguishment (12,066 ) - - (192,205 ) - (204,271 ) Foreign currency translation 269,047 - 200,600 1,304 - 470,951 Subtotal 3,302,100 - 6,446,000 12,631,284 435,210 22,814,594 Notes payable - long-term (2,843,475 ) - (2,384,850 ) (5,543,557 ) - (10,771,882 ) Notes payable - short-term $ 458,625 $ - $ 4,061,150 $ 7,087,727 $ 435,210 $ 12,042,712 |
Summary of Debt | Our outstanding debt as of March 31, 2022 is repayable as follows: March 31, 2022 2022 $ 4,116,483 2023 9,699,419 2024 253,694 2025 227,261 2026 and thereafter 140,923 Total debt 14,437,780 Less: fair value adjustments to assumed debt obligations (1,408,899 ) Less: notes payable - current portion (6,143,075 ) Notes payable - long term portion $ 6,885,806 | Our outstanding debt as of December 31, 2021 is repayable as follows: December 31, 2021 2022 $ 5,549,174 2023 11,709,951 2024 264,255 2025 268,724 2026 and thereafter 113,454 Total debt 17,905,558 Less: fair value adjustments to assumed debt obligations (86,670 ) Less: notes payable - current portion (5,462,504 ) Notes payable - long term portion $ 12,356,384 |
LEASES (Tables)
LEASES (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
LEASES | ||
Summary of Finance Leases | Maturity of Lease Liability Remainder of 2022 $ 62,941 2023 73,387 2024 56,654 2025 26,870 Thereafter 3,694 Total undiscounted finance lease payments $ 223,546 Less: Imputed interest (20,669 ) Present value of finance lease liabilities $ 202,877 | Maturity of Lease Liability 2022 $ 85,231 2023 72,849 2024 55,765 2025 27,744 2026 and thereafter 4,211 Total undiscounted finance lease payments $ 245,800 Less: Imputed interest (24,321 ) Present value of finance lease liabilities $ 221,479 |
Summary of Operating Leases | Maturity of Lease Liability Remainder of 2022 $ 154,095 2023 177,914 2024 108,485 2025 108,485 Thereafter 408,810 Total undiscounted operating lease payments $ 957,789 Less: Imputed interest (182,247 ) Present value of operating lease liabilities 775,542 | Maturity of Lease Liability 2022 $ 211,538 2023 182,316 2024 111,026 2025 111,026 2026 and thereafter 418,723 Total undiscounted operating lease payments $ 1,034,629 Less: Imputed interest (200,164 ) Present value of operating lease liabilities $ 834,465 |
EARNINGS PER SHARE (Tables)
EARNINGS PER SHARE (Tables) | 12 Months Ended |
Dec. 31, 2021 | |
EARNINGS PER SHARE | |
Schedule of Basic net income loss per share | 2021 2020 Numerator for Basic and Diluted Earnings Per Share: Net income (loss) $ (15,594,682 ) $ 820,786 Denominator for Basic Earnings Per Share: Weighted Average Shares 16,423,335 13,270,097 Potentially Dilutive Common Shares - 37,698 Adjusted Weighted Average Shares 16,423,335 13,307,795 Basic and Diluted Net Income (Loss) per Share (0.95 ) 0.06 |
Schedule of diluted net loss per share | 2021 2020 Common Stock Warrants 3,567,827 - Common Stock Options 37,000 - Convertible Debt 218,977 - Total 3,823,804 - |
STOCK OPTIONS AND WARRANTS (Tab
STOCK OPTIONS AND WARRANTS (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
STOCK OPTIONS AND WARRANTS | ||
Schedule of Option Activity | Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance outstanding, January 1, 2022 3,698,238 $ 2.02 2.03 $ 4,992,621 Granted 2,000,000 - - - Forfeited - - - - Exercised (2,748,797 ) - - - Expired - - - - Balance outstanding, March 31, 2022 2,949,441 $ 2.89 4.24 $ 113,933 Exercisable, March 31, 2022 2,949,411 $ 2.89 4.24 $ 113,933 | Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, January 1, 2020 74,000 $ 1.32 1.47 $ 64,800 Granted - - - - Forfeited (12,000 ) - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 62,000 $ 1.19 0.60 $ 242,200 Granted - - - - Forfeited - - - - Exercised - - - - Expired (25,000 ) - - - Balance Outstanding, December 31, 2021 37,000 $ 1.32 0.01 $ 75,850 Exercisable, December 31, 2021 37,000 $ 1.32 0.01 $ 75,850 |
Summary of Warrants Activity | Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance outstanding, January 1, 2022 37,000 $ 1.32 0.01 $ 75,850 Granted - - - - Forfeited - - - - Exercised - - - - Expired (37,000 ) - - - Balance outstanding, March 31, 2022 - $ - - $ - Exercisable, March 31, 2022 - $ - - $ - | Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, January 1, 2020 1,164,673 $ 6.41 4.01 $ - Granted - - - - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2020 1,164,673 $ 6.41 3.01 $ 5,360 Granted 2,533,565 2.02 2.04 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, December 31, 2021 3,698,238 $ 2.02 2.03 $ 4,992,621 Exercisable, December 31, 2021 3,698,238 $ 2.02 2.03 $ 4,992,621 |
DISAGGREGATION OF REVENUE (Tabl
DISAGGREGATION OF REVENUE (Tables) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
DISAGGREGATION OF REVENUE | ||
Schedule of Revenue Disaggregation | March 31, March 31, Country 2022 2021 Germany - 13,613 Greece 13,009,038 11,453,496 Italy - 15,727 Denmark - 54,686 Cyprus - 14,723 UK 51,426 66,831 Croatia 11,336 - Total $ 13,071,800 $ 11,619,076 | Country 2021 2020 Croatia $ 18,441 $ 24,840 Cyprus 112,640 36,987 Denmark 53,710 537,098 France - 18,988 Germany 13,370 1,314,381 Greece 55,564,240 51,259,784 Ireland - 36,349 Italy 15,446 75,183 Jordan - 29,635 Libya - 1,028 Netherlands - 188,890 Poland - 29,358 UK 461,820 1,853,816 Total $ 56,239,667 $ 55,406,337 |
ORGANIZATION, NATURE OF BUSIN_4
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Computers and software [Member] | Minimum [Member] | ||
Estimated Useful Life | 3 years | 3 years |
Computers and software [Member] | Maximum [Member] | ||
Estimated Useful Life | 5 years | 5 years |
Leasehold improvements and technical works [Member] | ||
Estimated useful life, description | Lesser of lease term or 40 years | Lesser of lease term or 40 years |
Vehicles [Member] | ||
Estimated Useful Life | 6 years | 6 years |
Machinery [Member] | ||
Estimated Useful Life | 20 years | 20 years |
Furniture, fixtures and equipment [Member] | Minimum [Member] | ||
Estimated Useful Life | 5 years | 5 years |
Furniture, fixtures and equipment [Member] | Maximum [Member] | ||
Estimated Useful Life | 10 years | 10 years |
ORGANIZATION NATURE OF BUSINESS
ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN (Details 1 - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Fair value of assets and liabilities | $ 12,551 | $ 11,468 | $ 222,792 |
Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Marketable securities - Divsersa S.A. [Member] | |||
Fair value of assets and liabilities | 0 | 218,183 | |
Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | 6,822 | 6,696 | 4,609 |
Level 2 [Member] | |||
Fair value of assets and liabilities | 5,729 | 4,772 | |
Level 2 [Member] | Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 2 [Member] | Marketable securities - Divsersa S.A. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | |
Level 2 [Member] | Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 3 [Member] | Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 3 [Member] | Marketable securities - Divsersa S.A. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | |
Level 3 [Member] | Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 1 [Member] | |||
Fair value of assets and liabilities | 6,822 | 6,696 | 222,792 |
Level 1 [Member] | Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 1 [Member] | Marketable securities - Divsersa S.A. [Member] | |||
Fair value of assets and liabilities | 0 | 218,183 | |
Level 1 [Member] | Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | $ 6,822 | $ 6,696 | $ 4,609 |
ORGANIZATION NATURE OF BUSINE_2
ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN (Details 2) - shares | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
BASIS OF PRESENTATION | ||||
Weighted average number of common shares outstanding Basic | 17,755,516 | 15,034,219 | 16,423,335 | 13,270,097 |
Potentially dilutive common stock equivalents | 0 | 0 | 37,698 | |
Weighted average number of common and equivalent shares outstanding - Diluted | 17,755,516 | 15,034,219 | 16,423,335 | 13,270,097 |
Weighted average number of common and equivalent shares outstanding - Diluted | 16,423,335 | 13,307,795 |
ORGANIZATION, NATURE OF BUSIN_5
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details 3) - integer | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
BASIS OF PRESENTATION | ||
Number of 10% clients | 1 | 1 |
Percentage of total revenue | 15.33% | 14.82% |
Percentage of total AR | 35.08% | 14.65% |
ORGANIZATION, NATURE OF BUSIN_6
ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details 4) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Euro [Member] | ||
Average exchange rate for the period | ||
USD exchange rate | 1.1318 | 1.2230 |
USD average exchange rate | 1.1830 | 1.1410 |
GBP [Member] | ||
Average exchange rate for the period | ||
USD exchange rate | 1.3500 | 1.3662 |
USD average exchange rate | 1.3764 | 1.2829 |
ORGANIZATION NATURE OF BUSINE_3
ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN (Details 5) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Fair value of assets and liabilities | $ 12,551 | $ 11,468 | $ 222,792 |
Equity securities - Pancreta Bank [Member] | |||
Fair value of assets and liabilities | 5,729 | 4,772 | |
Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | 6,822 | 6,696 | 4,609 |
Level 2 [Member] | |||
Fair value of assets and liabilities | 5,729 | 4,772 | |
Level 2 [Member] | Equity securities - Pancreta Bank [Member] | |||
Fair value of assets and liabilities | 5,729 | 4,772 | |
Level 2 [Member] | Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 2 [Member] | Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 3 [Member] | Equity securities - Pancreta Bank [Member] | |||
Fair value of assets and liabilities | 0 | 0 | |
Level 3 [Member] | Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 3 [Member] | Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 1 [Member] | |||
Fair value of assets and liabilities | 6,822 | 6,696 | 222,792 |
Level 1 [Member] | Equity securities - Pancreta Bank [Member] | |||
Fair value of assets and liabilities | 0 | 0 | |
Level 1 [Member] | Marketable securities - ICC International Cannabis Corp. [Member] | |||
Fair value of assets and liabilities | 0 | 0 | 0 |
Level 1 [Member] | Marketable securities - National Bank of Greece [Member] | |||
Fair value of assets and liabilities | $ 6,822 | $ 6,696 | $ 4,609 |
ORGANIZATION NATURE OF BUSINE_4
ORGANIZATION NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||
Nov. 21, 2017 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2020 | Jan. 01, 2020 | Dec. 19, 2018 | Mar. 23, 2017 | Feb. 28, 2017 | |
REVENUE | $ 13,071,800 | $ 11,619,076 | $ 56,239,667 | $ 55,406,337 | ||||||
Net income (loss) | 203,347 | (2,173,903) | (7,961,649) | 820,786 | $ 820,786 | |||||
NET CASH USED IN OPERATING ACTIVITIES | 2,337,276 | 665,339 | 7,097,174 | 11,501,718 | ||||||
WORKING CAPITAL DEFICIT | (10,950,492) | |||||||||
Accumulated deficit | 34,142,159 | 34,345,506 | 18,750,824 | 18,750,824 | ||||||
TOTAL STOCKHOLDERS' EQUITY | 5,151,001 | (2,804,680) | 4,379,463 | (4,161,013) | (4,161,013) | $ (6,460,829) | ||||
Accumulated depreciation | 7,393 | |||||||||
Goodwill and intangible assets | 4,772 | |||||||||
Salaries and wages | 531,556 | 2,082,453 | ||||||||
Customer deposits | 1,333 | |||||||||
Allowance for doubtful accounts | 1,668,893 | 1,702,743 | ||||||||
VAT net payable balance | 376,656 | 400,616 | ||||||||
Depreciation expense | 84,884 | 71,471 | 319,337 | 240,886 | ||||||
Amortization expense | 8,158 | 8,158 | 33,085 | 33,176 | ||||||
Reverse stock split, description | the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of common stock. | |||||||||
Customer deposits | 22,340 | 22,340 | ||||||||
Accounts Payable | 230,505 | 230,505 | ||||||||
Reclassified Liabilities, Current | 502,869 | 502,869 | ||||||||
Bad debt expenses | $ 1,087,339 | 96,237 | ||||||||
Income tax term | 5 years | |||||||||
Allowance for doubtful accounts | $ 1,702,743 | 715,845 | ||||||||
Cash on hand | 25,773 | 31,604 | 31,604 | |||||||
Accumulated deficit | (34,142,159) | (34,345,506) | (18,750,824) | (18,750,824) | ||||||
Net Cash Provided By Used In Operating Activitie | (2,337,276) | (665,339) | (7,097,174) | (11,501,718) | ||||||
Prepaid expenses and other current assets | 400,616 | 159,198 | 159,198 | |||||||
Goodwill | 49,697 | 49,697 | 49,697 | 49,697 | $ 49,697 | |||||
Potential retirement and termination benefits liability | $ 0 | 107,167 | 107,167 | |||||||
Periodic inventory level, percentage | 100.00% | |||||||||
Description of Potential retirement and termination benefits liability | If an employee remains with the company until full-benefit retirement, the employee is entitled to a lump-sum equal to 40% of the compensation to be received if the employee were to be dismissed on the same day. | |||||||||
Import/export license [Member] | ||||||||||
Estimated Useful Life | 5 years | |||||||||
Equity securities - Pancreta Bank [Member] | ||||||||||
Additional investments in equity securities | $ 5,729 | |||||||||
United Kingdom Of England [Member] | ||||||||||
Income tax rate | 19.00% | |||||||||
Total amounts in account | $ 144,489 | 448,659 | 448,659 | |||||||
Bulgaria [Member] | ||||||||||
Total amounts in account | 4,061 | 1,651 | 1,651 | |||||||
Greece [Member] | ||||||||||
REVENUE | $ 13,009,038 | $ 11,453,496 | 55,564,240 | 51,259,784 | ||||||
Total amounts in account | $ 101,589 | $ 134,935 | 134,935 | |||||||
Income tax rate | 22.00% | |||||||||
Acquisition of Cosmofarm [Member] | ||||||||||
Goodwill | $ 49,697 | |||||||||
National Bank of Greece [Member] | ||||||||||
Equity method investment shares acquired, shares | 16,666 | 16,666 | 16,666 | |||||||
Closing price | $ 0.41 | $ 0.40 | $ 0.28 | |||||||
Equity method investment shares acquired, value | $ 6,822 | $ 6,696 | $ 4,609 | 4,609 | ||||||
ICC International Cannabis Corp [Member] | ||||||||||
Equity method investment shares acquired, shares | 3,000,000 | 3,000,000 | 3,000,000 | |||||||
Closing price | $ 0 | $ 0 | $ 0 | |||||||
Equity method investment shares acquired, value | $ 0 | $ 0 | $ 0 | 0 | ||||||
Pancreta Bank [Member] | ||||||||||
Equity method investment shares acquired, value | $ 4,416 | $ 4,772 | 4,772 | |||||||
Decahedron Ltd [Member] | Stock Purchase Agreement [Member] | ||||||||||
Common stock shares reserved | 170,000 | |||||||||
SkyPharm [Member] | Second amendment to loan facility agreement [Member] | ||||||||||
Common stock shares reserved | 1,000,000 | |||||||||
Diversa S.A. [Member] | ||||||||||
Equity method investment shares acquired, shares | 40,000 | |||||||||
Closing price | $ 5.45 | |||||||||
Equity method investment shares acquired, value | $ 218,183 | $ 218,183 |
MARKETABLE SECURITIES (Details
MARKETABLE SECURITIES (Details Narrative) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Jul. 16, 2018USD ($)shares | May 17, 2018USD ($)shares | May 17, 2018USD ($)shares | Mar. 31, 2022USD ($)$ / sharesshares | Mar. 31, 2022CAD ($)shares | Mar. 31, 2022EUR (€)shares | Mar. 31, 2022USD ($)shares | Dec. 31, 2021USD ($)$ / sharesshares | Dec. 31, 2021CAD ($)shares | Dec. 31, 2021EUR (€)shares | Dec. 31, 2020USD ($)$ / sharesshares | Sep. 30, 2019 | Jun. 30, 2019 | |
Net unrealized loss on fair value investment | $ 1,678 | $ 2,541 | $ 2,246 | ||||||||||
Investement | $ 169,770 | $ 183,450 | |||||||||||
Marketable securities - Divsersa S.A. [Member] | |||||||||||||
Closing price of shares | $ / shares | $ 5.45 | ||||||||||||
Shares issued as marketable securities | shares | 40,000 | ||||||||||||
Stock issued during the period, amount | $ 218,183 | ||||||||||||
Marketable securities - National Bank of Greece [Member] | |||||||||||||
Closing price of shares | $ / shares | $ 0.40 | $ 0.28 | |||||||||||
Marketable securities | $ 6,696 | $ 4,609 | |||||||||||
Shares issued as marketable securities | shares | 16,666 | 16,666 | |||||||||||
Marathon Global Inc [Member] | May and July 2018 [Member] | |||||||||||||
Consideration for the distribution services, shares | $ 5,000,000 | ||||||||||||
Marathon Global Inc [Member] | Share Exchange Agreement [Member] | |||||||||||||
Gain on exchange of investment | $ 2,092,200 | $ 1,953,000 | $ 1,953,000 | ||||||||||
Shares of Marathon transferred by company to KBB | shares | 2,500,000 | ||||||||||||
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member] | |||||||||||||
Transfer of shares | shares | 2,500,000 | 2,500,000 | |||||||||||
Kaneh Bosm Biotechnology Inc [Member] | Share Exchange Agreement [Member] | Canadian Securities Exchange [Member] | |||||||||||||
Exchange of shares | shares | 5,000,000 | 5,000,000 | |||||||||||
ICC [Member] | Share Exchange Agreement [Member] | |||||||||||||
Net unrealized loss on fair value investment | $ 0 | ||||||||||||
Investement | $ 0 | $ 0 | 0 | ||||||||||
Exchange of shares | shares | 5,000,000 | ||||||||||||
Description for ownership percentage | The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC. | Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services | Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services | Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services | |||||||||
Additional shares issued, shares | shares | 3,000,000 | 3,000,000 | |||||||||||
Equity securities - Pancreta Bank [Member] | |||||||||||||
Additional investments in equity securities | $ 5,729 | ||||||||||||
Equity securities - Pancreta Bank [Member] | Share Exchange Agreement [Member] | |||||||||||||
Additional investments in equity securities | $ 5,729 | ||||||||||||
ICC [Member] | Share Exchange Agreement [Member] | |||||||||||||
Net unrealized loss on fair value investment | 0 | ||||||||||||
Investement | 0 | $ 0 | |||||||||||
Upfront cash received | $ 211,047 | ||||||||||||
Description for ownership percentage | The ten million shares of ICC owned by the Company constituted approximately 7% of the 141,219,108 shares of capital stock of KBB then issued and outstanding. The Company does not have the ability to exercise significant influence over ICC | Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement | Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement | Since no value was attributed to the 33 1/3% equity ownership interest in Marathon received as consideration for the distribution services, the Company would receive variable consideration in future for its services under the Distribution and Equity Acquisition Agreement | |||||||||
Additional shares issued, shares | shares | 3,000,000 | 3,000,000 | |||||||||||
Equity method investment shares acquired | shares | 5,000,000 | ||||||||||||
Additional shares issued, amount | $ 0 | $ 0 | |||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | |||||||||||||
Equity interest acquired description | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milest | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milest | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milest | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones | |||||||
Cash received upon gross sales | $ 2,750,000 | ||||||||||||
Gross sales | $ 6,500,000 | ||||||||||||
Upfront cash received | 2,000,000 | $ 2,000,000 | |||||||||||
Agreement term | 5 years | 5 years | 5 years | ||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales One [Member] | |||||||||||||
Cash received upon gross sales | 2,750,000 | $ 2,750,000 | |||||||||||
Gross sales | 13,000,000 | 13,000,000 | |||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales [Member] | |||||||||||||
Cash received upon gross sales | $ 2,750,000 | 2,750,000 | |||||||||||
Gross sales | $ 6,500,000 | ||||||||||||
Cosmo Farmacy LP [Member] | |||||||||||||
Investement | $ 166,395,000,000 | $ 166,395,000,000 | $ 169,770,000,000 | ||||||||||
Cash contributed to limited partner | € | € 150,000,000,000 | € 150,000 | |||||||||||
Initial share capital increased | € | 500,000,000,000 | 500,000 | |||||||||||
Pharmacy license value | € | € 350,000,000,000 | € 350,000 | |||||||||||
Maturity period of license | 30 years | 30 years | 30 years | 30 years | 30 years | 30 years | |||||||
Ownership equity | 70.00% | 70.00% | |||||||||||
Initial share capital | € | € 150,000,000,000 | € 150,000 | |||||||||||
Equity ownership remaining | 30.00% | 30.00% | |||||||||||
National Bank of Greece [Member] | |||||||||||||
Equity method investment shares acquired, value | $ 6,822 | 6,822 | $ 6,696 | $ 4,609 | |||||||||
Equity method investment shares acquired, shares | shares | 16,666 | 16,666 | 16,666 | 16,666 | 16,666 | 16,666 | 16,666 | ||||||
Closing price | $ / shares | $ 0.41 | $ 0.40 | $ 0.28 | ||||||||||
National Bank of Greece [Member] | Share Exchange Agreement [Member] | |||||||||||||
Equity method investment shares acquired, value | $ 6,822 | $ 6,822 | |||||||||||
Equity method investment shares acquired, shares | shares | 16,666 | 16,666 | 16,666 | ||||||||||
Closing price | $ / shares | $ 0.41 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Less: Accumulated depreciation | $ (993,688) | $ (934,473) | |
Total | 1,777,889 | 1,888,052 | $ 1,757,213 |
Property plant and equipment | 2,822,525 | 2,447,427 | |
Less: Accumulated depreciation | (941,866) | (690,214) | |
Computers and software [Member] | |||
Property plant and equipment | 141,490 | 149,005 | |
Vehicles [Member] | |||
Property plant and equipment | 94,735 | 96,657 | 105,057 |
Leasehold Improvements [Member] | |||
Property plant and equipment | 508,920 | 519,278 | 560,711 |
Furniture, fixtures and equipment [Member] | |||
Property plant and equipment | 2,027,470 | 2,065,100 | $ 1,632,654 |
Computer Equipment [Member] | |||
Property plant and equipment | $ 140,452 | $ 141,490 |
GOODWILL AND INTANGIBLE ASSET_2
GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 19, 2018 |
Less: Accumulated Amortization | $ (138,717) | $ (116,066) | $ (82,981) | |
Subtotal | 414,933 | 443,463 | 180,809 | |
Goodwill | 49,697 | 49,697 | 49,697 | $ 49,697 |
Total | 464,630 | 493,160 | 230,506 | |
Goodwill and intangible assets, gross | 559,529 | 263,790 | ||
Customer Base [Member] | ||||
Goodwill and intangible assets, gross | 176,793 | 176,793 | 176,793 | |
Trade name / mark [Member] | ||||
Goodwill and intangible assets, gross | 36,997 | 71,471 | 84,884 | |
License [Member] | ||||
Goodwill and intangible assets, gross | $ 339,860 | $ 345,739 | $ 50,000 |
LOAN RECEIVABLE (Details Narrat
LOAN RECEIVABLE (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
Oct. 30, 2021 | Mar. 31, 2022 | Dec. 31, 2021 | |
LOAN RECEIVABLE (Details Narrative) | |||
Principal payments | $ 90,626 | $ 60,942 | |
Short-term receivable | 375,195 | 377,590 | |
Long term receivables | $ 4,227,268 | $ 4,410,689 | |
Prepayments of loan | $ 4,849,221 | ||
Interest rate | 5.50% | ||
Loan receivables term | 360 years | ||
Decription of loan payment | the Company entered into an agreement for a ten-year loan with a third-party to memorialize €4,284,521 ($4,849,221) in prepayments the Company had made |
CAPITAL STRUCTURE (Details Narr
CAPITAL STRUCTURE (Details Narrative) - USD ($) | Dec. 08, 2021 | Aug. 04, 2021 | Jul. 19, 2021 | Feb. 05, 2021 | Jul. 13, 2020 | Feb. 28, 2022 | Dec. 29, 2021 | Sep. 15, 2021 | Jun. 23, 2021 | Nov. 30, 2020 | Oct. 31, 2020 | Sep. 30, 2020 | Aug. 31, 2020 | Jul. 31, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | May 03, 2022 | Dec. 21, 2021 | Jul. 13, 2021 | Oct. 29, 2020 |
Preferred stock, shares authorized | 100,000,000 | 100,000,000 | 100 | |||||||||||||||||||
Restricted shares of Common stock | 1,800,000 | 1,800,000 | ||||||||||||||||||||
Stock earned per month | 200,000 | 200,000 | ||||||||||||||||||||
Retained agreement descriptions | The shares were valued on the date of the agreement at $3.28 per share or $5,904,000, which was be amortized over the term of the agreement. | |||||||||||||||||||||
Expenses during Consulting Agreement | $ 0 | $ 1,189,451 | ||||||||||||||||||||
Conversion of Debt | 1,190,000 | $ 550,144 | ||||||||||||||||||||
Extinguishment of debt | 216,580 | $ 124,711 | ||||||||||||||||||||
Gain Extinguishment of debt | $ 216,580 | |||||||||||||||||||||
Fair value per share | $ 4.09 | |||||||||||||||||||||
Issue shares of common stock | 829,471 | |||||||||||||||||||||
Cashless exercise warrants | 2,748,797 | |||||||||||||||||||||
Common stock, shares authorized | 300,000,000 | 100,000,000 | 300,000,000 | |||||||||||||||||||
Common stock, shares issued | 18,611,980 | 17,544,509 | 13,485,128 | |||||||||||||||||||
Common stock, shares outstanding | 18,224,556 | 17,157,085 | 13,069,800 | |||||||||||||||||||
Equity increase related to the extinguishment of debt | 2,564,363 | |||||||||||||||||||||
Gain on extinguishment of debt | $ 1,004,124 | $ 445,636 | ||||||||||||||||||||
Series A preferred stock | 5,452,300 | $ 0 | $ 0 | |||||||||||||||||||
Cancellation of treasury shares | 57,120 | |||||||||||||||||||||
Extinguishment of debt | $ 2,564,363 | |||||||||||||||||||||
Cancellation of treasury shares, value | $ 171,360 | |||||||||||||||||||||
Common stock, shares issued | 17,544,509 | 13,485,128 | ||||||||||||||||||||
Common stock shares authorized | 300,000,000 | 300,000,000 | ||||||||||||||||||||
Stock-based compensation | $ 5,904,000 | |||||||||||||||||||||
Stock-based compensation, shares earned | 1,800,000 | |||||||||||||||||||||
Capital contribution | $ 959,025 | |||||||||||||||||||||
Stock held in treasury, value | $ 250,000 | $ 40,000 | ||||||||||||||||||||
Share price | $ 3.85 | |||||||||||||||||||||
Deemed dividend on warrants | (5,788,493) | |||||||||||||||||||||
Preferred stock, shares issued | 0 | 0 | ||||||||||||||||||||
Additional paid-in capital | 40,648,106 | $ 39,675,753 | $ 14,333,285 | |||||||||||||||||||
Gain on extinguishment of debt | $ 1,004,124 | $ 445,636 | (606,667) | (942,029) | ||||||||||||||||||
Debt Exchange Agreements | ||||||||||||||||||||||
Capital contribution | 10 | |||||||||||||||||||||
Principal amount | $ 3,000,000 | |||||||||||||||||||||
Exchange rate | $ 6 | |||||||||||||||||||||
Increase in equity | $ 750,000 | 1,000,000 | ||||||||||||||||||||
Derivative liability[Member] | ||||||||||||||||||||||
Additional paid-in capital | $ 284,169 | |||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||
Preferred stock, shares authorized | 6,000,000 | 6,000,000 | ||||||||||||||||||||
Preferred stock, Liquidation Preference | 6,000,000 | |||||||||||||||||||||
Preferred stock, shares issued | 6,000 | 0 | ||||||||||||||||||||
Private Placement [Member] | ||||||||||||||||||||||
Extinguishment of debt | $ 0 | |||||||||||||||||||||
Private Placement [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||||
Sales of shares | 6,000 | |||||||||||||||||||||
Warrants | 2,000,000 | |||||||||||||||||||||
Aggregate gross proceeds warrants | $ 6,000,000 | |||||||||||||||||||||
Warrants, Description | The Warrants are exercisable to purchase shares of common stock at $3.30 per share, or 110% of the Series A Shares initial conversion price and will expire five and one-half years following the initial exercise date of the Warrants. | |||||||||||||||||||||
Warrants Black-Scholes option pricing model , Description | The warrants were valued using the Black-Scholes option pricing model with the following terms: a) exercise price of $3.30, b) common stock fair value of $3.42, c) volatility of 118%, d) discount rate of $1.71%, and e) dividend rate of 0%. | |||||||||||||||||||||
Additional value of Warrants | 2,000,000 | |||||||||||||||||||||
Deemed dividend on warrants | $ (5,788,493) | |||||||||||||||||||||
Debt Conversions [Member] | ||||||||||||||||||||||
Capital contribution | $ 973,420 | $ 550,144 | ||||||||||||||||||||
Shares issued | 781,819 | 238,000 | 213,382 | |||||||||||||||||||
Common Stock | ||||||||||||||||||||||
Extinguishment of debt | $ 1,314,117 | |||||||||||||||||||||
Share price | $ 2.58 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | Sepetember [Member] | ||||||||||||||||||||||
Common stock, shares purchased | 10,000 | |||||||||||||||||||||
Common stock, purchase price | $ 4 | |||||||||||||||||||||
Aggregate common stock value | $ 40,000 | |||||||||||||||||||||
Payment made against shares purchased | 40,000 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | December [Member] | ||||||||||||||||||||||
Common stock, shares purchased | 94,216 | |||||||||||||||||||||
Common stock, purchase price | $ 4 | |||||||||||||||||||||
Aggregate common stock value | $ 376,863 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | July [Member] | ||||||||||||||||||||||
Common stock, shares purchased | 10,000 | |||||||||||||||||||||
Common stock, purchase price | $ 4 | |||||||||||||||||||||
Aggregate common stock value | $ 40,000 | |||||||||||||||||||||
Payment made against shares purchased | 40,000 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | August [Member] | ||||||||||||||||||||||
Common stock, shares purchased | 10,000 | |||||||||||||||||||||
Common stock, purchase price | $ 4 | |||||||||||||||||||||
Aggregate common stock value | $ 40,000 | |||||||||||||||||||||
Payment made against shares purchased | 40,000 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | October [Member] | ||||||||||||||||||||||
Common stock, shares purchased | 10,000 | |||||||||||||||||||||
Common stock, purchase price | $ 4 | |||||||||||||||||||||
Aggregate common stock value | $ 40,000 | |||||||||||||||||||||
Payment made against shares purchased | 40,000 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | November [Member] | ||||||||||||||||||||||
Common stock, shares purchased | 10,000 | |||||||||||||||||||||
Common stock, purchase price | $ 4 | |||||||||||||||||||||
Aggregate common stock value | $ 40,000 | |||||||||||||||||||||
Payment made against shares purchased | $ 40,000 | |||||||||||||||||||||
Stock Purchase Agreement [Member] | Shareholder [Member] | February [Member] | ||||||||||||||||||||||
Stock held in treasury, value | $ 250,000 | |||||||||||||||||||||
Share price | $ 3.85 | |||||||||||||||||||||
Treasury stock sell | 65,000 | |||||||||||||||||||||
Debt Exchange Agreement [Member] | ||||||||||||||||||||||
Common stock, shares issued | 321,300 | 259,741 | ||||||||||||||||||||
Share issued price per share | $ 3.85 | |||||||||||||||||||||
Debt Exchange Agreement [Member] | Chief Executive Officer [Member] | ||||||||||||||||||||||
Aggregate common stock value | 750,000 | |||||||||||||||||||||
Principal amount | $ 125,000 | $ 1,250,000 | $ 3,010,000 | $ 3,000,000 | $ 1,000,000 | |||||||||||||||||
Exchange rate | $ 6 | $ 6 | ||||||||||||||||||||
Increase in equity | 1,250,000 | |||||||||||||||||||||
Exchange share of common stock | 208,333 | |||||||||||||||||||||
Share issued price per share | 3.44 | $ 4.30 | $ 3.28 | $ 5 | $ 4.30 | |||||||||||||||||
Debt Exchange Agreement [Member] | Lender [Member] | ||||||||||||||||||||||
Shares issued | 781,819 | |||||||||||||||||||||
Principal amount | $ 1,606,500 | $ 3,010,000 | $ 3,000,000 | $ 1,000,000 | ||||||||||||||||||
Exchange rate | $ 6 | $ 5 | $ 3.85 | $ 6 | $ 6 | |||||||||||||||||
Exchange share of common stock | 750,000 | 166,667 | 500,000 | |||||||||||||||||||
Share issued price per share | $ 4.09 | $ 3.28 | $ 5 | $ 4.03 | ||||||||||||||||||
Increase in equity | $ 1,314,117 | $ 455,636 | 3,000,000 | |||||||||||||||||||
Gain on extinguishment of debt | $ 445,636 |
INCOME TAXES (Details)
INCOME TAXES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Loss before provision for income taxes | $ (7,847,638) | $ 1,198,321 |
Domestic [Member] | ||
Loss before provision for income taxes | (8,365,297) | (2,901,276) |
Foreign [Member] | ||
Loss before provision for income taxes | $ 517,659 | $ 4,099,597 |
INCOME TAXES (Details 1)
INCOME TAXES (Details 1) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Current tax provision | ||
Federal | $ 0 | $ 0 |
State | 0 | 0 |
Foreign | 802,364 | 555,965 |
Total current tax provision | 802,364 | 555,965 |
Deferred tax provision | ||
Domestic | 0 | 0 |
State | 0 | 0 |
Foreign | (688,354) | (178,430) |
Total deferred tax provision | (688,354) | (178,430) |
Total current provision | $ 114,010 | $ 377,535 |
INCOME TAXES (Details 2)
INCOME TAXES (Details 2) - USD ($) | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
INCOME TAXES | ||
Income (loss) before income taxes | $ (7,847,639) | $ 1,198,321 |
Taxes under statutory US tax rates | (1,648,004) | 251,647 |
Increase in valuation allowance | 3,001,899 | 216,518 |
Foreign tax rate differential | (24,977) | (55,540) |
Permanent differences | (734,428) | (218,216) |
US tax on foreign income | 493,028 | 604,419 |
163(j) catch up | (76,888) | 0 |
Prior period adjustments | 52,034 | (97,829) |
State taxes | (948,654) | (323,464) |
Income tax expense | $ 114,010 | $ 377,535 |
INCOME TAXES (Details 3)
INCOME TAXES (Details 3) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 19, 2018 | |
Allowance for doubtful accounts | $ 1,668,893 | $ 1,702,743 | |||
Accrued expenses | 3,100 | ||||
Gain on extinguishment of debt | 1,004,124 | $ 445,636 | (606,667) | $ (942,029) | |
Goodwill | $ 49,697 | 49,697 | 49,697 | $ 49,697 | |
Deferred Income Taxes [Member] | |||||
Net operating loss carryforward | 4,515,900 | 1,494,424 | |||
Capital loss carryforward | 801,744 | 801,744 | |||
Section 163(j) carryforward | 0 | 0 | |||
Nonqualified Stock Options | 96,104 | 170,297 | |||
Foreign exchange | 13,438 | 0 | |||
Allowance for doubtful accounts | 374,604 | 0 | |||
Accrued expenses | 528,895 | 7,389 | |||
Mark to market adjustment to securities | 358,761 | 357,829 | |||
Lease liability | 0 | 247,797 | |||
Gain on extinguishment of debt | 0 | 179,958 | |||
Depreciation | (6,765) | 4,226 | |||
Total Deferred tax assets | 6,936,211 | 3,263,664 | |||
Intangibles | (8,139) | (10,729) | |||
Inventory | (14,728) | 0 | |||
Right of use asset | (243,207) | (253,818) | |||
Goodwill | (10,979) | (14,473) | |||
Total Deferred tax liabilities | (277,053) | (279,020) | |||
Valuation allowance | (5,808,384) | (2,806,214) | |||
Net deferred tax assets (liabilities) | $ 850,774 | $ 178,430 |
INCOME TAXES (Details Narrative
INCOME TAXES (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Federal Statutory Income Tax Rate, description | subject to limitation under IRC Section 382. Of the $12.5 million Federal NOL carryforwards, $2.5 million are pre-2018 and begin to expire in 2031. The remaining balance of $10 million, are limited to utilization of 80% of taxable income but do not have an expiration | |||
Undistributed earnings | $ 1,700,000 | |||
Distribution expense | 350,300 | |||
Valuation allowances | $ 200,000 | |||
Net operating loss carry forward | 12,513,177 | |||
Deferred tax assets | $ 62,594 | $ (329,586) | (714,108) | $ (178,430) |
United States [Member] | ||||
Net operating loss carry forward | $ 546,683 | |||
Expiry | 2031 | |||
Grece [Member] | ||||
Income tax rate | 22.00% | |||
United States [Member] | ||||
Deferred tax assets | $ 65,667 | $ 315,912 |
RELATED PARTY TRANSACTIONS (Det
RELATED PARTY TRANSACTIONS (Details) - Notes Payable - Related Party [Member] - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Beginning Balance | $ 464,264 | $ 501,675 | $ 1,375,532 |
Foreign currency translation | (9,229) | (37,411) | |
Ending Balance | $ 455,035 | 464,264 | 501,675 |
Payments | $ 0 | $ (996,136) |
RELATED PARTY TRANSACTIONS (D_2
RELATED PARTY TRANSACTIONS (Details 1) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Conversion of debt | $ 973,420 | $ 2,564,364 | ||
Loans Payable - Related Party [Member] | ||||
Beginning Balance | 1,293,472 | $ 1,629,246 | $ 1,026,264 | |
Proceeds | 456,085 | 6,377,156 | 725,563 | |
Payments | (22,186) | (133,552) | (149,695) | |
Conversion of debt | 0 | 6,000,000 | ||
Settlement of lawsuit | 0 | (600,000) | 0 | |
Foreign currency translations | (23,490) | 20,623 | 27,114 | |
Ending Balance | $ 1,703,881 | $ 1,293,472 | $ 1,629,246 |
RELATED PARTY TRANSACTIONS (D_3
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) | May 10, 2021 | Oct. 10, 2020 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2020 | Dec. 20, 2018 | Dec. 20, 2018 |
Revenue | $ 13,071,800 | $ 11,619,076 | $ 56,239,667 | $ 55,406,337 | |||||
Foreign curreny translation | 13,106 | 423,245 | |||||||
Accrued interest | 1,033,866 | 1,019,889 | 742,374 | $ 742,374 | |||||
Net income (loss) | 203,347 | (2,173,903) | $ (7,961,649) | $ 820,786 | $ 820,786 | ||||
Shares issued | 17,544,509 | 13,485,128 | 13,485,128 | ||||||
DOC Pharma S.A. [Member] | |||||||||
Prepaid balance | 4,368,794 | $ 3,263,241 | $ 3,468,653 | $ 3,468,653 | |||||
Accounts payable balance | 220,518 | 565,756 | |||||||
Net prepaid balance | 4,148,276 | ||||||||
Accounts receivable balance | 2,844,572 | 2,901,300 | 3,468,564 | 3,468,564 | |||||
Payments to purchase products | 687,382 | 589,261 | 3,084,805 | 5,983,809 | |||||
Revenue | $ 383,688 | $ 290,598 | $ 978,321 | 2,843,260 | |||||
Description of research and development | Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($289,860) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025. | Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). In the year ended December 31, 2021, SkyPharm bought 67 licenses at value of €261,300 ($295,739) from Doc Pharma which was the 18.33% of the total cost. The agreement will be terminated on December 31, 2025. | |||||||
Foreign curreny translation | $ 37,411 | 122,279 | |||||||
Pieces per product | 1,000 pieces | ||||||||
Inventroy purchase | $ 2,010,517 | ||||||||
DOC Pharma S.A. [Member] | Outsourcing Agreement [Member] | |||||||||
Pieces per product | 1,000 | ||||||||
Inventroy purchase | $ 517,566 | ||||||||
Agreement term | 5 years | ||||||||
Grigorios Siokas [Member] | |||||||||
Interest rate | 4.70% | 4.70% | |||||||
Accrued interest | 201,835 | 200,683 | 193,585 | 193,585 | |||||
Outstanding principal balance | 443,720 | 452,720 | 489,200 | 489,200 | |||||
Borrowing | $ 1,718,400 | $ 1,718,400 | |||||||
Maturity date | Mar. 18, 2019 | ||||||||
Litigation settlement | $ 600,000 | ||||||||
Plantiff attorney fees | 120,000 | ||||||||
Litigation cost | $ 4,137 | ||||||||
Dimitrios Goulielmos [Member] | |||||||||
Outstanding principal balance | 11,315 | 11,544 | 12,475 | 12,475 | |||||
Gain incured | 9,229 | ||||||||
Grigorios Siokas Three [Member] | |||||||||
Foreign curreny translation | 20,623 | 27,114 | |||||||
Outstanding principal balance | 1,293,472 | $ 1,629,246 | $ 1,629,246 | ||||||
Borrowing | 2,040,635 | ||||||||
Additional proceeds from debt | 356,085 | 275,306 | |||||||
Repayment of loans | 22,186 | $ 133,552 | |||||||
Net income (loss) | 23,490 | ||||||||
Debt instrument conversion price | $ 6 | ||||||||
Convertible share description | Mr. Siokas whereby the Company exchanged an aggregate total of $6,000,000 of debt into 1,000,000 shares of Common Stock at above market prices. | ||||||||
Debt instrument converted amount | $ 2,250,000 | ||||||||
Shares issued | 375,000 | ||||||||
Grigorios Siokas Four [Member] | |||||||||
Additional proceeds from debt | $ 100,000 |
LINES OF CREDIT (Details)
LINES OF CREDIT (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
Subtotal | $ 4,548,199 | $ 5,109,728 | $ 5,076,684 |
Reclassification of National-COVID - Long-term | (185,872) | (366,171) | (502,869) |
Line of credit | 4,362,327 | 4,743,557 | 4,573,815 |
Pancreta [Member] | |||
Line of credit | 417,671 | 489,985 | |
National [Member] | |||
Line of credit | 2,887,143 | 3,265,236 | 3,540,550 |
Alpha [Member] | |||
Line of credit | 927,008 | 947,333 | 1,106,894 |
National - COVID [Member] | |||
Line of credit | $ 316,377 | 407,174 | 429,240 |
Pancretan [Member] | |||
Line of credit | $ 489,985 | $ 0 |
LINES OF CREDIT (Details Narrat
LINES OF CREDIT (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | |||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | Jun. 23, 2020 | |
Lines of credit classified | $ 366,171 | $ 366,171 | |||
Interest Expense | $ 584,176 | $ 731,826 | 2,823,842 | 2,761,004 | |
Lines of credit | $ 4,362,327 | $ 4,743,557 | 4,573,815 | ||
Common Stock | |||||
Interest Rate | 2.70% | ||||
Interest Expense | $ 1,753 | 3,910 | |||
Lines of credit | 407,174 | 429,240 | |||
Line of Credit [Member] | |||||
Interest Rate | 6.00% | 4.35% | |||
Interest Expense | $ 413 | $ 0 | |||
Line of Credit [Member] | National Bank of Greece Two [Member] | |||||
Borrowing | 1,109,300 | 1,131,800 | 1,123,000 | $ 611,500 | |
Outstanding debt balance | $ 1,053,749 | $ 1,079,823 | 1,129,368 | ||
Interest Rate | 4.35% | 4.35% | |||
Line of Credit [Member] | Alpha Bank of Greece [Member] | |||||
Borrowing | $ 1,109,300 | $ 1,131,800 | 1,123,000 | ||
Outstanding debt balance | $ 927,008 | $ 947,333 | 1,106,894 | ||
Interest Rate | 6.00% | 6.00% | |||
Line of Credit [Member] | Pancreta Bank of Greece [Member] | |||||
Borrowing | $ 554,650 | $ 565,900 | |||
Outstanding debt balance | $ 417,671 | $ 489,985 | |||
Interest Rate | 6.10% | 6.10% | |||
Interest Expense | $ 17,175 | $ 16,501 | $ 283,415 | 270,655 | |
National Bank of Greece One [Member] | Line of Credit [Member] | |||||
Borrowing | 3,300,168 | 2,489,960 | 2,690,600 | ||
Outstanding debt balance | $ 1,833,394 | $ 2,185,413 | $ 2,411,182 | ||
Interest Rate | 6.00% | 6.00% |
CONVERTIBLE DEBT (Details)
CONVERTIBLE DEBT (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
DEBT | |||
Beginning balance notes | $ 640,000 | $ 1,447,000 | $ 1,500,000 |
New notes | 0 | 625,000 | 540,000 |
Payments | 0 | (907,000) | (593,000) |
Conversion to common stock | 0 | (525,000) | 0 |
Subtotal notes | 640,000 | 640,000 | 1,447,000 |
Debt discount at year end | $ (191,085) | (258,938) | (494,973) |
Convertible note payable net of discount | $ 381,062 | $ 952,027 |
CONVERTIBLE DEBT (Details 1)
CONVERTIBLE DEBT (Details 1) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
DEBT | |||
Issuances to debt discount | $ 0 | $ 62,619 | $ 456,570 |
Reduction of derivative related to conversions | 0 | (284,169) | |
Change in fair value of derivative liabilities | 15,001 | (193,513) | 4,158 |
Ending balance | 30,664 | 45,665 | 460,728 |
Beginning balance | $ 45,665 | $ 460,728 | $ 0 |
CONVERTIBLE DEBT (Details 2)
CONVERTIBLE DEBT (Details 2) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Dividend yield | 0.00% | 0.00% | 0.00% |
Minimum [Member] | |||
Expected life | 6 months | 1 year | |
Risk-free interest rate | 1.40% | 0.41% | 0.11% |
Maximum [Member] | |||
Expected life | 6 months 7 days | ||
Risk-free interest rate | 0.44% | 0.12% | |
Expected volatility | 107.30% | 142.50% |
CONVERTIBLE DEBT (Details Narra
CONVERTIBLE DEBT (Details Narrative) - USD ($) | Sep. 04, 2018 | Sep. 17, 2021 | Jun. 18, 2021 | Dec. 21, 2020 | Sep. 23, 2020 | Mar. 23, 2020 | Nov. 15, 2017 | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2018 | Dec. 21, 2021 | Sep. 30, 2021 | Aug. 16, 2021 | Jul. 14, 2021 | Mar. 31, 2021 | Feb. 05, 2021 | Jan. 07, 2021 | Dec. 16, 2020 | Dec. 31, 2019 | May 31, 2019 | May 17, 2019 |
Average price per share | $ 3.85 | |||||||||||||||||||||
Convertible notes payable, principal amount | $ 448,915 | $ 5,462,504 | $ 12,042,712 | $ 100,000 | ||||||||||||||||||
Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||||||||||||
Interest expense | $ 375,195 | $ 377,590 | ||||||||||||||||||||
Shares issued | 17,544,509 | 13,485,128 | ||||||||||||||||||||
Derivative liability | 30,664 | $ 45,665 | $ 460,728 | $ 0 | ||||||||||||||||||
Extinguishment of debt | 216,580 | $ 124,711 | ||||||||||||||||||||
Third Forbearance Agreement [Member] | ||||||||||||||||||||||
Forbearance period description | The Scheduled Required Prepayments are $62,000 upon the first scheduled required prepayment and five (5) payments thereafter aggregating $287,000 with the remainder outstanding under the Note due on November 16, 2021. | |||||||||||||||||||||
Interest rate | 10.00% | |||||||||||||||||||||
Forbearance and Amendment Agreement [Member] | ||||||||||||||||||||||
Event of default descriptions | The Note provides that upon an Event of Default, the Buyer may, among other things, require the Company to redeem all or a portion of the Note at a redemption premium of 120%, multiplied by the product of the conversion rate ($6.00 per share) and the then current market price. | |||||||||||||||||||||
Exercise price | 6.0 | |||||||||||||||||||||
Prepayment amount | $ 63,000 | $ 100,000 | ||||||||||||||||||||
Aggregate outstanding amount | 480,000 | $ 200,000 | ||||||||||||||||||||
Remaining outstanding amount | $ 607,000 | |||||||||||||||||||||
Breach of agreement description | the time of any breach by the Company of the Agreement or the occurrence of an Event of Default that is not an Existing Default (the “Forbearance Expiration Date), (b) during the Forbearance Period (as defined) waive the prepayment premium to any Company Optional Redemption (which will result in the 120% redemption premium effectively replaced with 100%), and (c) during the Forbearance Period, waive the repayment in full of the Note other than the Required Payments (as defined) prior to June 16, 2021. | |||||||||||||||||||||
Placement agent [Member] | Roth Capital Partners, LLC [Member] | ||||||||||||||||||||||
Interest Rate | 25.00% | |||||||||||||||||||||
Convertible Notes [Member] | September 2018 [Member] | ||||||||||||||||||||||
Interest Rate | 5.00% | 5.00% | ||||||||||||||||||||
Common Stock | ||||||||||||||||||||||
Average price per share | $ 2.58 | |||||||||||||||||||||
Accrued interest | $ 25,144 | |||||||||||||||||||||
Fees into common stock shares | 213,382 | |||||||||||||||||||||
Common stock, par value | $ 0.001 | |||||||||||||||||||||
Securities Purchase Agreement [Member] | ||||||||||||||||||||||
Amortization of debt discount | 127,916 | $ 60,063 | ||||||||||||||||||||
Accrued intetest | 28,291 | $ 15,166 | ||||||||||||||||||||
Remaining debt discount | 191,084 | 258,937 | ||||||||||||||||||||
Convertible note payable net | 333,916 | 266,063 | ||||||||||||||||||||
Series A preferred stock issued | 5,000,000 | |||||||||||||||||||||
Average price per share | $ 1 | $ 2.58 | $ 2.58 | |||||||||||||||||||
Series A preferred stock issued value | $ 5,000,000 | |||||||||||||||||||||
Description of series A preferred stock | The Series A Preferred Stock will be convertible into the Company’s Common Stock as determined by multiplying the number of shares of Series A Preferred Stock to be converted by the lower of (i) $4.00 or (ii) 80% of the average volume weighted average price for the Company’s Common Stock for the five (5) days prior to the date of Uplisting, subject to a floor of $3.00 per share. | |||||||||||||||||||||
Convertible notes payable, principal amount | 525,000 | $ 525,000 | $ 525,000 | |||||||||||||||||||
Accrued interest | $ 25,144 | $ 25,144 | ||||||||||||||||||||
Fees into common stock shares | 213,382 | 213,382 | ||||||||||||||||||||
Gain on change in fair value of derivative liability | 13,127 | |||||||||||||||||||||
Securities Purchase Agreement [Member] | Warrants [Member] | ||||||||||||||||||||||
Maturity period | 5 years | |||||||||||||||||||||
Securities Purchase Agreement [Member] | Holder [Member] | May 2019 Note [Member] | ||||||||||||||||||||||
Convertible notes payable, principal amount | $ 907,000 | |||||||||||||||||||||
Event of default conversion price, description | Upon an Event of Default (regardless of whether such event has been cured), the Buyer may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the then Volume-Weighted Average Price (as defined, the “VWAP”). | |||||||||||||||||||||
Common stock shares issuable upon conversion of debt/convertible securities | 250,000 | |||||||||||||||||||||
Repayment of amount | $ 525,000 | |||||||||||||||||||||
Conversion price | $ 6 | |||||||||||||||||||||
Payment amount to related party | $ 12,000,000 | |||||||||||||||||||||
Customary events of default, description | 2019 Note includes customary Events of Default and provides that the Buyer may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Note at a redemption premium equal to the greater of: (i) the product of the redemption premium of one hundred twenty-five (125%) percent, multiplied by the conversion amount, and (ii) the product of the conversion rate ($6.00 per share) multiplied by the product of 125% multiplied by the then current market price. The Buyer may also require redemption of the May 2019 Note upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Company has the right to redeem the May 2019 Note at any time, in whole or in part, in cash at a price equal to 120% of the then outstanding conversion amount. | |||||||||||||||||||||
Terms of Blocker Provision | common stock would exceed 9.99% of the Company’s issued and outstanding common stock. | |||||||||||||||||||||
Accrued expense | $ 15,420 | |||||||||||||||||||||
Securities Purchase Agreement [Member] | InstitutionalInvestor [Member] | ||||||||||||||||||||||
Convertible notes payable, principal amount | $ 1,500,000 | |||||||||||||||||||||
Cash commission description | Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, received a cash commission for this transaction equal to six (6%) percent of the total gross proceeds of the offering. This 6% fee or $90,000 was recorded as debt discount along with the $30,000 in legal fees associated with the May 2019 Note. | |||||||||||||||||||||
Amortization fees | $ 29,509 | |||||||||||||||||||||
Securities Purchase Agreement [Member] | Institutional investors [Member] | September 2018 Notes [Member] | ||||||||||||||||||||||
Legal fees | $ 15,000 | |||||||||||||||||||||
Securities Purchase Agreement [Member] | Senior Convertible Note 1 [Member] | Institutional investors [Member] | ||||||||||||||||||||||
Convertible notes payable, principal amount | $ 15,000 | |||||||||||||||||||||
Interest expense | $ 6,568 | |||||||||||||||||||||
Shares issued | 213,382 | |||||||||||||||||||||
Shares issued at a fair value | $ 959,024 | |||||||||||||||||||||
Outstanding debt | 550,144 | |||||||||||||||||||||
Derivative liability | 3,949 | 460,728 | 5,822 | 284,169 | $ 284,169 | |||||||||||||||||
Extinguishment of debt | $ 124,711 | |||||||||||||||||||||
Debt discount | 456,570 | |||||||||||||||||||||
Transaction expenses | 43,000 | |||||||||||||||||||||
Amortized cost | $ 4,597 | 568,826 | 494,973 | $ 499,570 | ||||||||||||||||||
Other income | 1,873 | $ 4,158 | 170,737 | $ 44,215 | ||||||||||||||||||
Securities Purchase Agreement [Member] | Convertible Promissory Note [Member] | ||||||||||||||||||||||
Amortization of debt discount | 62,619 | 62,619 | ||||||||||||||||||||
Gain on change in fair value of derivative liability | $ 22,776 | |||||||||||||||||||||
Derivative liability | $ 26,716 | 39,843 | 62,619 | |||||||||||||||||||
Debt original issue discount | $ 25,000 | $ 40,000 | $ 25,000 | |||||||||||||||||||
Default interest rate | 18.00% | |||||||||||||||||||||
Interest rate | 8.00% | 10.00% | 10.00% | |||||||||||||||||||
Cash proceeds from conversion | $ 500,000 | $ 500,000 | ||||||||||||||||||||
Conversion discount to price | 30.00% | 30.00% | ||||||||||||||||||||
Event of default descriptions | Note since inception shall be the Interest Rate plus eighteen percent (18.0%), the Default Interest. Unless previously converted, the principal and accrued interest on the Note is due and payable in cash (USD) upon the earlier of (i) December 31, 2021, (ii) a Change of Control (as defined in the SPA) or (iii), an Event of Default (collectively, the “Maturity Date”). | |||||||||||||||||||||
Financing cost | $ 3,000 | |||||||||||||||||||||
Purchase price principal amount | $ 100,000 | |||||||||||||||||||||
Note issued | 540,000 | |||||||||||||||||||||
Principal balance | $ 100,000 | |||||||||||||||||||||
Accrued interest | $ 5,736 | |||||||||||||||||||||
Beneficial conversion feature's intrinsic value | $ 294,000 | |||||||||||||||||||||
Note issued upon exchange for cash | $ 500,000 |
DEBT (Details)
DEBT (Details) - USD ($) | Feb. 05, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 |
Beginning balance loans | $ 22,814,594 | $ 12,029,724 | |||
Proceeds | $ 0 | 565,900 | 16,556,710 | ||
Payments | (265,421) | (5,230,725) | |||
Conversion of debt | (4,616,500) | (807,795) | |||
Reclass of long-term portion of debt | (1,402,396) | (86,670) | 0 | ||
Debt extinguishment | (169,770) | (204,271) | |||
Foreign currency translation | (423,245) | 470,951 | |||
Subtotal | 17,818,888 | 22,814,594 | |||
Foreign currency translation | (13,106) | (423,245) | |||
Notes payable - long-term | (6,885,806) | (12,356,384) | (10,771,882) | ||
Notes payable - short-term | 6,143,075 | 5,462,504 | 12,042,712 | ||
Foreign currency translation | (405,229) | $ (473,578) | (1,006,517) | 871,235 | |
Debt extinguishment | $ 445,636 | ||||
Bridge Loan | |||||
Beginning balance loans | 191,287 | ||||
Proceeds | 0 | ||||
Payments | (191,287) | ||||
Subtotal | 0 | ||||
Notes payable - long-term | 0 | ||||
Notes payable - short-term | 0 | ||||
Debt extinguishment | 0 | ||||
Foreign currency transaction | 0 | ||||
COVID Loans | |||||
Beginning balance loans | 234,117 | 435,210 | 0 | ||
Proceeds | 0 | 0 | 435,210 | ||
Payments | (3,233) | 0 | |||
Conversion of debt | 0 | 0 | 0 | ||
Reclass of long-term portion of debt | 0 | 0 | 0 | ||
Debt extinguishment | 0 | (169,770) | 0 | ||
Subtotal | 229,088 | 234,117 | 435,210 | ||
Notes payable - long-term | (221,781) | (51,478) | 0 | ||
Notes payable - short-term | 7,307 | 182,639 | 435,210 | ||
Foreign currency translation | (5,029) | (28,090) | 0 | ||
Trade Facility [Member] | |||||
Beginning balance loans | 1,299,784 | 6,446,000 | 6,245,400 | ||
Proceeds | 0 | 0 | 0 | ||
Payments | (124,242) | (57,835) | 0 | ||
Conversion of debt | (1,190,000) | 0 | 0 | ||
Reclass of long-term portion of debt | 0 | 0 | |||
Subtotal | 118,848 | 6,207,010 | 6,446,000 | ||
Notes payable - long-term | 0 | (2,450,000) | (2,384,850) | ||
Foreign currency translation | 54,861 | (181,155) | 200,600 | ||
Debt extinguishment | 78,445 | 0 | 0 | ||
Notes payable- short -term | 118,848 | 3,757,010 | 4,061,150 | ||
Third Party [Member] | |||||
Beginning balance loans | 10,077,977 | 12,631,284 | 2,514,595 | ||
Proceeds | 0 | 565,900 | 16,121,500 | ||
Payments | (2,030,814) | (62,878) | (5,006,115) | ||
Conversion of debt | (3,010,000) | (807,795) | |||
Reclass of long-term portion of debt | (1,204,356) | 0 | |||
Debt extinguishment | 0 | 192,205 | |||
Foreign currency translation | (21,433) | (46,329) | 1,304 | ||
Subtotal | 6,821,374 | 10,077,977 | 12,631,284 | ||
Notes payable - long-term | (6,664,025) | (9,854,906) | (5,543,557) | ||
Notes payable - short-term | 157,349 | 223,071 | 7,087,727 | ||
Loan Facility [Member] | |||||
Beginning balance loans | 6,027,010 | 3,302,100 | 3,078,442 | ||
Proceeds | 0 | 0 | 0 | ||
Payments | (107,894) | (141,475) | 0 | ||
Conversion of debt | 0 | (1,606,500) | |||
Reclass of long-term portion of debt | (198,040) | (86,670) | |||
Debt extinguishment | 0 | 0 | 12,066 | ||
Foreign currency translation | (41,505) | (167,671) | 269,047 | ||
Subtotal | 5,859,571 | 1,299,784 | 3,302,100 | ||
Notes payable - long-term | 0 | 0 | (2,843,475) | ||
Notes payable - short-term | $ 5,859,571 | $ 1,299,784 | $ 458,625 |
DEBT (Details 1)
DEBT (Details 1) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
DEBT | |||
2022 | $ 4,116,483 | ||
2023 | 9,699,419 | $ 5,549,174 | |
2024 | 253,694 | 11,709,951 | |
2025 | 227,261 | 268,724 | |
26 and Thereafter | 140,923 | 113,454 | |
Total Debt | 14,437,780 | 17,905,558 | |
Less: fair value adjustments to assumed debt obligations | (1,408,899) | (86,670) | |
Notes payable - long term portion | (6,143,075) | ||
Less: notes payable - current portion | 6,885,806 | ||
2025 | 264,255 | ||
Notes payable - long term portion | 6,885,806 | 12,356,384 | $ 10,771,882 |
Less: notes payable - current portion | $ (6,143,075) | $ (5,462,504) | $ (12,042,712) |
DEBT (Details Narrative)
DEBT (Details Narrative) | Mar. 03, 2022USD ($) | Aug. 04, 2021USD ($)shares | Feb. 05, 2021USD ($)$ / sharesshares | Dec. 30, 2020USD ($) | Aug. 04, 2020USD ($) | Jul. 03, 2020USD ($) | May 12, 2020USD ($) | May 08, 2020USD ($) | May 05, 2020USD ($) | Jun. 30, 2021 | Nov. 19, 2020USD ($) | Jun. 24, 2020 | May 18, 2020USD ($) | Feb. 25, 2020USD ($) | Oct. 17, 2018USD ($) | Mar. 31, 2022CAD ($)shares | Mar. 31, 2022USD ($)shares | Mar. 31, 2021USD ($)shares | Dec. 31, 2021CAD ($)shares | Dec. 31, 2021USD ($)shares | Dec. 31, 2020USD ($)shares | Dec. 31, 2019USD ($) | Dec. 20, 2018 | Dec. 20, 2018 | Dec. 08, 2021$ / shares | Jul. 30, 2021USD ($) | Jul. 19, 2021$ / shares | Jul. 13, 2021$ / shares | Jun. 23, 2021$ / shares | Jan. 07, 2021USD ($) | Oct. 29, 2020USD ($)$ / sharesshares | Nov. 16, 2015USD ($) |
Accrued and unpaid interest | $ 81,813 | $ 563,613 | ||||||||||||||||||||||||||||||
Debt repayment during period | 50,059 | 3,233 | ||||||||||||||||||||||||||||||
Repayments of debt | $ 55,465 | 56,508 | ||||||||||||||||||||||||||||||
Capitalized fees | $ 200,000 | |||||||||||||||||||||||||||||||
Debt instrument carrying amount | 2,564,363 | |||||||||||||||||||||||||||||||
Debt instruments final payament | $ 1,800,000 | |||||||||||||||||||||||||||||||
Senior promissory notes to unaffiliated third party | $ 510,000 | |||||||||||||||||||||||||||||||
Debt outstanding amount | $ 64,347 | 3,010,000 | $ 578,850 | |||||||||||||||||||||||||||||
Percentage of forgiveness | 50.00% | 50.00% | 50.00% | 50.00% | ||||||||||||||||||||||||||||
Forgiveness recorde as other income | $ 177,450 | $ 177,450 | ||||||||||||||||||||||||||||||
Loan received from related party | $ 366,900 | 166,395 | 169,770 | $ 2,500,000 | ||||||||||||||||||||||||||||
Decription of loan payment for interest | Company of 781,819 shares of common stock (the “Exchange Shares”), at the rate of $3.85 per share, in exchange for an aggregate of $3,010,000 principal amount of existing loans made by the Lender to the Company. The market price at the time this Agreement was negotiated was $3.28 per share | The loan will be repaid in 40 equal monthly installments beginning on January 1, 2022 and bears an interest rate of 0.94% per annum. | the Company received a loan £50,000 ($68,310) from the United Kingdom government. The loan has a six-year maturity and bears interest at a rate of 2.5% per annum beginning 12-months after the initial disbursement. | |||||||||||||||||||||||||||||
Common stock exchange shares | shares | 781,819 | |||||||||||||||||||||||||||||||
Gain on debt extinguisment | $ 445,636 | |||||||||||||||||||||||||||||||
Convertible notes payable, principal amount | 448,915 | 5,462,504 | 12,042,712 | $ 100,000 | ||||||||||||||||||||||||||||
Accrued expenses | 3,100 | |||||||||||||||||||||||||||||||
Notes payable long term | 477,637 | |||||||||||||||||||||||||||||||
Accrued interest expense | 527,604 | |||||||||||||||||||||||||||||||
Agreement description | The note matures on August 5, 2026 and bears an annual interest rate that applies to 60% of the principal of the note that is based on a 365-day year, of 5.84% plus 3-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grace period for principal repayment during which interest is accrued. The principal is to be repaid in 18 quarterly installments of €27,000 commencing three months from the end of the grace period. | |||||||||||||||||||||||||||||||
Gain on extinguishment of debt | $ 1,004,124 | $ 445,636 | $ (606,667) | $ (942,029) | ||||||||||||||||||||||||||||
Shares issued | shares | 17,544,509 | 13,485,128 | ||||||||||||||||||||||||||||||
Restricted shares | shares | 1,800,000 | 1,800,000 | 1,800,000 | |||||||||||||||||||||||||||||
Loans payable | $ 1,000,000 | $ 0 | ||||||||||||||||||||||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | ||||||||||||||||||||||||||||||||
Cash received upon gross sales | $ 2,750,000 | |||||||||||||||||||||||||||||||
Upfront cash received | $ 2,000,000 | $ 2,000,000 | ||||||||||||||||||||||||||||||
Equity interest acquired description | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milest | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milest | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones | a 33 1/3% equity interest or 5 million shares in Marathon as partial consideration for the Company’s distribution services; and (b) received cash of CAD $2,000,000, subject to repayment in common shares of the Company if it fails to meet certain performance milestones | ||||||||||||||||||||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales One [Member] | ||||||||||||||||||||||||||||||||
Cash received upon gross sales | $ 2,750,000 | $ 2,750,000 | ||||||||||||||||||||||||||||||
Gross sales | 2,750,000 | 6,500,000 | ||||||||||||||||||||||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales [Member] | ||||||||||||||||||||||||||||||||
Cash received upon gross sales | 2,750,000 | 2,750,000 | ||||||||||||||||||||||||||||||
Gross sales | $ 13,000,000 | |||||||||||||||||||||||||||||||
Distribution and Equity Acquisition Agreement [Member] | Marathon Global Inc [Member] | Gross Sales [Member] | ||||||||||||||||||||||||||||||||
Cash received upon gross sales | 2,750,000 | |||||||||||||||||||||||||||||||
Gross sales | 13,000,000 | |||||||||||||||||||||||||||||||
Upfront cash received | $ 2,000,000 | |||||||||||||||||||||||||||||||
Grigorios Siokas [Member] | ||||||||||||||||||||||||||||||||
Interest Rate | 4.70% | 4.70% | ||||||||||||||||||||||||||||||
Debt instrument maturity date | Mar. 18, 2019 | |||||||||||||||||||||||||||||||
Notes payable- short -term | $ 443,720 | $ 452,720 | 489,200 | |||||||||||||||||||||||||||||
Unaffiliated Third Party [Member] | Senior Promissory Notes [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | $ 3,000,000 | $ 2,000,000 | $ 2,000,000 | $ 2,000,000 | ||||||||||||||||||||||||||||
Debt instrument maturity date | Jun. 8, 2020 | Dec. 31, 2020 | Dec. 31, 2020 | |||||||||||||||||||||||||||||
Interest rate | 18.00% | 18.00% | 18.00% | |||||||||||||||||||||||||||||
Loans payable | $ 4,000,000 | $ 3,000,000 | $ 1,000,000 | |||||||||||||||||||||||||||||
Description of loan repayment | The August 4 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The August 4 Note matured on December 31, 2020. | The May 8 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 8 Note matured on June 8, 2020. | The May 18 Note bears interest at the rate of eighteen (18%) percent per annum, paid quarterly in arrears. The May 18 Note matured on December 31, 2020. On February 23, 2022, the Company entered into an allonge with the lender extending the maturity date to June 30, 2023 | the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). | the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). | the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2021, the Company would be required to issue 431,270 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial instruments issued by the Company were not affected | the CAD $2 million cash received noted in (b) above, the Company accounted for its obligation to issue a variable number of the Company’s Common Shares as Share-settled debt obligation in accordance with ASC 480 measured at fair value or the settlement amount of $1,554,590 (CAD $2 million). If settlement were to occur on December 31, 2021, the Company would be required to issue 431,270 common shares to settle its debt obligation. The Company could be obligated to potentially issue an unlimited number of common shares to settle its Share-settled debt obligation. If such events were to occur, the Company would be required to increase its authorized share capital and since increasing the authorized share capital is within the control of the Company, as our CEO controls greater than 50% of the outstanding common stock of the Company, the original classification of equity-classified financial instruments issued by the Company were not affected | |||||||||||||||||||||||||
Loan Facility [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | $ 118,848 | $ 1,299,784 | 3,302,100 | $ 2,000,000 | ||||||||||||||||||||||||||||
Notes payable long term | 2,843,475 | |||||||||||||||||||||||||||||||
Accrued interest expense | $ 16,849 | $ 4,414 | 33,021 | |||||||||||||||||||||||||||||
Gain on extinguishment of debt | 749,824 | |||||||||||||||||||||||||||||||
Restricted shares | shares | 1,000,000 | 1,000,000 | 1,000,000 | 1,000,000 | ||||||||||||||||||||||||||||
Gain (loss) on extinguishment of debt, principal and accrued interest | 12,066 | |||||||||||||||||||||||||||||||
Description of loan repayement | The Company will make quarterly payments of €125,000 beginning May 6, 2021, with a final payment of €2,200,000 on May 6, 2022. The Company evaluated the settlement agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $3,772,446 of principal and accrued interest was written off and the new debt was recorded at fair value as of June 30, 2020 in the amount of $3,033,990. For the year ended December 31, 2020, the Company recorded a gain on extinguishment of debt in the amount of $749,824, of which $12,066 related to the principal of the loans and the balance related to the accrued interest. As of December 31, 2020, the Company has accrued interest expense of $33,021 and the principal balance of the debt is $3,302,100, of which $2,843,475 is classified as Notes payable - long term portion on the consolidated balance sheet. | The Company will make quarterly payments of €125,000 beginning May 6, 2021, with a final payment of €2,200,000 on May 6, 2022. The Company evaluated the settlement agreement for debt modification in accordance with ASC 470-50 and concluded that the debt qualified for debt extinguishment as the 10% cash flow test was met. As a result, the $3,772,446 of principal and accrued interest was written off and the new debt was recorded at fair value as of June 30, 2020 in the amount of $3,033,990. For the year ended December 31, 2020, the Company recorded a gain on extinguishment of debt in the amount of $749,824, of which $12,066 related to the principal of the loans and the balance related to the accrued interest. As of December 31, 2020, the Company has accrued interest expense of $33,021 and the principal balance of the debt is $3,302,100, of which $2,843,475 is classified as Notes payable - long term portion on the consolidated balance sheet. | ||||||||||||||||||||||||||||||
Debt Exchange Agreement [Member] | ||||||||||||||||||||||||||||||||
Repayments of debt | $ 30,814 | $ 62,878 | ||||||||||||||||||||||||||||||
Debt outstanding amount | $ 611,500 | 462,208 | 503,022 | 611,500 | 565,900 | |||||||||||||||||||||||||||
Accrued expenses | $ 5,642 | 4,815 | 60,166 | $ 8,514 | ||||||||||||||||||||||||||||
Notes payable long term | 429,582 | 377,270 | 543,557 | 477,637 | ||||||||||||||||||||||||||||
Agreement description | The note matures on November 18, 2025 and bears an annual interest rate, based on a 360-day year, of 3.3% plus .6% plus 6-month Euribor when Euribor is positive. Pursuant to the terms of the agreement, there is a six-month grievance from the first deposit date, which was November 19, 2020, for principal repayment. The principal is to be repaid in 18 quarterly installments of €27,000 with the first payment due 9 months from the first deposit | |||||||||||||||||||||||||||||||
Shares issued | shares | 321,300 | 259,741 | ||||||||||||||||||||||||||||||
Gain on settlement of debt upon shares issuance | $ 292,383 | $ 192,205 | ||||||||||||||||||||||||||||||
Common stock shares issuable upon listing on nasdaq | shares | 238,000 | |||||||||||||||||||||||||||||||
Settlement of debt, shares issuable upon listing on nasdaq | $ 1,190,000 | |||||||||||||||||||||||||||||||
Settlement of debt | 1,606,500 | |||||||||||||||||||||||||||||||
Gain from extinguishment of debt | $ 6,642 | $ 216,580 | ||||||||||||||||||||||||||||||
Discount rate | 11.66% | |||||||||||||||||||||||||||||||
Principal amount of existing loan | $ 1,000,000 | |||||||||||||||||||||||||||||||
Fair value of price per share | $ / shares | $ 3.11 | |||||||||||||||||||||||||||||||
Upon issuance of common stock | shares | 238,000 | 238,000 | ||||||||||||||||||||||||||||||
Share issued price per share | $ / shares | $ 3.85 | |||||||||||||||||||||||||||||||
Repayment of debt, accrued interest | 5,642 | |||||||||||||||||||||||||||||||
Debt Exchange Agreement [Member] | Chief Executive Officer [Member] | ||||||||||||||||||||||||||||||||
Share issued price per share | $ / shares | $ 3.28 | $ 3.44 | $ 4.30 | $ 4.30 | $ 5 | |||||||||||||||||||||||||||
Loan Agreement [Member] | Panagiotis Drakopoulos [Member] | ||||||||||||||||||||||||||||||||
Repayments of debt | 5,862 | |||||||||||||||||||||||||||||||
Debt outstanding amount | $ 8,874 | 9,054 | 9,784 | |||||||||||||||||||||||||||||
Accrued expenses | 7,143 | 7,151 | 5,852 | $ 3,100 | ||||||||||||||||||||||||||||
Short term debt borrowing capacity | $ 3,751,901 | $ 42,832 | ||||||||||||||||||||||||||||||
Synthesis facility agreement [Member] | TFF [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | $ 5,629,555 | |||||||||||||||||||||||||||||||
Accrued expenses | 524,094 | |||||||||||||||||||||||||||||||
Synthesis facility agreement [Member] | TFF [Member] | Principal Balance One [Member] | ||||||||||||||||||||||||||||||||
Accrued interest expense | 10,466 | |||||||||||||||||||||||||||||||
Debt instrument, transferred amount | $ 2,000,000 | |||||||||||||||||||||||||||||||
Debt instrument, accrue interest rate | 5.50% | |||||||||||||||||||||||||||||||
Debt instruments periodic payment | $ 50,000 | |||||||||||||||||||||||||||||||
Debt intrument split, principal balance | $ 2,000,000 | |||||||||||||||||||||||||||||||
Synthesis facility agreement [Member] | TFF [Member] | Principal balance 2 [Member] | ||||||||||||||||||||||||||||||||
Convertible notes payable, principal amount | 56,805 | 2,446,000 | ||||||||||||||||||||||||||||||
Accrued expenses | 402 | 16,185 | ||||||||||||||||||||||||||||||
Notes payable long term | 2,384,850 | |||||||||||||||||||||||||||||||
Accrued interest expense | 104,220 | |||||||||||||||||||||||||||||||
Debt instrument maturity date | Aug. 31, 2021 | |||||||||||||||||||||||||||||||
Notes payable- short -term | $ 2,450,000 | |||||||||||||||||||||||||||||||
Stated interest rate | 6.00% | |||||||||||||||||||||||||||||||
Debt instrument, extended maturity, month and year | January 10, 2023 | January 2023 | January 2023 | January 2023 | January 2023 | |||||||||||||||||||||||||||
Debt split, balance | $ 4,000,000 | $ 4,000,000 | 4,000,000 | |||||||||||||||||||||||||||||
Interest rate description | 6% per annum plus one-month Libor on the USD balance | |||||||||||||||||||||||||||||||
Frequency of periodic payments | quarterly | |||||||||||||||||||||||||||||||
July 30, 2021 Debt Agreement [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | $ 554,650 | |||||||||||||||||||||||||||||||
Notes payable long term | 438,799 | |||||||||||||||||||||||||||||||
Accured interest | 3,042 | |||||||||||||||||||||||||||||||
Modification of May 18, 2020, July 3, 2020, and August 4, 2020 Senior Promissory Notes [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | 5,795,644 | |||||||||||||||||||||||||||||||
Modification agreement amount | 9,000,000 | |||||||||||||||||||||||||||||||
Restructuring fees | 506,087 | |||||||||||||||||||||||||||||||
Fair value of debt | 7,706,369 | |||||||||||||||||||||||||||||||
Gain on extinguishment of debt | 787,544 | |||||||||||||||||||||||||||||||
Debt principal payment | 2,000,000 | |||||||||||||||||||||||||||||||
Non cash interest expenses | 89,275 | |||||||||||||||||||||||||||||||
Accured interest | $ 443,341 | |||||||||||||||||||||||||||||||
February Note [Member] | Senior Promissory Note [Member] | Grigorios Siokas [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | $ 1,000,000 | |||||||||||||||||||||||||||||||
Interest Rate | 18.00% | |||||||||||||||||||||||||||||||
Debt instrument maturity date | Apr. 30, 2020 | |||||||||||||||||||||||||||||||
July 3, 2020 [Member] | Senior Promissory Notes [Member] | ||||||||||||||||||||||||||||||||
Debt outstanding amount | $ 5,000,000 | |||||||||||||||||||||||||||||||
Accrued expenses | 210,574 | 148,685 | ||||||||||||||||||||||||||||||
Notes payable long term | $ 5,000,000 | $ 5,000,000 | ||||||||||||||||||||||||||||||
Interest Rate | 18.00% | 18.00% | 18.00% | 18.00% | ||||||||||||||||||||||||||||
Debt instrument maturity date | Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2022 | ||||||||||||||||||||||||||||
Repayment of may five note | 2,000,000 | |||||||||||||||||||||||||||||||
Repayment of may eight note | 2,000,000 | |||||||||||||||||||||||||||||||
Repayment of february note | $ 1,000,000 | |||||||||||||||||||||||||||||||
August 4, 2020 [Member] | Senior Promissory Notes [Member] | ||||||||||||||||||||||||||||||||
Debt instrument maturity date | Dec. 31, 2020 | Dec. 31, 2020 | Dec. 31, 2020 | Dec. 31, 2020 | ||||||||||||||||||||||||||||
Interest rate | 18.00% | 18.00% |
LEASES (Details)
LEASES (Details) - Operating Lease [Member] - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Remainder of 2022 | $ 154,095 | $ 211,538 |
2023 | 177,914 | 182,316 |
2024 | 108,485 | 111,026 |
2025 | 108,485 | 111,026 |
2026 and Thereafter | 408,810 | 418,723 |
Total undiscounted operating lease payments | 957,789 | 1,034,629 |
Less: Imputed interest | (182,247) | (200,164) |
Present value of operating lease liabilities | $ 775,542 | $ 834,465 |
LEASES (Details 1)
LEASES (Details 1) - Finance Lease [Member] - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Remainder of 2022 | $ 62,941 | $ 85,231 |
2023 | 73,387 | 72,849 |
2024 | 56,654 | 55,765 |
2025 | 26,870 | 27,744 |
2026 and Thereafter | 3,694 | 4,211 |
Total undiscounted finance lease payments | 223,546 | 245,800 |
Less: Imputed interest | (20,669) | (24,321) |
Present value of finance lease liabilities | $ 202,877 | $ 221,479 |
LEASES (Details Narrative)
LEASES (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
LEASES | ||||
Operating lease, term of agreements | The Company has various lease agreements with terms up to 10 years, comprising leases of office space | The Company has various lease agreements with terms up to 10 years, comprising leases of office space. | ||
Operating lease expense | $ 54,124 | $ 65,577 | $ 260,664 | $ 188,400 |
Operating lease weighted-average remaining lease term | 6.47 years | 6.6 years | ||
Operating lease, weighted average discount rate | 6.74% | 6.74% | ||
Finance lease, weighted average remaining lease term | 2.93 years | 3.2 years | ||
Finance lease, interest expense | $ 3,507 | $ 4,453 | $ 11,576 | 13,759 |
Finance lease, weighted average discount rate | 6.74% | 6.74% | ||
Finance lease, amortization expense | $ 19,580 | $ 97,270 | 123,533 | |
Finance lease total cash used | $ 22,358 | |||
Operating lease cash flows used in finance lease | $ 92,105 | $ 85,804 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |
Jul. 31, 2021 | Mar. 31, 2022 | Dec. 31, 2021 | |
Description for advisory agreement | The term of the agreement is a minimum of 45 days and will continue until 5 business days following the date in which a party receives written notice from the other party of termination. As consideration for services rendered, the Company shall pay: a) a cash fee equal to 10% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering; b) 1% of the gross proceeds of any securities sold in the offering payable at closing of the offering from the gross proceeds of the offering for unaccountable expenses; c) warrants to purchase shares of the Company’s common stock equal to 10% of the number of shares issued in the offering or to be issued thereafter upon conversion of any convertible securities issued in the offering. These warrants will have a 5-year term and an exercise price equal to the price per share of common stock sold in the offering or conversion or exercise price into common stock of any convertible security sold and will have the same provisions, terms, conditions, rights and preferences as the securities sold in the offering; d) a cash fee equal to 10% of the exercise price of all securities constituting warrants, options or other rights to purchase securities sold in the offering payable only upon exercise. | ||
Description for compensation payable under agreement to consultants | a) a cash fee or as an underwritten offering an underwriter discount equal to 7% of the aggregate gross proceeds raised in each offering. For all investors referred directly to the Company by the agent, a cash fee or as an underwritten offering an underwriter discount equal to 5% of the aggregate gross proceeds invested by such investors. b) the Company shall issue to the agent or its designees at each closing, warrants to purchase shares of the Company’s common stock equal to 5% of the aggregate number of shares of common stock placed in each offering. c) out of the proceeds of each closing, the Company also agreed to pay the agent up to $35,000 for non-accountable expenses (up to $50,000 for a public offering) along with up to $50,000 for fees and expenses of legal counsel and other out-of-pocket expenses (increase to up to $100,000 for public offerings) plus additional miscellaneous costs. The agent would also have the right of first refusal from the date of the agreement until the 12-month anniversary following consummation of any offerings for total proceeds of at least $3 million raised by investors introduced by the agent. | ||
July 1, 2021 [Member] | Advisory Agreement [Member] | |||
Consulting fee payable monthly until listing | $ 4,000 | $ 4,000 | |
Description for consulting fees payable under agreement | the Company shall pay $10,000 per month, with $4,000 per month paid on a monthly basis and $6,000 per month accrued until such time as the Company raises an aggregate of $10,000,000. In addition, the consultant will receive a $100,000 bonus upon NASDAQ listing and when the Company has raised an aggregate of $10,000,000. Finally, the Company has agreed that the Consultant shall receive a total of 250,000 shares of the Company’s common stock, 50,000 of such shares that have been previously issued pursuant to previous agreements and 200,000 shares to be issued when the Company commences trading on NASDAQ. | Company shall pay $10,000 per month, with $4,000 per month paid on a monthly basis and $6,000 per month accrued until such time as the Company raises an aggregate of $10,000,000. In addition, the consultant will receive a $100,000 bonus upon NASDAQ listing and when the Company has raised an aggregate of $10,000,000. Finally, the Company has agreed that the Consultant shall receive a total of 250,000 shares of the Company’s common stock, 50,000 of such shares that have been previously issued pursuant to previous agreements and 200,000 shares to be issued when the Company commences trading on NASDAQ. | |
Consulting fee payable monthly after listing | $ 10,000 |
EARNINGS PER SHARE (Details)
EARNINGS PER SHARE (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Numerator for Basic and Diluted Earnings Per Share: | ||||
Net income (loss) | $ (15,594,682) | $ 820,786 | ||
Denominator for Basic Earnings Per Share: | ||||
Weighted Average Shares | 17,755,516 | 15,034,219 | 16,423,335 | 13,270,097 |
Potentially Dilutive Common Shares | 0 | 37,698 | ||
Adjusted Weighted Average Shares | 16,423,335 | 13,307,795 | ||
Basic and Diluted Net (Loss) Income per Share | $ (0.95) | $ 0.06 |
EARNINGS PER SHARE (Details 1)
EARNINGS PER SHARE (Details 1) - shares | 12 Months Ended | |
Dec. 31, 2021 | Dec. 31, 2020 | |
Excluded from computation of diluted net loss per share | 3,823,804 | 0 |
Convertible Debt [Member] | ||
Excluded from computation of diluted net loss per share | 218,977 | 0 |
Options [Member] | ||
Excluded from computation of diluted net loss per share | 37,000 | 0 |
Warrants [Member] | ||
Excluded from computation of diluted net loss per share | 3,567,827 | 0 |
STOCK OPTIONS AND WARRANTS (Det
STOCK OPTIONS AND WARRANTS (Details) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Exercised | 5,788,493 | ||
Stock Options [Member] | |||
Number of Shares Outstanding, Beginning | 3,700 | 62,000 | 74,000 |
Granted | 0 | 0 | 0 |
Forfeited | 0 | 0 | (12,000) |
Exercised | 0 | 0 | 0 |
Expired | (37,000) | (25,000) | 0 |
Number of Shares Outstanding, Ending | 0 | 37,000 | 62,000 |
Number of Shares Exercisable | 0 | 37,000 | |
Weighted Average Exercise Price Outstanding, Beginning | $ 1.32 | $ 1.19 | $ 1.32 |
Weighted Average Exercise Price Outstanding, Ending | 0 | 1.32 | 0 |
Weighted Average Exercise Price Exercisable | $ 0 | $ 1.32 | $ 1.19 |
Weighted Average Remaining Contractual Term Outstanding, Beginning | 4 days | 7 months 6 days | 1 year 5 months 19 days |
Aggregate Intrinsic Value Outstanding, Beginning | $ 0 | $ 242,200 | $ 64,800 |
Aggregate Intrinsic Value Outstanding, Ending | 75,850 | 75,850 | 0 |
Aggregate Intrinsic Value Exercisable | $ 0 | $ 75,850 | $ 242,200 |
Weighted Average Remaining Contractual Term Outstanding, Ending | 3 days | ||
Weighted Average Remaining Contractual Term Exercisable | 3 days | 7 months 6 days |
STOCK OPTIONS AND WARRANTS (D_2
STOCK OPTIONS AND WARRANTS (Details 1) - USD ($) | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Exercised | 5,788,493 | ||
Warrants [Member] | |||
Number of Shares Outstanding, Beginning | $ 3,698,238 | $ 1,164,673 | $ 1,164,673 |
Granted | 2,000,000 | 2,533,565 | 0 |
Forfeited | 0 | 0 | 0 |
Exercised | 2,748,797 | 0 | |
Expired | 0 | 0 | 0 |
Number of Shares Outstanding, Ending | $ 2,949,441 | $ 3,698,238 | $ 1,164,673 |
Number of Shares Exercisable | 2,949,411 | 3,698,238 | |
Weighted Average Exercise Price Outstanding, Beginning | $ 2.02 | $ 6.41 | $ 6.41 |
Weighted Average Exercise Price Outstanding, Granted | 0 | 2.02 | |
Weighted Average Exercise Price Outstanding, Ending | 2.89 | 2.02 | $ 6.41 |
Weighted Average Exercise Price Exercisable | $ 2.89 | $ 2.02 | |
Weighted Average Remaining Contractual Term Outstanding, Beginning | 2 years 11 days | 3 years 4 days | 4 years 3 days |
Weighted Average Remaining Contractual Term Outstanding, Ending | 4 years 2 months 26 days | 2 years 10 days | 3 years 3 days |
Weighted Average Remaining Contractual Term Exercisable | 4 years 2 months 26 days | 2 years 10 days | |
Aggregate Intrinsic Value Outstanding, Beginning | $ 4,992,621 | ||
Aggregate Intrinsic Value Outstanding, Ending Balance | 113,933 | $ 4,992,621 | $ 5,360 |
Weighted Average Remaining Contractual Term Outstanding, Granted | 2 years 14 days | ||
Aggregate Intrinsic Value Exercisable | $ 113,933 | $ 4,992,621 |
STOCK OPTIONS AND WARRANTS (D_3
STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended |
Mar. 31, 2022 | Dec. 31, 2021 | |
Risk free interest rate | 0.41% | |
Exercise price | $ 2.02 | |
Exercise price after re-pricing | $ 2.02 | |
Fair value of terms rePricing | terms of 1.40 years, 1.97 years, 2.20 years and 2.26 years | |
Debt issuance price | $ 2.02 | |
Warrant to purchase common stock | 2,533,565 | |
Weighted average contractual term | 2 years 14 days | |
fair value of warrants immediately before the re-pricing | $ 1,915,077 | |
fair value of warrants immediately After re-pricing | 9,548,110 | |
Dividend amount | $ 7,633,033 | |
Fair value of cmmon stock before Re pricing | $ 3.75 | |
Fair value of exercise prices before rePricing | exercise prices of $5.00, $6.00 and $7.50 before re-pricing | |
Divined rate | 0.00% | |
Warrants [Member] | ||
Number of Shares Exercisable | 2,949,411 | 3,698,238 |
Number of Shares Outstanding, Beginning | 2,949,411 | 3,698,238 |
Expired dates description | exercisable with expiration dates from May 2023 through August 2027 | expiration dates from May 2023 through March 2024 |
Options [Member] | ||
Number of Shares Exercisable | 0 | 37,000 |
Number of Shares Outstanding, Beginning | 0 | 37,000 |
Expired dates description | expiration dates of January 2022 |
DISAGGREGATION OF REVENUE (Deta
DISAGGREGATION OF REVENUE (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue | $ 13,071,800 | $ 11,619,076 | $ 56,239,667 | $ 55,406,337 |
Greece [Member] | ||||
Revenue | 13,009,038 | 11,453,496 | 55,564,240 | 51,259,784 |
Croatia [Member] | ||||
Revenue | 11,336 | 0 | 18,441 | 24,840 |
Cyprus [Member] | ||||
Revenue | 0 | 14,723 | 112,640 | 36,987 |
Denmark [Member] | ||||
Revenue | 0 | 54,686 | 53,710 | 537,098 |
Germany [Member] | ||||
Revenue | 0 | 13,613 | 13,370 | 1,314,381 |
Italy [Member] | ||||
Revenue | 0 | 15,727 | 15,446 | 75,183 |
UK [Member] | ||||
Revenue | $ 51,426 | $ 66,831 | 461,820 | 1,853,816 |
Libya [Member] | ||||
Revenue | 0 | 1,028 | ||
France [Member] | ||||
Revenue | 0 | 18,988 | ||
Ireland [Member] | ||||
Revenue | 0 | 36,349 | ||
Jordan [Member] | ||||
Revenue | 0 | 29,635 | ||
Netherlands [Member] | ||||
Revenue | 0 | 188,890 | ||
Poland [Member] | ||||
Revenue | $ 0 | $ 29,358 |
SUBSEQUENT EVENTS (Details Narr
SUBSEQUENT EVENTS (Details Narrative) - USD ($) | May 03, 2022 | Mar. 03, 2022 | Feb. 28, 2022 | Feb. 23, 2022 | Apr. 27, 2022 | Mar. 31, 2021 | Dec. 31, 2021 |
Stock issued during period, shares | 238,000 | ||||||
Debt instrument, settlement, amount | $ 1,190,000 | ||||||
Outstanding amount | $ 2,564,363 | ||||||
Sale of stock, consideration received on transaction | $ 250,000 | ||||||
SkyPharm SA | Loan | |||||||
Debt instrument, maturity, month and year | January 2023 | ||||||
Senior Promissory Notes | |||||||
Debt instrument, maturity date | June 30, 2023 | ||||||
Private Placement | |||||||
Stock issued during period, shares | 39,339 | ||||||
Cashless exercise of warrant | 739,374 | ||||||
Warrant issued | 455,316 | ||||||
Principal amount | $ 26,515 | ||||||
Outstanding amount | $ 0 | ||||||
Warrants, issued | 2,000,000 | ||||||
Sale of stock, consideration received on transaction | $ 6,000,000 | ||||||
Private Placement | Series A Convertible Preferred Stock | |||||||
Sale of stock, number of shares issued in transaction | 6,000 | ||||||
Sale of stock, price per share | $ 1,000 |